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Abstract 
Purpose: 
The purpose of this thesis was to evaluate the potential of contact lenses (CLs) as an 
antifungal drug delivery device, and to develop an in vitro eye model to test thereof. 
Methods: 
The first three chapters focused on developing a CL to function as a drug delivery device 
for natamycin, the only commercially available antifungal: 
 In the first experiment (Chapter 3), the in vitro uptake and release characteristics of 
natamycin from several commercially available CLs were evaluated 
 In the second experiment (Chapter 4), to improve the release characteristics of 
natamycin from contact lenses, an attempt was made to incorporate novel drug-
encapsulated nanoparticles (Dex-b-PLA) within the CLs  
 In the third experiment (Chapter 5), an alternative strategy employing the 
incorporation of cyclodextrin (CDs) within the CL polymer matrix was evaluated as a 
potential modification to prolong the release of natamycin  
The second half of the thesis was aimed at developing a sophisticated in vitro ocular model 
capable of adequately measuring drug release from CLs:  
 In Chapter 6, the design of a novel in vitro eye model to simulate the physiological 
ocular environment was outlined  
 In Chapter 7, this model was used to evaluate the release of the antifungal fluconazole 
from commercially daily disposable CLs  
 
  v 
 In chapter 8, as an extension of the developed in vitro eye model, an agar eye model 
was developed to test the effects of natamycin and fluconazole-releasing CLs on 
Candida albicans  
Results 
Commercial CLs, after drug incubation with natamycin, will release the drug rapidly 
within the first half hour, followed by a plateau phase. However, when CL materials were 
loaded instead with natamycin encapsulated within novel Dex-b-PLA nanoparticles, the 
release duration was extended to 12 hours. Modifying the CL polymer with methacrylated 
CDs did not significantly improve drug release. On the contrary, high loading of CDs 
decreased overall drug delivery efficiency, likely resulting from unfavourable arrangements 
of the CDs within the polymer network. 
The developed ocular platform, termed Ocuflow, simulates physiological tear flow, 
tear volume, air exposure and mechanical wear. When this system was used to analyze the 
release of fluconazole from commercial CLs, the drug release was sustained for up to 24 
hours. This observation significantly contrasts drug release observed in a vial, which 
typically follows a burst-plateau profile. When CLs releasing natamycin and fluconazole 
were tested on agar eye models that were inoculated with Candida albicans, the growth of 
the yeast was limited by natamycin-containing CLs. The cell morphology of the yeast also 
differed noticeably based on drug-lens combinations.  
 
  
  vi 
Conclusions 
This thesis details potential strategies to develop novel CLs for antifungal ocular drug 
delivery. The Ocuflow system developed from this thesis is highly versatile; not only can it 
be used effectively to measure drug release from CLs, but it can also be applied to other in 
vitro analyses with CLs.  
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Chapter 1 – General Introduction 
Since their conception, contact lenses (CLs) have enjoyed considerable success in the 
vision correction market.1 With significant progress within the last two decades in material 
science, nanotechnology, and microelectronics, various novel applications for CLs also have 
been explored such as drug delivery,2-5 intraocular pressure monitoring,6-9 glucose monitoring,10-
17 and visual reality augmentation.18, 19 Not surprisingly, this research has evolved the CL field 
well beyond its original focus as a simple refractive error correcting device. This evolution has 
attracted the attention of other disciplines, as well as major technology and pharmaceutical 
companies such as Google and Novartis.16 As such, there is enormous potential for unique and 
rapid growth in this field. 
The focus of this thesis is to investigate the potential of CLs as an ocular drug delivery 
device to treat various ocular diseases, in particular fungal keratitis.2, 20 Amongst ocular 
infections, fungal keratitis is a major concern throughout the world due to its rapid progression to 
vision loss and potentially blindness.21, 22 Currently, topical administration using eye drops 
account for 90% of all ophthalmic formulations.23-26 However, the ocular structures present 
numerous barriers to effective drug absorption and penetration.27-29 As a result, multiple dosing 
is often required for aggressive fungal infections, which in turn leads to problems with patient 
compliance30, 31 and potential drug overdose.32 The application of CL as a drug delivery vehicle 
presents two advantages: (1) drug protection from corneal removal mechanisms and (2) the 
intrinsic ability of a soft lens material to absorb and release drugs over time. The latter aspect, to 
increase the amount and extend the release duration of drugs from a CL, will be a primary focus 
of this thesis.  
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To better understand the current state in this area, the following introduction chapter will 
provide an overview of the anatomical features of the eye, ocular drug delivery approaches, 
development of CLs, and ocular mycoses. The chapter will conclude with current research 
towards developing a CL that could be useful in the management of fungal keratitis, and 
potential in vitro models to evaluate these devices.  
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1.1 Anatomy of the eye 
 
Figure 1-1 Anatomy of the eye (Figure courtesy of the National Eye Institute, National Institute 
of Health,33) 
The anatomical structures of the eye present several unique ocular barriers for ophthalmic 
drug delivery. In this regard, the structures of the eye can be divided into the anterior and 
posterior segments; the division occurs anterior and posterior to the physiological crystalline 
lens.34 This division helps classify the ocular tissues that can be reached using topical treatment 
such as eye drops, and those tissues which will need invasive or systemic routes.34 The main 
structures of the eye are highlighted in Figure 1-1. Because the focus of this thesis is topical drug 
delivery, only the structures of the anterior segment will be discussed. 
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1.2 Anterior segment barriers 
The anterior segment includes the cornea, sclera, iris, ciliary body, pupil, trabecular 
meshwork, Schlemm’s canal, anterior chamber, and the posterior chamber.23, 34 The cornea is the 
most anterior structure of the eye and consists primarily of an organized, avascular, hydrated 
collagen network, which is partitioned into three main layers.23, 34 When the eye is closed, the 
ocular adnexa, consisting of the eyelashes and eyelids, cover the cornea. The conjunctiva, a 
mucous membrane, covers the front of the eye and lines the inside of the eyelids. 
The anterior most layer of the cornea consists of the corneal epithelium, which is several 
layers thick and held together by tight junctions. The function of the corneal epithelium is to seal 
off the ocular surface and control the influx and efflux of water and aqueous soluble 
substances.23, 34 Posterior to the epithelium is the stroma, which accounts for 90% of the corneal 
thickness. It is composed of transparent networks of collagen fibers. The posterior side of the 
cornea is covered by a single layer of specialized endothelium, which functions to control 
corneal hydration and transparency.35, 36  
The three distinct sections of the cornea pose a significant barrier for topical drug 
absorption. The epithelium and endothelium limit the penetration of hydrophilic molecules, 
while allowing lipophilic molecules to pass through. In contrast, the hydrated stroma behaves in 
the opposite fashion and prevents lipophilic molecules from passing.34 As such, in order for a 
drug to successfully penetrate through the cornea, the drug or its delivery vehicle need to possess 
both hydrophilic and hydrophobic properties.37 Other drug properties, such as molecular size, 
shape and ionization will also determine a drug’s ability to pass through the cornea.23, 36 
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Figure 1-2 Ocular surface barriers to drug absorption 
 
The area surrounding the cornea is the limbus, a highly vascularized network comprised 
of corneal epithelial stem cells and the conjunctiva.38 Due to the significantly higher surface area 
and vascular supply, a significantly larger portion of the drugs instilled from topical routes are 
absorbed into the conjunctiva compared to the cornea.23, 37 Drug uptake into the conjunctiva is 
not considered ideal, as these drugs are quickly transferred to the systemic circulation via the 
surrounding blood vessels and the lymphatic system.34  
The sclera is a continuation of the cornea, consisting of white opaque collagen fibers 
organized into very tough tissue.38 The entire ocular surface is lubricated through the production 
of tears, which are secreted by the lacrimal and associated glands. The tear fluid functions to 
lubricate the eye, transport nutrients, remove waste and acts as a first line of defense against 
pathogens.39 However, in conjunction with blinking, tear fluid can also act as a drug barrier by 
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effectively washing,27-29 dispersing,40 and draining drugs from the eye following topical 
administration.27, 29 
 Posterior to the cornea is the anterior chamber. The iris, which controls the amount of 
light that enter the eye, separates the anterior chamber from the posterior chamber. The anterior 
chamber is filled with the aqueous humor, a protein-fluid secreted by the ciliary body.41 The 
posterior chamber contains the aqueous humor and houses the lens, which serves as the physical 
separation between the anterior and posterior segment of the eye.41 The crystalline lens is the 
most posterior structure in which drugs applied topically can penetrate.34 Structures beyond the 
lens are minimally affected by topical administration.38 
Table 1-1 Ocular barriers to drug absorption 
Ocular barriers Drug loss 
Cornea Hydrophobic and hydrophilic barriers prevent 
drug penetration.34 
Conjunctiva Drugs absorbed into the conjunctiva are 
removed by systemic routes.23, 37 
Tear fluid Dilutes and drains drugs from the ocular 
surface27-29 
Eyelid Disperses and removes drugs from the ocular 
surface40 
 
 
2.1 Ocular drug delivery 
The eye is readily accessible to topical treatment, and thus local therapy is often preferred 
over systemic therapy to minimize side effects.42 Furthermore, the two blood barriers, the blood 
aqueous barrier (BAB) and the blood retinal barrier (BRB), present a significant hurdle for 
effective drug absorption via the systemic route.36, 42 Topical therapy also bypasses the hepatic 
first pass metabolism of drugs in the liver.37 In the ideal scenario, the administered drug from a 
topical dosing can treat the disease in a timely fashion with minimal side effects. For this to 
happen, drug penetration must be effective and exclusive to the targeted corneal tissue. However, 
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due to the ocular anatomy, in conjunction with mechanisms to remove unwanted substances from 
the ocular surface, drug penetration is very ineffective. The ocular residence time of a typical eye 
drop is less than 5 minutes.37 Consequently, it has been estimated that only between 1-7% of the 
drugs administered from an eye drop will reach the target tissue,40 while the remainder is cleared 
or absorbed into systemic circulation.43 To compensate for low residence time and poor drug 
penetration, the viscosity of the drop can be increased44 or frequent dosing can be employed. 
However, these strategies come at a cost to convenience, patient compliance30, 31 and side effects 
of drug overdosing.32 In order to effectively address the above problems, the ideal drug delivery 
vehicle must be able to ensure effective corneal penetration, while concurrently limiting drug 
loss. Furthermore, treatments for diseases should also preserve visual function in order to ensure 
acceptance by practitioner and patients.36, 45  
 
2.2 Eye drops and ophthalmic formulations 
The anterior structures of the eye are readily accessible, and thus eye drops are an 
obvious choice for the treatment of many ocular disorders. However, for many conditions, 
frequent dosing is necessary and patient compliance becomes a primary concern.30, 31 For 
instance, in the treatment of fungal keratitis, eye drops have to be instilled at hourly intervals 
over the course of several days to a week.46 Ophthalmic ointments can significantly improve the 
ocular residence time of a drug, as the increased viscosity of the ointment makes it more difficult 
for them to be removed from the ocular surface through tears and blinking.47 However, ointments 
are often associated with blurred or “smeary” vision,37 and their usefulness is typically limited to 
overnight applications.48 
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2.3 Anterior drug delivery approach 
Table 1-2 summarizes currently available drug delivery systems for the anterior eye.  
The first commercial drug delivery device for the anterior segment was introduced by 
Alza in 1974.49 The ocular insert, branded as Ocusert® pilocarpine, was designed to control 
intraocular pressure for the treatment of glaucoma by releasing pilocarpine over 7 days.23 The 
device consists of a layer of pilocarpine, sandwiched between two semipermeable ethylene vinyl 
acetate membranes. Drug release was continuous, in contrast to a pulsatile delivery, often 
observed with eye drops.20 One of the main disadvantages with the ocular insert was patient 
discomfort.49 As such, it was not recommended to wear the device for more than 12 hours.49 
Furthermore, it was difficult to insert and remove, and on occasions, would be expelled from the 
lid.38, 50 Over the decades, as the treatment for glaucoma shifted away from pilocarpine, the 
device became obsolete.  
 Ocusert® would later inspire the design for other ocular inserts. The Lacrisert® system, 
from Merck, is a rod-shaped device that is inserted in the conjunctival fornix, designed to release 
hydroxypropyl cellulose for the treatment of dry eyes for 24 hours.51 From clinical trials, patients 
preferred the use of Lacrisert® over frequent dosing with artificial tears.51 Another insert, from 
Bausch & Lomb (acquired by Valeant Pharmaceuticals), is the Minidisc Ophthalmic Therapeutic 
System designed to fit the shape of the superior or inferior sclera.49 In trials, it was able to release 
the antibiotics gentamicin and sulfisoxazole for more than 100 hours. It also was reported to be 
easier to insert and provide greater comfort than the Lacrisert®. Unfortunately, the device was 
never released commercially.49  
The next notable ocular surface drug delivery invention were collagen shields. These 
dissolvable shields, made from porcine sclera, were developed to be used as therapeutic 
bandages to treat damaged or scratched corneas. Studies were conducted to investigate if these 
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devices could deliver drugs such as antibiotics, anti-inflammatories, and anti-glaucoma drugs.52-
55 Unfortunately, while extensive work was conducted, no commercial product of this kind 
remains available.52-55  
 Another strategy to improve the residence time of drugs is the development of eye drops 
with mucoadhesive properties.56, 57 One example is Durasite® (Insite vision, California), a 
polycarbophil vehicle designed to interact with the ocular epithelium and mucin layer. The 
vehicle is well tolerated in patients.38 Azasite® (Inspire Pharmaceuticals, North Carolina) was 
the first formulation containing Durasite® released onto the market.38  
Since a major route of drug loss is through the nasolacrimal duct, the development of a 
punctal plug may improve residence time. Several studies have examined their effectiveness in 
the treatment of glaucoma,58, 59 allergic conjunctivitis and microbial infections.38, 60 While drug 
residence time is improved with these devices, their overall effectiveness in terms of delivery 
remains unclear.38 Furthermore, they have to be used with caution since they can cause excessive 
tearing due to them blocking tear drainage from the eye. 
The last route of drug delivery to the front of the eye worthy of discussion is through an 
injectable implant into the anterior chamber. One of these devices, Surodex™ (Allergan), is used 
to manage postoperative inflammation from cataract surgery. The biodegradable device is 
comprised of poly lacto-co-glycolide (PLGA), which can release anti-inflammatory 
dexamethasone for 7-10 days. However, from current clinical trials, the device does not seem to 
produce better clinical outcome than conventional topical anti-inflammatory therapy.35 
The use of CLs for ocular drug delivery can overcome several of the drawbacks 
associated with eye drops and previous ophthalmic drug delivery devices. The advantages of 
using CLs are that drugs are released directly to the cornea, while protected from corneal 
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removal mechanisms. Furthermore, CLs can be engineered to deliver drugs over extended time 
periods, which simplifies dosing regimens. 
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Table 1-2 Summary of commercially developed anterior segment drug delivery devices. This table has been adopted from Alex Hui’s 
thesis, with permission.61 
Device Manufacturer Composition Active agent (s) Release 
duration 
Treatment Design REF 
Ocusert® Alza Corp Ethylene vinyl acetate Pilocarpine 
7 days, 12h 
recommended 
wear time 
Primary open angle 
glaucoma 
Small disc placed 
in inferior cul-de-
sac 
a
49
 
Lacrisert® Merck Hydroxypropyl cellulose 
Hydroxypropyl 
cellulose 
1 day Dry eye 
Rod placed in 
upper or lower 
fornix 
a
51
 
Minidisc 
Ocular 
Therapeutic 
System 
Bausch & Lomb 
(Valeant) 
Polyhydroxymethylmethacrylate, 
hydroxypropyl cellulose, 
proprietary monomers 
Gentamicin and 
sulfisoxazole 
100-300 hours 
Prophylaxis against 
bacterial infections 
Miniaturized 
contact lens to fit 
sclera 
a
49
 
AzaSite® 
Inspire 
Pharmaceuticals 
Durasite®, polycarbophil vehicle Azithromycin 1 day 
Bacterial 
conjunctivitis 
Mucoadhesive 
eyedrop 
a
38
 
SurodexTM Allergan Poly-lacto-co-glycolide (PLGA) Dexamethasone 7-10 days 
Postoperative 
inflammation 
Injection into 
anterior chamber 
a
35
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3.1 Contact lenses 
The first documented concept of CLs belongs to Leonardo da Vinci, who approximately 
500 years ago, illustrated his ideas for using water to change the refractive power of the eye.62 
While there were many reiterations of his idea over the next centuries, it was not until 1888 that 
the first functional design of the CL in the form of scleral lenses was proposed.63 However, 
because these lenses were originally made from glass, they were uncomfortable and oxygen 
impermeable, and thus could not be worn for an extended period of time. The first breakthrough 
in material synthesis came in 1934 with the invention of polymethylmethacrylate (PMMA), an 
acrylate polymer with desirable optical properties and biocompatibility with the ocular surface.63, 
64 This material would later contribute to the successful development of rigid CLs.64 
In 1960, two Czech scientists, Otto Wichterle and Drahoslav Lím, revolutionized contact 
lens fitting with their introduction of the first soft CL material, poly(hydroxyethylmethacrylate) 
(pHEMA), a biocompatible hydrogel that could absorb and retain a significant amount of 
water.63, 65 Compared to rigid lenses made from PMMA, pHEMA lenses had significantly 
improved comfort.66 Wichterle described the fabrication of these lenses using a simple and 
efficient method of spin casting, and his patents would later be acquired by the National Patent 
Development Corporation in the United States in 1965, and subsequently commercialized by 
Bausch & Lomb in the early 1970s.63  
For the next few decades, pHEMA and its polymer derivatives enjoyed considerable 
success in the CL market. However, adverse symptoms associated with wearing these CLs began 
to emerge, in particular reduced oxygen permeability to the ocular surface.64, 66 Extended wear 
with these CLs would lead to hypoxia-related symptoms, including corneal edema,67 
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vascularization,67 inflammation,67 and increased susceptibility to ocular infections.68 The next era 
for CLs would aim to address these hypoxia-related problems.  
 
3.2 Silicone hydrogels 
The amount of oxygen that can be transported through pHEMA CLs are influenced by 
both lens thickness and the amount of water content within the lens.64 This latter factor poses a 
significant limitation in the amount of oxygen that these lenses can transmit to the ocular surface. 
One potential solution to the hypoxia dilemma is to use silicone-based lenses, which are well 
documented to be highly oxygen permeable.69-71 However, due to the hydrophobicity of silicone, 
these lenses have very low wettability and suffer from extensive deposition of hydrophobic tear 
film components.71 These problems result in considerable discomfort, which limits their 
commercial viability.  
 Thus, the question to solve this oxygen problem was how to incorporate silicone 
properties into CLs, to provide oxygen transmission, while still preserving the high water content 
of previous hydrogels for comfort.72 For many years, the chemistry behind this concept 
elucidated scientists, as it would be difficult to combine a hydrophobic component, such as 
silicone, with hydrophilic monomers. Conventional wisdom would predict that the combination 
of these two components would result in non-uniformity and phase separation, leading to a 
significant reduction in optical transparency of the final material.73 In addition, the overall 
architecture of the silicone hydrogel also had to be co-continuous to allow for proper ion flow 
and oxygen transmission throughout the lens.73 It was not until the late 1990s that these design 
problems would be successfully tackled, and the first generation of silicone hydrogels were 
finally introduced.  
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3.3 Generation of silicone hydrogels 
Bausch & Lomb and CIBA Vision were first to launch the first generation silicone 
hydrogels, PureVision (balafilcon A) and Focus Night and Day (lotrafilcon A) respectively. To 
mask the hydrophobicity of the silicone within their materials, the surfaces of these lenses were 
modified with plasma processes. PureVision lenses underwent a plasma oxidation process,72 
whereas Focus Night and Day lenses were coated with an even thin layer of plasma.72 These 
processes successfully improved surface wettability of the materials, but they were also costly 
and thus new alternative methods were explored. This eventually led to the development of the 
second generation silicone hydrogels such as Acuvue Oasys (senofilcon A) and Acuvue Advance 
(galyfilcon) from Johnson & Johnson. In contrast to previous surface treatment approaches, the 
wettability of these lenses were improved by incorporating an internal wetting agent, 
polyvinylpyrollidone.72 The third generation silicone hydrogels, Biofinity (comfilcon A) from 
CooperVision, addressed the wettability issue by incorporating silicone polymers which are 
inherently wettable.66 However, despite considerable efforts over the past decade to improve the 
wettability of silicone hydrogels, there have been little improvements in CL comfort. Thus, while 
silicone hydrogels have addressed problems associated with hypoxia, the problem of CL 
discomfort continues to challenge researchers and manufacturers in this field.  
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3.4 Contact lens manufacturing 
There are three primary techniques for creating CLs: lathe cutting, spin casting, and cast 
moulding. In lathe cutting, a solid cylindrical or round piece of material is mounted on a spinning 
shaft, and excess material is cut away from the front and back surface to produce the desired CL 
shape.74 This technique was initially used to make glass CLs. However, this practice is time 
consuming, and highly dependent on the machine operator, which can lead to high variability in 
lens production. With the introduction of liquid monomers as the starting materials, the 
technique of spin casting could be used to create CLs.75 In this method, the liquid mixture is 
placed into a mould corresponding to the front surface of the lens. As the mould is spun at the 
desired rotational speed, the centripetal force creates the desired shape for the posterior surface 
of the lens, and the mixture is subsequently polymerized to produce the lens.76 The final and 
most conventional method for creating CLs is cast moulding. In this process, the polymerization 
mixture is injected between two moulds corresponding to the front and back surface of the lens. 
The solution is then polymerized in a chamber to produce the CLs.76 
 
  
 16 
 
3.5 Lens chemistry 
Soft CLs are produced through a polymerization reaction of a monomer mixture. Many of 
the important lens properties, such as optical transparency,73 water content,73, 77, protein 
sorption,77 lipophilicity,73 oxygen permeability,73 porosity,73 and lens modulus73 are derived from 
the properties of the monomers in the mixture. For this reason, varying the ratios of the 
monomers within the mixture will result in different lens materials. For conventional hydrogel 
CLs, the base monomer is typically hydroxyethyl methacrylate (HEMA), shown in figure 1-2. 
This monomer, which was first introduced by Witcherle for the synthesis of CLs, produces 
desirable hydrogels with high water content and low modulus.65  
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Figure 1-3 chemical structure of A hydroxylethyl methacrylate (HEMA) B poly-hydroxylethyl 
methacrylate (pHEMA) C ethylene glycol dimethacrylate (EGDMA), a cross-linker. 
Polymerization reaction occurs at the double bond structure highlighted in red. 
 
N
CH2
O
OH
O
CH3
H2C
N
O
H2C CH3
CH3
OH
n
H2C
CH3
O
O
Si
O
O
O
SiMe3
SiMe3
SiMe3
A
B C D E
 
Figure 1-4 chemical structure of other base monomers used in hydrogels A 3-[tris-
(trimethylsiloxy)silyl] propyl methacrylate (TRIS) B -vinylpyrrolidone (NVP) C methacrylic 
acid (MAA) D dimethylacrylamide (DMAA) E poly-vinyl alcohol (PVA)73 
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As the CL industry evolved to produce materials with higher biocompatibility, new 
monomers were introduced (Figure 1-3). One important monomer, 3-[tris-(trimethylsiloxy)silyl] 
propyl methacrylate (TRIS), and similar silicone derivatives are responsible for the high oxygen 
permeability within the lens materials.73 However, the compatibility of TRIS with HEMA is 
poor, and thus more compatible hydrophilic monomers such as N-vinylpyrrolidone (NVP), 
methacrylic acid (MAA), dimethylacrylamide (DMAA) were introduced.73 The demand for high-
throughput, automated, and lower cost manufacturing also have placed pressures to produce new 
and better monomers. Among them is a daily disposable lens material, nelfilcon A, a poly-vinyl 
alcohol (PVA) based hydrogel.73 The demand to improve comfort continues to stimulate the 
research in developing new CL monomers. 
The typical monomer mixture will include the (1) base monomers, which provides the 
properties of the lens, (2) a cross-linker, which acts to form the polymer meshwork (3) and an 
initiator. The overall reaction schematic (Figure 1-4) begins with the activation of the initiator, 
which generates highly energetic free electrons. These free radicals subsequently react with the 
double bonds within the monomers, which in turn generates highly reactive species that react 
with other monomers. The result is a rapid polymerization process, as monomers are covalently 
linked together. This process continues until all the monomers have been exhausted or the free 
radical generation is stopped.  
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Figure 1-5 schematic for free radical polymerization of hydroxylethyl methacrylate (HEMA)  
 
Initiator activation can be accomplished by temperature control or light initiation. 
However, for heat initiated polymerization, the reaction is typically slower and produces variable 
and unreacted side chains.76 In contrast, light initiated photo-polymerization occurs rapidly, and 
the process can be stopped simply by modifying the amount of exposure to the light source.76  
 
3.6 Demographics 
CL wear has seen several changes over the last decades. Initially, CLs were used 
primarily to correct spherical refractive error, hyperopia, and myopia, but have extended to 
include correction for astigmatism and presbyopia.78 The prevalence for rigid CL wear has 
decreased.79 The prevalence for CL extended wear is also decreasing due to the associated 
complications such as microbial keratitis.80 Instead, there is an increasing trend towards 
prescribing daily disposable (DD) lenses.79, 81 These lenses, which are worn straight from the 
packaging and replaced daily, overcome the potential complications associated with extended 
wear. DD lenses also have included silicone hydrogels to provide adequate oxygen permeability, 
even on a daily wear basis.82 However, currently the lens cost for DD lenses is a significant 
factor affecting its widespread use.79  
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4.1 Prevalence of fungal keratitis 
Ocular fungal infections (mycoses), in particular that of the cornea (fungal keratitis), 
while an uncommon occurrence can lead to loss of vision and blindness.21, 22 In temperate 
regions such as the United Kingdom and Northern United States, the prevalence is typically 
low.83-85 However, in tropical regions, particularly South India, Ghana, and China, the prevalence 
of these infections is high.83, 86-90 In these countries, fungal keratitis is a major cause of vison 
loss.91, 92  
4.2 Etiology 
Fungal infections are caused primarily by fungal penetration through a compromised 
corneal epithelium, typically following corneal trauma with vegetable matter.93 There also have 
been numerous case reports of fungal keratitis associated with both therapeutic and daily soft CL 
wear.94-96 Topical steroids also have been implicated with ocular fungal growth.93, 97 In North 
America, the importance of fungal keratitis only became known following the worldwide 
outbreak of fungal keratitis, associated with a multipurpose contact lens solution (ReNu 
MoistureLoc), in 2006.98-100  
Filamentous fungi are the major etiologic agents causing fungal keratitis with Fusarium 
spp (species) being the primary agents, followed by Aspergillus spp.91, 93, 95, 97 Candida spp, 
although rare, can also cause fungal keratitis.101 These fungal agents, such as Fusarium spp, are 
common plant pathogens in corn crops or onion fields.102 
 
4.3 Clinical features and diagnosis 
 Fungal ulcers are typically described as dry and painless, with a tough raised surface.93, 
103, 104 In the early stages, the ulcers appear dendritic and inflammation is minimal compared to 
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microbial keratitis. Generally, there is an absence of lid edema. Fungal infiltrates are grayish- or 
yellowish-white, and produce a soft and creamy exudates at the base of the ulcer. 93, 103, 104 
 Laboratory diagnosis of fungal keratitis can be made through a variety of methods. 
Obtaining a sample of the ulcer from the cornea and then smearing it on a glass slide, followed 
by direct microscopic evaluation is the most common and rapid method for diagnosis. Stains 
such as the Giemsa stain, Gram stain, and potassium hydroxide are highly sensitive in detecting 
fungal elements.105, 106 Further diagnosis can be performed using fungal cultures, which are 
processed within 48 to 72 hours in blood agar or Sabouraud dextrose agar at room temperature 
(27ºC).83, 93, 97 The detection accuracy for fungal cultures depends on the severity of the infection 
and the criteria established for positive culture, but generally is very high.83, 93, 97 However, 
culture techniques are lengthy, requiring anywhere from 2 days to 2 weeks to obtain results. New 
diagnostic tools to evaluate fungal infections have been explored, notably polymerase chain 
reaction (PCR) and confocal microscopy. PCR assays only require 4 hours to generate results,107 
whereas confocal microscopy can be used to noninvasively image the infected cornea.108 
Unfortunately, these techniques are expensive and not readily accessible in areas where fungal 
keratitis is highly prevalent.  
 
4.4 Treatment 
Current therapies for fungal eye infection are inadequate, as many agents are only 
fungistatic, requiring a prolonged course of treatment. Fungi that affect the ocular system are 
rarely encountered among systemic mycoses, and thus therapeutic principles for systemic 
infections are not applicable to the cornea.109 
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Drugs to treat mycoses are generally found in two classes of antifungal agents, polyenes 
and azoles. However, only natamycin, a polyene antifungal, is commercially available and 
United States Food & Drug Administration (FDA)-approved for ocular treatment109-111 The 
treatment plan, depending on the severity of the infection, involves applying eye drops at hourly 
or two-hourly intervals for the first 48 hours. After this period, the frequency may be reduced, 
but treatment is continued for 6 weeks or until the infection is resolved.46 The dosing regimen for 
fungal keratitis is considered very taxing, and patients are often hospitalized to ensure 
compliance. In cases where topical treatments are ineffective, keratoplasty, or corneal surgery to 
remove the infected tissue can be employed.112-114 
 
4.5 Fungal agents 
4.5.1 Natamycin (Polyene) 
In North America, natamycin (pimaricin) is currently the only FDA-approved antifungal 
for topical ocular administration, formulated as a 5% ophthalmic suspension.109-111, 115 It is 
classified as a polyene antifungal, and similar to other polyenes, has a broad inhibition spectrum 
against fungi such as Fusarium, Aspergillus, and Candida.111, 116 The drug binds to ergosterol, a 
sterol found only in fungal cytoplasmic membranes, and consequently inhibits the functional 
effects of ergosterol.116, 117 In many countries, natamycin is the favored drug to treat mycotic 
keratitis.111, 118-120 However, the availability of natamycin is sporadic, and thus the drug is 
expensive compared to other antifungals. Furthermore, natamycin is insoluble in water (30-50 
mg/L)121 and alcohols, and sensitive to ultraviolet degradation.122  
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4.5.2 Fluconazole, Econazole, Miconazole (Azoles) 
The azole class of antifungals are fungistatic at low drug concentrations, and only 
become fungicidal at higher concentrations.123 Their mechanism of action occurs via inhibition 
of 14-α-demethylase, a pivotal enzyme in the ergosterol synthesis pathway.115 While the majority 
of azoles are hydrophobic,115 the development of new azoles in the 1980s have yielded more 
hydrophilic drugs.115 Fluconazole is one of the new generation azoles, and it is a stable, low 
molecular weight, hydrophilic drug. Other attractive properties of fluconazole include high 
bioavailability and low toxicity, while maintaining a broad inhibition spectrum against fungi. 
However, it has not been FDA approved, but has been proposed to be an ideal candidate to treat 
ocular mycoses.115 Several studies have examined the delivery of fluconazole from CLs.124, 125 
Two other azoles, econazole and miconazole, also have been investigated with CL materials.126  
 
4.5.3 Terbinafine, Natifine (Allylamines)  
 Unlike polyenes and azoles, clinical uses for allylamines are less common. Two of these 
antifungals, terbinafine and naftifine, have broad range inhibition against yeast and 
dermatophytes, and are well tolerated.115 Terbinafine inhibits fungal growth by binding to fungal 
squale oxidase, which prevents the biosynthesis of ergosterol.127 Naftifine functions in a similar 
manner, but also exhibits anti-inflammatory properties.115 There have been some published 
studies examining the release of allylamines from hydrogels, but their applications for the eye 
have not been explored.128, 129 
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Figure 1-6 Structure of representative antifungal compounds.130 Adopted from Phan et al with 
permissions3 
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5.1 CLs for ocular drug delivery 
The idea of using CLs for ocular drug delivery is not new, and has been proposed in the 
1960s by the inventor of modern day soft CLs, Otto Wichterle.65, 131 Unfortunately, there were 
too many complications associated with early materials, in particular inadequate oxygen 
transmission to the cornea. The resulting hypoxia-related complications, especially during 
overnight wear, limited the long term therapeutic potential of CLs.132, 133 It was not until several 
decades later that this issue was resolved with the introduction of oxygen permeable silicone 
hydrogel (SH) CLs in the 1990s. These new lenses, which overcame the significant hypoxic 
hurdle, re-kindled the interest in developing CLs to deliver drugs.  
The use of CLs for ocular drug delivery can overcome several of the ocular barriers that 
limit effective drug absorption and penetration. When a CL is placed on the cornea, it separates 
the natural tear film into the pre- and post-lens tear compartment. Several studies suggest that the 
post-lens compartment has limited tear mixing and exchange.134-136 Consequently, drugs released 
into this compartment from the CL should have prolonged contact with the cornea, resulting in 
higher bioavailability.137, 138 Furthermore, CLs can be engineered to deliver drugs over extended 
periods of time, which significantly simplifies the dosing requirements. For ocular infections 
where frequent applications are necessitated,46 this improvement can drastically enhance the 
treatment regimen.  
In developing CLs for ocular drug delivery, the focus has been on extending the release 
duration of drugs from CLs. The most basic method, simple drug loading via incubating a 
commercial CL in a pharmaceutical preparation, often results in rapid drug release, which may 
not be clinically useful.124, 139 Consequently, various strategies to develop novel CL materials 
have been explored including molecular imprinting,140 vitamin E coatings124 and encapsulation 
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using nanoparticles.141, 142 In vitro studies with these materials have shown that they are capable 
of releasing ophthalmic drugs up to several days.124, 140, 142  
5.2 Commercial contact lenses to deliver antifungals 
 The development of an antifungal contact lens could significantly improve the treatment 
process for fungal keratitis. There only have been a limited number of antifungal drugs that have 
been reported for drug delivery with CLs. The following section, adapted from our previous 
published review paper,3 overviews various approaches to modify CLs for antifungal ocular drug 
delivery. The goal in developing these lenses is to form specific polymer-drug interactions to 
increase the amount of drugs that can be loaded on the lenses, and to extend the drug release 
duration. These strategies are summarized in table 1-3. 
Several commercial CLs, such as alphafilcon A (Bausch+Lomb), balafilcon A 
(Bausch+Lomb), etafilcon A (Johnson & Johnson), and lotrafilcon A (Alcon) are FDA approved 
for use as bandage lenses in corneal wound healing.143-148 To reduce infections, antibiotics and 
anti-inflammatory drugs are often administered with these lenses.149 This has sparked the idea of 
using commercial CLs as a vehicle to deliver drugs to the eye.143 
 Several studies have examined the ability of commercial CLs to deliver drugs to the 
eye,149-152 but studies specifically examining release of antifungals are limited.124 In one study by 
Peng et al, the uptake and release of fluconazole was examined from several commercial 
lenses.124 These lenses were soaked with fluconazole dissolved either in PBS or methanol. 
However, the method of loading did not affect the release of the drugs from the CLs, which 
occurred within 1-10h.124 According to this study, commercial CLs are not ideal for extended 
drug delivery.  
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 The effectiveness of drug uptake and release from a CL has been linked to the material 
properties of the lens.149 It has been theorized that if the CL cannot form sufficient interactions 
with the drug, then release occurs rapidly. For hydrophobic drugs, drugs can also bind 
irreversibly to the lens polymer.149 These drugs will favor partitioning in the lens polymer rather 
than the surrounding aqueous media. In contrast, hydrophilic drugs will partition higher in the 
release media, resulting in rapid drug release from the CLs.124, 149, 150, 152, 153  
 
5.3 Commercial contact lenses with Vitamin E coating 
 A simple method of extending drug release from commercial CLs has been proposed by 
Peng et al.124 Their approach was to create diffusion barriers within the lens, accomplished by 
pre-soaking the CLs in vitamin E.124 The rationale behind using vitamin E over other similar 
agents is unclear, besides the fact that ‘it works’ and vitamin E is non-toxic. The amount of 
vitamin E that can be sorbed is dependent on the CL material.124 When these Vitamin E-coated 
lenses were loaded with fluconazole, they could maintain the drug release duration up to one 
week.124 Vitamin E coating did reduce ion permeability and oxygen permeability of the lenses, 
but the authors suggested that these reductions were within acceptable limits. Vitamin E did not 
leach from the CLs under storage conditions. This method has been applied to other drugs,4, 124, 
154, 155 and also has shown high efficacy in animal studies.4  
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Figure 1-7 Strategies to modify contact lens materials for antifungal drug delivery 
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Table 1-3 Strategies to deliver antifungal drugs from contact lens materials. Adopted from Phan et al with permissions3 
 
Method Antifungal Drugs Release Duration Advantages Disadvantages 
 
 
Drug soaking with 
commercial CLs 
 
 
fluconazole124 
 
1-10 hours (h)124  
 
convenience,  
easy to use 
 
burst release 
Vitamin E coating fluconazole124 7 days (d)124  convenience,  
easy to use, 
extended release, compatibility with a 
wide range of drugs 
 
cannot increase total drug release 
Impregnated drug 
film 
 
econazole142 21 d142 extended release cannot be used with UV-sensitive 
drugs 
Cyclodextrin 
hydrogel 
miconazole,
126 
naftifine129 and 
terbinafine129 
8h129 - 7 d
126
 increased drug loading, 
extended release, 
compatibility with a wide range of drugs 
 
drugs in this studies are not FDA-
approved for ocular administration 
Polyelectrolytes 
hydrogel 
terbinafine 
hydrochloride
128
 
< 12 h
128
 release can be controlled using pH can only be used with ionizable 
drugs, 
pH sensitive,  
prone to protein deposition 
 
Molecular 
imprinting 
fluconazole 1-5 d
125
 extended release, compatibility with a 
wide range of drugs 
only compatible with one target drug 
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5.4 Drug-embedded hydrogels 
 One straightforward approach, provided the drugs are stable to the polymerization 
methods, is to incorporate the drugs within the polymer mixture before polymerization.142, 156, 157 
After polymerization by ultraviolet 
 (UV) irradiation, the drugs are entrapped within the matrix of the hydrogel, and the release of 
the drug is significantly extended.142, 156, 157 In a study by Ciolino et al, a poly(lactic-co-glycolic) 
acid (PLGA) film containing econazole was polymerized between two sheets of pHEMA 
hydrogel.142 The efficacy of the lens was tested against Candida albicans and was shown to 
release enough drug to inhibit the growth of the fungi for up to 21 days in vitro. Not surprisingly, 
the potency of the material was dependent on the amount of econazole loaded on the lens.142 
There are two major drawbacks to this approach. The first is that PLGA-econazole films are 
opaque.142 To achieve optical transparency appropriate for CLs, the center of the material was 
kept drug free. The second drawback is PLGA is biodegradable when stored in solution.142 As a 
result, the drug film continuously degraded while in storage.  
 
5.5 Cyclodextrin hydrogels 
In the pharmaceutical field, cyclodextrins (CD), due to their ability to form complexes 
with a range of drugs, have been employed in a variety of drug delivery applications.158 This 
versatility is attributed to their unique structure, consisting of a hydrophilic shell and a lipophilic 
central cavity.158 The cavity can host a hydrophobic agent, while the entire CD dissolves readily 
in solution. They have been shown to increase solubility,159 bioavailability,159 and stability159 of a 
wide range of drugs, including antifungals.160-163 CDs have been polymerized with various 
hydrogels to produce materials with improved drug uptake and release profiles.126, 129, 164-168 
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Studies with HEMA-based hydrogels containing α-,β-, and γ-CDs with miconazole show that 
these hydrogels could release drugs for 1 week.126 In vitro, these gels inhibited the biofilm 
formation of Candida albicans.126 In another study, the release of naftifine and terbinafine from 
β-CD hydrogels were observed for 8 hours.129  
 
5.6 Polyelectrolyte hydrogels 
 For the release of charged drugs, poly-electrolytes polymers can be employed to increase 
material-drug interactions. These polymers contain a large number of ionizable functional 
groups, which allow them to interact strongly with oppositely charged drugs. Furthermore, the 
high sensitivity of these hydrogels to changes in pH could be exploited for controlled release.128 
In a study with poly(N-vinyl 2-pyrrolidone/itaconic acid) hydrogels, terbinafine hydrochloride 
could be absorbed and released from these hydrogels in a controlled manner over 12 hours.128 
One potential drawback of using these types of hydrogels on the eye is that these materials would 
accumulate significant amounts of tear components.169 
 
5.7 Molecularly imprinted hydrogels 
 The idea behind molecular imprinting is to use molecular templates to create specific 
sites within the polymer matrix that can recognize the target drug.170 This concept has been filed 
in a 2008 patent, which outlines the synthesis of a biomimetic contact lens designed to release a 
wide range of antifungals (azoles, polenes, and allylamines) for large animals.125 The templates, 
typically the target drug or a compound structurally similar to the drug, are polymerized with 
monomers capable of interacting with the target drug. These monomers can include n-vinyl 
pyrrolidone (NVP), hydroxyethyl methacrylate (HEMA), diethylaminoethyl methacrylate 
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(DEAM), acrylamide (AM), and polyethylene glycol dimethacrylate (PEGDMA).125 The one 
apparent limitation of this approach is that each biomimetic material is only attuned to its target 
drug.  
 
6.1 In vitro models to evaluate CL drug delivery 
In the past, the demands for sophisticated in vitro eye models were low, and extremely 
simple, static volume, vial-based models were adequate for many research purposes. The current 
standard for in vitro eye models for evaluating CL drug delivery default to using vial-based 
assessments.2, 124, 152, 171 Unfortunately, the volume of fluid in a vial greatly exceeds 
physiological amounts; thus it should not be surprising that these studies report rapid drug 
release kinetics.2, 124, 152, 171 Furthermore, the simple vial model lacks a natural tear flow 
component and blinking mechanism to expose the material to the atmosphere. These parameters 
are defining factors of the ocular environment, and will significantly affect the behavior of the 
CL material on the eye.  
The recognition for better in vitro eye models have been acknowledged by research groups 
across the world. Attempts have been made towards developing models to simulate ocular 
parameters such as microfluidic tear flow,172-177 intermittent air exposure,178 and in vitro 
spoilation.179 Not surprisingly, the results generated from these experiments are considerably 
different than those obtained with the conventional vial model, and may more closely resemble 
in vivo data.172-179 As the CL drug delivery field advances further in the near future, better in 
vitro eye models will be necessary to properly assess how these devices will perform on the eye.  
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7.1 Conclusion 
The anatomical structures of the eye present numerous barriers to ocular drug delivery, many of 
which can be addressed with a CL drug delivery device. The main challenge in developing a CL 
suitable for ocular drug delivery is to engineer materials capable of sustained drug release over 
several days. Currently, in vitro models to test CLs are limited, and better models may be 
necessary to give a better representation of on-eye performance. The successful development of a 
CL device for ocular mycoses, a potentially blinding infection, will be invaluable not only in 
improving fungal therapy, but also pushing the ocular drug delivery field forward.  
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Chapter 2 – Rationale and objectives 
Topical eye drops, due to their ease of dosing, accessibility and cost,1 account for 90% of 
all ophthalmic formulations.1-4 However, the anatomy of the eye, in fulfilling its role to ‘keep 
out’ foreign substances, prevents the effective delivery of drugs to the affected ocular tissue. 
Continuous tear dilution,5-7 dispersion and drainage during blinking and tear flow, 5, 7, 8 non-
specific absorption,1, 5, 7 and variable drug penetration4 limits effective drug bioavailability to 
only 1-7% at the target site.8 The remaining dose either spills over onto the cheek, drained 
through nasolacrimal duct or is absorbed into the systemic circulation.9 Consequently, to achieve 
therapeutic drug concentration, multiple dosing over extended periods is often required. This, in 
turn, exacerbates problems with patient compliance10, 11 and the side effects of drug overdose.12  
In recent years, new applications for contact lenses (CLs) have been explored, including 
their use for ocular drug delivery. In the past, CLs have been used as bandage lenses for 
managing pain, and promoting re-epithelialization in ocular post-surgery or ocular trauma.13-19 
Typically, to prevent microbial infections, antibiotics and anti-inflammatory drugs are 
administered concurrently during lens insertion.13, 20 This clinical practice resulted in an interest 
in whether it was feasible to specifically design a CL with drug delivering therapeutic properties. 
The initial concept of using CLs for ocular drug delivery was suggested as early as 1960,21, 22 but 
at that time (and for several decades later), long term wear with CL without hypoxic compromise 
was not possible.23, 24 It was not until hypoxic problems were solved with the commercialization 
of silicone hydrogel (SH) materials in the late 1990s, that the safe use of CL for long-term 
medical applications became a real possibility.25, 26 An ophthalmic survey in the United States and 
Canada suggested that such a concept would be well received by practitioners.13 
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There are two apparent advantages of using CLs to deliver drugs. The first stems from the 
physical placement of the CL on the cornea, which effectively separates the natural tear film into 
pre- and a post-lens (between the lens and cornea) compartments. The physical CL barrier limits 
tear mixing and exchange in the post-lens tear film,27, 28 as well as shielding this layer from the 
blinking reflex. Consequently, it has been proposed that a drug released from a CL into this post-
lens area has prolonged contact time with the cornea.29 Mathematical model simulations for drug 
delivery with a CL predicts that approximately 50% of the drugs released from a CL can diffuse 
into the cornea, making it 35 times more efficient than a conventional eye drop.30 The second 
advantage of using a CL for drug delivery is the intrinsic ability of any hydrogel material to 
absorb and release molecules. Thus, in theory, CLs can serve a drug reservoir to release drugs 
over an extended period of time at a slow and sustained rate. For microbial keratitis, where 
frequent eye-drop dosing is often necessary, the design of a slow drug releasing CL device would 
eliminate the need for multiple dosing and simplify the treatment therapy.31  
 Amongst ocular infections, fungal keratitis is a major cause of vision loss and blindness 
throughout the world.32, 33 However, since these infections occur predominantly in India and 
China,34-39 their impact has been minimal in North America. While several case reports of fungal 
keratitis associated with CL wear exist,40-42 it was not until a severe outbreak of fungal eye 
infections associated with a multipurpose solution (Renu MoistureLoc) occurred in 2006 that 
significant interest in this area arose. 43-45 Currently, treatment for fungal infections remains 
inadequate, and only one antifungal (natamycin) is United States Food & Drug Administration 
(FDA) approved for topical application.46-48 The treatment regimen is intensive, requiring dosing 
at 1-2 hour intervals for two weeks.31 Thus, there is a definite demand for a better method of 
treatment for fungal keratitis.  
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 One of the major road blocks to progress in the CL drug delivery field is the limited 
number of in vivo studies to support the effectiveness of this delivery platform. Currently, there 
only have been three published animal studies to validate this claim.49-51 On the in vitro side, 
models to simulate the cornea are also substantially lacking. For instance, the majority of in vitro 
studies to measure drug release from CLs have used a fixed volume vial model, containing a 
certain amount of fluid, as the accepted standard.51-54 However, not only does this model contain 
too much fluid to properly simulate the tear film, it also lacks both the natural tear flow 
component and the blinking reflex, both of which are defining factors of the ocular environment. 
Thus, it is very difficult - and potentially erroneous - to use the data generated from these in vitro 
studies to predict the in vivo outcomes of these medical devices.  
In recent years, researchers have recognized the limitations of using a fixed volume, 
static fluid vial model as a method of evaluating drug delivering CLs. Subsequently, to better 
simulate the ocular environment, several unique in vitro eye models have been developed to 
simulate different on-eye parameters, such as microfluidic tear flow,55-60 intermittent air 
exposure,61 or deposition of lipid tear film components.62 Not surprisingly, the results generated 
from these experiments are significantly different than those obtained with the conventional vial 
model, and may more closely resemble in vivo data.55-62 However, the number of parameters 
emulated on these models are still limited, and while many models have been proposed, no 
model has been accepted as a “gold standard”. Thus, the development of a physiologically 
relevant eye model to test the performance of drug delivering CLs will be invaluable in 
progressing this technology towards a viable commercial product. 
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In summary, to advance the CL drug delivery technology, it is important to develop new 
materials as well as a sophisticated in vitro eye model to test these materials. For these reasons, 
there are two main aims to this thesis:  
 
a) The first objective is to investigate the potential for a CL to function as a drug delivery device 
for a commercially available antifungal (natamycin). To this end, chapter 3 sets the foundation 
for subsequent experiments, by evaluating the in vitro uptake and release of natamycin from 
several commercially available CLs. To improve the release characteristics of natamycin from 
CLs, chapter 4 details an attempt to incorporate novel drug-encapsulated nanoparticles within the 
CLs. In chapter 5, an alternative strategy employing the incorporation of cyclodextrin molecules 
within the CL polymer matrix was evaluated as a potential modification to prolong the release of 
natamycin.  
 
b) The second objective is to develop a sophisticated in vitro ocular model capable of adequately 
measuring drug release from CLs. Chapter 6 outlines the design of a novel in vitro eye model to 
simulate the physiological ocular environment. In chapter 7, the release of the antifungal 
fluconazole from commercially daily disposable CLs was explored using this model. In chapter 
8, as an extension of the developed in vitro eye model, an agar eye piece was developed to test 
the effects of natamycin and fluconazole releasing CLs on Candida albicans.  
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3.1 Overview 
3.1.1 Objective 
To investigate the uptake and release of the antifungal ocular drug, natamycin, from 
commercially available conventional hydrogel (CH) and silicone hydrogel (SH) contact lens 
(CL) materials and to evaluate the effectiveness of this delivery method.  
3.1.2 Methods 
Five commercial SH contact lenses (balafilcon A, comfilcon A, galyfilcon A, senofilcon A, 
lotrafilcon B) and four CH contact lenses (etafilcon A, omafilcon A, polymacon, vifilcon A) 
were examined in this study. These lenses were incubated with natamycin solubilized in DMSO, 
and the release of the drug from these lenses, in Unisol 4 pH 7.4 at 32±1oC, was determined 
using UV-Visible spectrophotometry at 305 nm over 24 hours.  
3.1.3 Results 
There was a significant uptake of natamycin between 0 hour and 24 hours (p<0.05) for all CL 
materials. However, there was no significant difference between any of the lens materials, 
regardless of their composition (p >0.05). There was a significant difference in release between 
all the SH materials (p<0.05) and between all CH materials (p<0.05). All CL materials had a 
significant increase in the release of natamycin until 1 hour (p<0.05), which was followed by a 
plateau (p>0.05). Overall, the release of natamycin was higher in CH than SH lenses (p<0.001).  
3.1.4 Conclusions 
All CLs released clinically relevant concentrations of natamycin within 30 minutes, but this 
release reached a plateau after approximately one hour. Further CL material development will be 
necessary to produce a slow and sustained drug releasing device for the delivery of natamycin. 
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3.2 Introduction 
Ocular fungal infections, in particular fungal keratitis, while an uncommon occurrence 
can lead to vision loss and blindness.1, 2 These infections are caused by fungal penetration of a 
compromised corneal epithelium, typically following corneal trauma with vegetable matter.3 
While the prevalence of fungal keratitis is relatively high in tropical regions such as South India, 
Ghana, and China,4-9 it is generally much lower in temperate regions such as the United 
Kingdom and the Northern United States.4, 10, 11 However, there have been numerous case reports 
of fungal keratitis associated with both therapeutic and daily soft contact lens wear.12-14 
Furthermore, the worldwide outbreak of ocular fungal infections in 2006 associated with the 
multipurpose contact lens solution ReNu MoistureLoc demonstrated that there is a substantial 
need for further research in the management of ocular fungal infections.15-17  
Currently available antifungal treatments often fail to restore vision to its original level 
following an ocular infection.18, 19 Common topical ophthalmic antifungal formulations suffer 
from low drug bioavailability as they are drained out through the naso-lacrimal duct.20 Multiple 
dosing is therefore required, and patients often are hospitalized to ensure treatment compliance. 
Thus, the development of a slow-release antifungal drug-delivery device that would provide 
adequate drug concentration over extended periods of time would be a valuable addition to the 
options for treating ocular surface infections. 
Contact lenses have been suggested for use as ocular drug delivery devices since 1960, 21, 
22 but long-term wear complications with low oxygen permeability conventional hydrogel (CH) 
soft contact lenses have made them undesirable for medical use.23, 24 During overnight or 
“extended” wear these contact lenses are unable to transmit adequate oxygen to the cornea to 
maintain normal metabolic activities, for the majority of wearers.23, 24 The introduction of highly 
oxygen permeable silicone hydrogel (SH) lenses a decade ago has made hypoxic-free overnight 
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wear possible,25, 26 and the use of contact lenses as medical devices has become increasingly 
popular.27, 28 Several researchers have already developed model contact lens materials for use as 
drug delivery devices, but no commercial products are yet available.29-33 
The only commercially available and FDA-approved ocular antifungal is natamycin 
(pimaricin).19, 34, 35 It is a macrolide polyene antifungal with a fairly broad inhibition spectrum 
against various infectious fungi, including Fusarium, Aspergillus, and Candida.19, 36 Natamycin 
elicits its inhibition by binding to ergosterol, a sterol unique to fungal cytoplasmic membranes, 
which consequently inhibits ergosterol from performing its functional effects.36, 37 The drug has 
poor water solubility at physiological pH, and therefore is prescribed as a 5% ophthalmic 
suspension (Alcon, Fort Worth, TX). The suspension is instilled in the conjunctival sac, and is 
generally well tolerated.38 
The kinetics of drug delivery from modern CH and SH contact lens materials is not yet 
well understood. Several publications have investigated the uptake and release of topical 
ophthalmic drugs from commercial contact lens materials, 39-42 but to our knowledge no such 
work has been undertaken with antifungal drugs. Thus, the purpose of the current study was to 
investigate the in vitro uptake and release of natamycin from five commercially available SH and 
four CH contact lens materials and to evaluate their potential use as antifungal ocular drug 
delivery devices.  
3.3 Materials and methods 
3.3.1 Contact lens materials 
Five commercially available SH contact lens materials [balafilcon A (PureVision, Bausch 
& Lomb, Rochester, NY), comfilcon A (Biofinity, CooperVision, Pleasanton, CA), galyfilcon A 
(Acuvue Advance, Johnson & Johnson, Jacksonville, FL), lotrafilcon B (Air Optix, CIBA 
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Vision, Duluth, GA), and senofilcon A (Acuvue OASYS, Johnson & Johnson)], and four CH 
lens materials (etafilcon A [Acuvue 2, Johnson & Johnson], omafilcon A [Proclear, 
CooperVision], vifilcon A [Focus Monthly, CIBA Vision] and polymacon [SofLens 38, Bausch 
& Lomb]) were evaluated in the study. All lenses had a dioptric power of -3.00 and base curve of 
8.6mm, obtained from the manufacturer in the original packaging. Table 3-1 and Table 3-2 
details the properties of the SH and CH contact lenses respectively. 
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Table 3-1 Properties of silicone hydrogels used in the study57,58 
 PureVisionTM Biofinity Acuvue 
OASYSTM 
Air 
OptixTM 
Acuvue 
AdvanceTM 
United States 
adopted name 
(USAN) 
balafilcon A comfilcon A senofilcon 
A 
lotrafilcon 
B 
galyfilcon 
A 
Manufacturer Bausch & 
Lomb 
CooperVision Johnson & 
Johnson 
CIBA 
Vision 
Johnson & 
Johnson 
Centre 
thickness (mm) 
0.09 0.08 0.07 0.08 0.07 
Water content 
(%) 
36 48 38 33 47 
Oxygen 
permeability (x 
10-11) 
91 128 103 110 60 
Oxygen 
Transmissibility 
(x 10-9)  
101 160 147 138 86 
FDA group III I I I I 
Surface 
treatment 
Plasma 
oxidation 
process 
None No surface 
treatment. 
Internal 
wetting 
agent 
(PVP) 
25 nm 
plasma 
coating 
with high 
refractive 
index 
No surface 
treatment. 
Internal 
wetting 
agent 
(PVP) 
Principal 
monomers 
NVP + 
TPVC + 
NVA + 
PBVC 
FM0411M + 
HOB + IBM 
+ M3U + 
NVP + TAIC 
+ VMA 
mPDMS + 
DMAA + 
HEMA + 
siloxane 
macromer 
+ 
TEGDMA 
+ PVP 
DMA + 
TRIS + 
siloxane 
macromer 
 
mPDMS + 
DMAA + 
EGDMA 
HEMA + 
siloxane 
macromer 
+ PVP 
DMAA, N,N-dimethylacrylamide; EGDMA, ethyleneglycol dimethacrylate; FM0411M, -
Methacryloyloxyethyl imninocarboxyethyloxypropylpoly(dimethylsiloxy)-butyldimethylsilane; 
HEMA, hydroxyethyl methacrylate; HOB, 2-hydroxybutyl methacrylate; IBM, isobornyl 
methacrylate; MA, methacrylic acid; mPDMS, monofunctional polydimethylsiloxane; NVP, N-
vinyl pyrrolidone; TEGDMA, tetraethyleneglycol dimethacrylate; TPVC, tris-
(trimethylsiloxysilyl) propylvineyl carbamate; TRIS, trimethylsiloxy silane; M3U,  -
bis(methacryloyloxyethyliminocarboxy ethyloxypropyl)-poly(dimethylsiloxane)-
poly(trifluoropropylmethylsiloxane)-poly(-methoxy-poly(ethyleneglycol)propyl 
methylsiloxane); NVA – N-vinyl amino acid; PBVC, poly(dimethysiloxy) di(silylbutanol) 
bis(vineyl carbamate); PC, phosphorylcholine; PVP, polyvinyl pyrrolidone; TAIC, 1,3,5-triallyl-
1,3,5-triazine-2,4,6(1H,3H,5H)-trione; VMA, N-vinyl-N-methylacetamide. 
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Table 3-2 Properties of conventional hydrogels used in the study57,58 
 SofLens38 
(Formerly 
Optima FW) 
Proclear Acuvue 2 Focus 
Monthly 
United States 
adopted 
name 
(USAN) 
polymacon omafilcon A etafilcon A vifilcon A 
Manufacturer Bausch & 
Lomb 
CooperVision Johnson & 
Johnson 
CIBA Vision 
Water 
content (%) 
38 62 58 55 
Oxygen 
permeability 
(x 10-11) 
10 27 22 16 
FDA group I II IV IV 
Surface 
treatment 
None None None None 
Principal 
monomers 
pHEMA pHEMA + PC pHEMA + MA pHEMA + 
PVP + MA 
pHEMA, poly(2-hydroxethyl methacrylate); MA, methacrylic acid; NVP, N-vinyl pyrrolidone; 
PC, phosphorylcholine; PVP, poly(vinyl pyrrolidone). 
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3.3.2 Preparation of the drug solution 
Ophthalmic natamycin eye drops are formulated as a 5% (w/v) suspension in sterile 
water. The solubility of natamycin in water at physiological pH is 30-50 mg/L,43 which is low for 
the purpose of the study. Natamycin is soluble in dimethyl sulfoxide (DMSO) at concentrations 
up to 3.2 mg/mL.44 A stock solution of natamycin (EMD Millipore, Billerica, MA, USA) was 
completely solubilized in a solution of DMSO (Sigma Aldrich, Oakville, ON) at a concentration 
of 2.6 mg/mL. The experiments and storage of natamycin were performed using amber vials. 
 
3.3.3 Spectrophotometric determination of natamycin 
The absorbance spectra of natamycin was determined using a SpectraMax M5 UV-Vis 
Spectrophotometer (Molecular Devices, Sunnyvale, CA) between 250 to 400nm at 34oC using a 
4 mL-disposable methacrylate cuvettes (Fischer Scientific, Ottawa, ON). The spectra had an 
absorption maxima corresponding to the 305 nm wavelength, which is similar to values reported 
in the literature.45 Thus, 305 nm was the wavelength used to detect Natamycin in this study.  
 
3.3.4 Determination of natamycin concentration-standard curve 
The stock solution of natamycin was diluted to a range between 1.56 µg/mL to 25.00 
µg/mL in an unpreserved saline solution (Unisol 4, Alcon Labs Ltd, Fort Worth, Texas) and in 
DMSO, to generate a linear calibration curve to correlate absorbance readings to natamycin 
concentrations.  
 
3.3.5 Uptake studies 
Three lenses of each type were removed from their original packaging and placed in 5mL 
of Unisol 4 in a 12-well clear plate (VWR International, Mississauga, Ontario) and gently shaken 
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for 24 hours (h) at room temperature, to remove any packaging solution. The lenses were then 
pre-treated with 2.5mL of DMSO in a 12-well clear plate for 24 hours at room temperature. The 
lenses were removed from the DMSO solution and blot dried on lens paper before being 
transferred into an amber vial (Wheaton, Millville, New Jersey) containing 2 mL of 2.6 mg/mL 
natamycin in DMSO. The vial was incubated between 32±1oC with constant rotation over 24 h to 
simulate eye conditions.46 At specified time intervals (t = 0 min, 1 min, 5 min, 15 min, 30 min, 1 
h, 2 h, 4 h, 8 h, 16 h, 24 h), 5 µL of the solution was removed and diluted 400 fold to obtain a 
reading within the linear range of the standard curve. 
 
3.3.6 Release studies 
After the 24 hour uptake period, lenses were removed from the natamycin solution and 
briefly rinsed with DMSO to remove any residual drug solution not sorbed onto the lens. The 
lenses were then partially dried on lens paper and placed into an amber vial containing fresh 5 
mL solution of Unisol 4 (pH 7.4) for SH contact lens materials. CH lens materials were placed in 
an 8 mL solution of Unisol 4. Preliminary release studies (not shown) determined the adequate 
volume of Unisol 4 needed to obtain natamycin release concentrations within the linear ranges of 
the standard curve. The vial was incubated at 32±1oC with constant rotation over 24 h to 
simulate eye conditions. At specified time intervals (t = 0 min, 1 min, 5 min, 15 min, 30 min, 1 h, 
2 h, 4 h , 8 h, 16 h, 24 h), 2 mL of the release solution was removed and measured with 
spectrophotometry, and then carefully pipetted back into the vial. After the 24 h release period, 
the lenses were incubated in fresh release solution; the release of natamycin from the lenses was 
monitored for an additional 24 h.  
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3.3.7 Metrology studies 
Metrology measurements using Chiltern Optimec Soft Contact Lens Analyzer 
(Malvern, UK) were performed for CH contact lenses, which increased in size following their 
pre-treatment with DMSO. No such diameter changes were seen with the SH lenses.  
 
3.3.8 Statistical analysis 
Statistical analysis was performed using Statistica 8 software (StatSoft, Tulsa, OK). All 
data are reported as mean ± standard deviation, unless otherwise stated. All calculations took into 
account volume change associated with sampling. Two repeated measures of analysis of variance 
were performed to determine the differences across various time points within the same lens 
type, and the differences between lens types. Post-hoc Tukey’s multiple comparison tests were 
used when necessary. In all cases, statistical significance was considered significant for p value 
of < 0.05. Graphs were plotted using GraphPad Prism 5 software (GraphPad, La Jolla, CA).  
 
3.4 Results 
The uptake curves over 24 hours for the five SH contact lenses are shown in Figure 3-1, 
and the uptake curves for the four CH contact lenses are shown in Figure 3-2. The quantity of 
natamycin uptake (µg/lens) from all contact lens types is summarized in Table 3-3. Figures 3-1 
and 3-2 show that there was significant increase in the uptake of natamycin between 0 hour and 
24 hours (p<0.05) for both SH and CH lens materials, however, there was no significant 
difference between any SH and CH lenses (p >0.05). Overall, there were no statistical 
significances in the uptake of natamycin between SH and CH materials (p>0.05). 
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Figure 3-1 Natamycin uptake (µg/lens) for balafilcon A (■), lotrafilcon A (), senofilcon A 
(▲), comfilcon A (▼), and galyfilcon A () over 24 hours as measured by spectrophotometry. 
The values plotted are the mean ± standard deviation. Galyfilcon A had the highest uptake of 
Natamycin amongst the silicone hydrogel lenses after incubation (763.5 ± 89.1 µg/lens), but the 
differences in uptake were not statistically significant (P=0.5576).  
 
Figure 3-2 Natamycin uptake (µg/lens) for omafilcon A (), etafilcon A (■), vifilcon A (▲), 
polymacon (▼) over 24 hours as measured by spectrophotometry. The values plotted are the 
mean ± standard deviation. Polymacon had the highest uptake of natamycin amongst the 
conventional hydrogel lenses (1264.2 ± 51.5 µg/lens), but the differences in uptake were not 
statistically significant (P=0.1993).  
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Table 3-3 Summary of uptake of natamycin into different lens type  
 Microgram of Natamycin uptake µg/lens 
Lens 60 min 120 min 240 min 480 min 1 440 min 
Balafilcon A 91.8 ± 43.7 173.6 ± 66.6 401.46 ± 93.9  434.15 ± 52.0  495.0 ± 
120.8 
Comfilcon A 93.3 ± 63.2  158.8 ± 36.8 199.8 ± 65.2 247.9 ± 45.4 533.7 ± 24.6 
Galyfilcon A 50.4 ± 42.0 118.1 ± 51.2 151.2 ± 11.1 264.0 ± 40.0 763.5 ± 89.1 
Lotrafilcon B 112 ± 125.6 151.8 ± 135.3 223.3 ± 15.2 224.1 ± 49.2 688.6 ± 
102.9 
Senofilcon A 86.9 ± 63.7  162.8 ± 37.6  257.9 ± 84.2 254.4 ± 50.9 632.0 ± 38.1 
Etafilcon A 190.3 ± 102.9 267.3 ± 92.4 453.6 ± 102.7 423.3 ± 70.6 578.7 ± 35.8 
Omafilcon A 124.4 ± 112.2  300.0 ± 111.7 368.0 ± 1.9 338.8 ± 90.8 816.6 ± 53.1 
Vifilcon A 156.8 ± 66.5  355.9 ± 62.8 510.5 ± 88.0 608.2 ± 24.5 970.5 ± 86.6 
Polymacon 56.1 ± 33.3 193.5 ± 67.8 227.5 ± 52.0 476.1 ± 51.2 1264.2 ± 
51.5 
Results are expressed as the mean ± standard deviation of 3 lenses. 
  
The typical release curves over 24 hours for the five SH lens materials are shown in 
Figure 3-3, and the release curves for the four CH CL materials are shown in Figure 3-4. The 
quantity of natamycin release (µg/lens) from all contact lens types is summarized in Table 3-4. 
All the lenses released a statistically significant amount of drug in comparison to the initial time 
point (p<0.001). There was a significant difference between all the SH lens materials (p<0.05) 
and there was a significant increase in the release of natamycin from all SH lens materials until 1 
hour post soaking (p<0.05), after which the materials reached a plateau (p>0.05). Among the SH 
lens materials, balafilcon A released significantly higher amounts of natamycin (p<0.05) across 
all the time points. Similarly, there was a significant difference between all the CH lens types 
(p<0.05) and there was a significant increase in the release of natamycin from all CH lens 
materials until 1 hour post soaking in Unisol 4 (p<0.05), and then the materials reached a plateau 
(p>0.05). No further drug release was observed when the lenses were placed in a fresh solution 
of Unisol 4. Overall, the release of natamycin was higher in CH lenses than SH lens materials 
(p<0.001). 
 49 
 
 
Figure 3-3 Natamycin release for balafilcon A (■), lotrafilcon B (), senofilcon A (▲), 
comfilcon A (▼), and galyfilcon A () over 24 hours as measured by spectrophotometry. The 
values plotted are the mean ± standard deviation. Balafilcon A had the highest release of 
Natamycin amongst the silicone hydrogel lenses after incubation (108 ± 15 µg/lens), followed by 
galyfilcon A (78.2 ± 5.2 µg/lens). The differences in release amongst all silicone contact lenses 
were statistically significant (P<0.001). 
 
Figure 3-4 Natamycin release (µg/lens) for omafilcon A (), etafilcon A (■), vifilcon A (▲), 
polymacon (▼) over 24 hours as measured by spectrophotometry. The values plotted are the 
mean ± standard deviation. Polymacon A had the highest release of Natamycin (199.4 ± 29.9 
µg/lens). The differences in release amongst all conventional contact lenses were statistically 
significant (P<0.05).  
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Table 3-4 Summary of release of natamycin from different lens materials 
 Microgram of Natamycin release µg/lens 
Lens 60 min 120 min 240 min 480 min 1 440 min 
Balafilcon A 97 ± 13 104 ± 18 106 ± 19 104.8 ± 17.6 108 ± 15 
Comfilcon A 33.9 ± 4.2  36.3 ± 3.4 34.5 ± 3.5 34.5 ± 3.5 33.6 ± 3.6 
Galyfilcon A 59.9 ± 7.0 66.0 ± 9.6 69.6 ± 7.0 71.7 ± 6.1 78.2 ± 5.2 
Lotrafilcon B 19.2 ± 5.3 16.7 ± 5.2 17.0 ± 4.3 17.0 ± 4.3 16.6 ± 4.0 
Senofilcon A 20.3 ± 2.4  24.5 ± 3.0 26.1 ± 2.9 26.1 ± 2.9 26.7 ± 3.3 
Etafilcon A 160.2 ± 1.8 172.1 ± 5.5 171.0 ± 1.3 171.0 ± 1.3 170.3 ± 1.7 
Omafilcon A 161.2 ± 4.3 163.8 ± 6.2 163.4 ± 5.7 167.6 ± 5.3 165.1 ± 6.2 
Vifilcon A 147.5 ± 7.5 155.5 ± 6.3 156.0 ± 6.0 156.2 ± 6.4 157.3 ± 6.9 
Polymacon 148.6 ± 25.3  157.5 ± 23.4 160.4 ± 27.1 172.0 ± 25.1 199.4 ± 29.9 
Results are expressed as the mean ± standard deviation of 3 lenses.  
All the contact lenses in this study remained clear throughout the uptake and release phases 
of the experiment. One notable observation was the expansion of CH lens materials to 
approximately 2 to 2.4 times their original size when exposed to DMSO, as shown in Table 3-5 
after 24 h. However, upon exposure to Unisol 4 in the release studies, all the CH lenses reverted 
back to their original sizes within one hour.  
Table 3-5 Summary of conventional hydrogel contact lenses diameter expansion  
Lens Etafilcon A Omafilcon A Polymacon Vifilcon A 
Diameter Original 
(mm) 
14.0 14.1 13.8 14.0 
Diameter in 
DMSO (mm) 
34.0 29.0 34.0 29.0 
Size Increase % 243  200 246 207 
 
3.5 Discussion 
To our knowledge, this is the first study that has investigated the uptake and release of 
the antifungal drug natamycin from commercially available SH and CH contact lens materials. 
While there are several antifungal drugs available worldwide, natamycin (pimaricin) is currently 
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the only FDA approved antifungal for the treatment of fungal keratitis.19, 34, 35 Natamycin has 
minimal ocular toxicity, is well tolerated, and effective against fungal pathogens.36-38 However, 
because of its high molecular weight (665.73 g/mol) and its conjugated double bond structure, 
the drug is poorly soluble in water 47 and thus is prescribed as a 5% ophthalmic suspension.38 
Several solvent systems have been suggested to dissolve natamycin, including methanol, glacial 
acetic acid and dimethyl sulfoxide (DMSO).44, 45 The latter solution was chosen as the 
appropriate solvent system for this study.  
DMSO is a universal solvent which has several beneficial pharmacological properties 
with regards to ocular drug delivery, including penetration of biological membranes, 
bacteriostasis, and anti-inflammatory effects.48 These properties may be beneficial in aiding the 
delivery of natamycin into intraocular tissues. Toxicology studies with DMSO in rabbit models 
showed no long-term toxic effects.49 Even a single dose of absolute DMSO (100%) has minimal 
ocular toxicity, and has been suggested as a potential vehicle for drug delivery.49 Furthermore, 
toxicology studies in rabbits with intravitreal administration of several antifungals in 100% 
DMSO, including ketoconazole, itraconazole, and oxiconazole showed minimal toxic side 
effects.50-52 These reports all suggest that DMSO use with antifungals is relatively non-toxic, and 
may actually prove to be beneficial in treating severe ocular fungal infections.  
Contact lenses placed on the cornea can increase the residence time of the drug in the pre-
corneal tear film, which improves overall drug bioavailability and effectiveness. 53, 54 Fungal 
keratitis, which results from an injury to the cornea,38 may benefit from the therapeutic use of 
contact lenses. Contact lenses have been shown to be effective in treating corneal perforation 
(trauma) by preventing painful contact between the eyelids and the torn cornea, enhancing 
corneal healing, and preventing further corneal damage and infections.27, 55, 56 However, the 
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therapeutic use of contact lenses with fungal keratitis has not yet been studied in great detail, and 
will need to be investigated further before it can become acceptable in the treatment of fungal 
infections. 
The uptake and release of several hydrophobic drugs, including ciprofloxacin and 
dexamethasone, on SH and CH lens materials have been previously reported.39, 41 These studies 
suggest that CH lens materials typically have a higher uptake and release of hydrophobic drugs 
than SH lens materials.39, 41 CH lens materials are primarily composed of co-polymers of poly(2-
hydroxyethyl methacrylate) (polyHEMA), which are hydrophilic.57 In contrast, SH materials 
contain various siloxane based monomers and macromers, consequently resulting in a more 
hydrophobic polymer.57 The structure of natamycin is amphipathic, in which the bulk of the 
molecule is hydrophobic, but the carboxyl group and mycosamine moiety are hydrophilic.47 This 
inherent property would suggest that natamycin could interact with both CH and SH materials. 
However, because the drug is mainly hydrophobic, it would be expected that it has stronger 
interactions with SH materials than CH materials. Not surprisingly, in this study CH lens 
materials released 15-30% of the drug sorbed, as compared to SH lens materials which released 
only 2-10% of the drug sorbed, with the exception of balafilcon A, which released approximately 
21% of the drug sorbed. The reason for the observed partial release of natamycin may be due to 
its strong interaction with the CL material. An uptake study looking at the interaction between 
commercially available SH materials with Vitamin E (which is hydrophobic), revealed that even 
after six months of storage, the amount of vitamin E sorbed by the lenses did not diffuse into the 
storage buffer (PBS).32 A similar study looking at ciprofloxacin uptake with commercial lenses 
also suggested that some of the drug sorbed was partially irreversible.40 Similarly, because of its 
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hydrophobic nature, there may be a large percentage of the natamycin sorbed within the matrix 
of the CL material that is irreversibly bound.  
The water content of the CL material also has been suggested as a factor influencing drug 
uptake and release.41 With the exception of polymacon, all CH lens materials have a higher water 
content than SH lens materials.57 High drug release is a common feature of high water content 
CL materials, which could be due to the higher amount of water solvating the drug and 
transporting it through the CL material.41 This transport mechanism may be aided by the relative 
flexibility of the CL material, and consequently its ability to swell. In this study, CH lens 
materials swelled up to 2-2.46 times their original sizes when submerged in DMSO, and reverted 
back to the original sizes when incubated in Unisol 4. This observed flexibility in CH lenses, 
which is not seen in SH lenses, may facilitate the uptake and release of the drug in CH lenses.  
The ionicity of the CL material is also a major determinant of drug uptake and release.41 
In this study, etafilcon A, vifilcon A, and balafilcon A were charged CL materials. The increase 
in charge density will result in an increase in effective pore size, as a consequence of the charged 
repulsion, which will permit higher drug uptake and release.58 However, ionicity did not seem to 
be a major factor in drug uptake and release from CH materials. In contrast, balafilcon A had the 
highest drug release at 104 ± 18 µg/lens, which was significantly higher than other SH lens 
materials (Figure 3-3). Lotrafilcon B had the lowest drug release, followed by senofilcon A, 
comfilcon A, and galyfilcon A (Figure 3-3). A previous study which investigated the uptake and 
release of ciprofloxacin also found that balafilcon A had the highest drug released amongst the 
SH lenses.39 Similar to other SH lenses in this study, balafilcon A is a low water content lens 
material. However, unlike other SH materials, it contains a negative charge due to the presence 
of the carboxylic acid group on the N-vinyl amino acid (see Table 3-1), and is classified as a 
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group III lens material under the United States Food & Drug Administration.57, 58 Based on 
previous studies, the ionicity of balafilcon A has been suggested as a factor for the observed 
increase in drug release.39, 41 Natamycin is an amino acid, with an isoelectric point of 6.5.47 In the 
uptake phase, neither natamycin nor balafilcon A is charged due to the aprotic nature of DMSO. 
However, in the release medium (Unisol 4 at pH 7.4), both the drug and the CL material are de-
protonated and will have an overall negative net charge. As a consequence, the drug is repelled 
from the material, resulting in an increase release of the drug. In addition, the increased porosity 
of the surface and internal network of balafilcon A compared to other SH lens material, may also 
facilitate the enhanced uptake and release of natamycin.59  
The common infectious agents associated with ocular fungal infections are strains of 
Fusarium and Aspergillus in tropical regions, and Candida in other parts of the world.3 Based on 
previous ocular studies with natamycin, the minimum inhibitory concentration for 90% of the 
fungal isolates for Fusarium spp are 8 µg/mL, 32 µg/mL for Aspergillus spp, and 1 – 4 µg/mL 
for most Candida spp.60, 61 In a 2 mL volume, all contact lenses would release sufficient drug to 
meet the MIC90 concentrations for both Candida spp and Fusarium spp within the first 30 
minutes. With the exception of lotrafilcon B, comfilcon A, and senofilcon A, the remaining 
contact lens materials released enough drugs to meet the MIC90 for the more resistant 
Aspergillus spp. The typical frequency of application for natamycin is one drop at hourly or two-
hourly intervals for the first 48 hours depending on the severity of the infection, and may be 
reduced thereafter. The therapy is generally continued for 6 weeks or until there is a resolution of 
fungal keratitis.62 Thus, to be considered as a viable drug delivery device, the drug-soaked 
contact lenses should be capable of sustained drug release for a minimum of one day. However, 
in this study the release of the drug is too rapid, and the tested lens materials released the 
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maximum amount of drug within the first hour. This burst release profile is typical in uptake and 
release studies with unmodified commercial contact lens materials; however, it is 
disadvantageous because it creates a period of drug overdose followed by a period of non-
release.39 
In conclusion, a total of nine commercially available contact lenses, five SH and four CH 
lens materials, were tested for their ability to uptake and release natamycin. All lens materials 
were able to release clinically relevant concentrations of natamycin into the solution after 30 
minutes. However, a sustained release profile was not demonstrated and the drug release 
plateaued after approximately one hour under experimental conditions. CH lens materials had the 
highest release of natamycin, however, the swelling of these materials in DMSO may not make 
them practical to be used in this form. Although SH lenses had a much lower release of drug, 
they are ideal bandage devices because of their high oxygen transmissibility. Among the SH 
lenses, balafilcon A delivered the highest quantity of drug and showed the most promise as a 
drug delivery device. This material is also FDA approved for use as a therapeutic lens, and has 
been shown previously to be effective as a bandage lens.27, 55, 56 Nonetheless, due to the burst 
release of natamycin observed with all these materials, none of the commercially available 
contact lens materials in this study are suitable as antifungal ocular drug delivery devices in their 
current state. Further work is needed to develop a contact lens material which is able to release 
natamycin at a slow and sustained rate.  
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4.1 Overview 
4.1.1 Objective 
To evaluate the uptake and release of the antifungal agent natamycin encapsulated within 
poly(D,L-lactide)-dextran nanoparticles (Dex-b-PLA NPs) from model contact lens (CL) 
materials.  
4.1.2 Methods 
Six model CL materials (gel 1:poly(hydroxyethyl methacrylate, pHEMA); gel 2:85% pHEMA: 
15% [Tris(trimethylsiloxy)silyl]-propyl methacrylate (TRIS); gel 3: 75% pHEMA: 25% TRIS; 
gel 4: 85% N,N dimethylacrylamide (DMAA): 15% TRIS; gel 5:75% DMAA: 25% TRIS; gel 
6: DMAA) were prepared using a photoinitiation procedure. The gels were incubated in: (1) 
natamycin dissolved in deionized (DI)water, (2) natamycin encapsulated within Dex-b-PLA NPs 
in dimethylsulfoxide (DMSO)/DI water. Natamycin release from these materials was monitored 
using UV-Visible spectrophotometry at 304 nm over 7 d. 
4.1.3 Results 
Natamycin uptake by all model CL materials increased between 1 and 7 d (p<0.001). The uptake 
of natamycin-NPs was higher than the uptake of the drug alone in DI water (p<0.05). Drug 
release was higher in materials containing DMAA than pHEMA (p<0.05). All gels loaded with 
natamycin-NPs also released more drug compared to gels soaked with natamycin in DI water 
(p<0.001). After 1 h, CL materials loaded with natamycin alone released 28% - 82% of the total 
drug release. With the exception of gel 6, this burst released was reduced to 21% - 54% for CL 
materials loaded with natamycin-NPs. 
4.1.4 Conclusions 
Model CL materials loaded with natamycin-Dex-b-PLA NPs were able to release natamycin for 
up to 12 h under infinite sink conditions. DMAA-TRIS materials may be more suitable for drug 
delivery of natamycin due to the higher drug release observed with these materials.  
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4.2 Introduction 
Ocular fungal infections, in particular fungal keratitis, while an uncommon occurrence 
can lead to vision loss and blindness[1, 2]. These infections are caused by fungal penetration of a 
compromised corneal epithelium, typically following corneal trauma with vegetable matter[3]. 
While the prevalence of fungal keratitis is relatively high in tropical regions such as South India, 
Ghana, and China[4-9], it is generally much lower in temperate regions such as the United 
Kingdom and the Northern United States[4, 10, 11]. However, there have been numerous case 
reports of fungal keratitis associated with both therapeutic and daily soft contact lens wear[12-
14]. Furthermore, the worldwide outbreak of ocular fungal infections in 2006 associated with the 
multipurpose contact lens solution ReNu MoistureLoc demonstrated that there is a substantial 
need for further research in the management of ocular fungal infections[15-17]. 
The only commercially available and United States Food & Drug Administration (FDA) 
approved ocular antifungal is natamycin (pimaricin)[18-20]. The drug has low water solubility at 
physiological pH, and therefore is prescribed as a 5% ophthalmic suspension (Alcon, Fort Worth, 
TX). However, in this form, it suffers from low drug bioavailability as the drugs are effectively 
drained out through the naso-lacrimal duct or non-specifically absorbed[21]. As a result, the 
treatment regimen for ocular fungal infections requires applying drops at hourly or two-hourly 
intervals for the first 48 hours, and this frequency may be reduced thereafter[22]. This dosing 
regimen can be very taxing, and patients have to be hospitalized to ensure treatment compliance. 
As such, a suitable drug delivery platform which can provide sustained drug release will greatly 
improve the current treatment method. 
One strategy to enhance drug delivery to the ocular surface involves the use of contact 
lenses (CLs). Therapeutic or “bandage” CLs have been used to treat corneal trauma by 
preventing painful contact between the eyelids and the damaged cornea, enhancing corneal 
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healing, and preventing further corneal compromise and infections[23-25]. Furthermore, their 
placement on the eye allows for drug release directly to the cornea, enhancing overall drug 
bioavailability. The lens polymer can also act as a barrier to slow down drug release to provide 
sustained drug levels over extended periods, eliminating the need for multiple dosing[26]. 
However, simple drug loading methods, such as soaking a lens with the drug, often results in 
rapid drug release[26]. A previous study examining the uptake of natamycin in 
dimethylsulfoxide (DMSO), and its release from commercial contact lenses indicated that this 
method resulted in a burst release of the drug from the lens materials within the first hour, 
followed by a plateau phase[27]. To overcome this problem, a second drug delivery platform 
using colloidal carriers can be incorporated[28]. Colloidal systems, such as liposomes[29], 
microemulsions[30], nanosuspension[31], and nanoparticles (NPs)[32]are known to provide 
selective targeting and sustained drug release. The ladder approach has been shown to be suitable 
for incorporation with CL materials[26]. 
Various polymeric materials consisting of poly (D,L-lactide) (PLA), poly(glycolide) 
(PGA), poly(lactide-co-glycolide) (PLGA), polyethylene glycol (PEG) and poly(caprolactone) 
(PCL) have been employed for drug delivery using NPs[33, 34]. One of the most commonly 
used polymers for making biodegradable NPs, PLGA-PEG, produces drug carriers with sizes 
greater than 150 nm[35]. However, to be effectively incorporated into the lens materials, the NPs 
should be smaller than the pore size of the desired lens material. For low-water content lens 
materials, the effective pore size is estimated to be 500 nm and approximately 3500 nm for high-
water content materials[36]. Commercially available silicone hydrogel (SH) materials, however, 
can contain pore sizes well below 150 nm[37]. While the sizes of PLGA-PEG NPs could be 
made under 100 nm, they tend to suffer from low drug encapsulation and rapid drug release[35]. 
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A recent study has shown that a copolymer consisting of PLA and dextran (Dex-b-PLA) can 
self-assemble into a core-shell structured NP with sizes below 40 nm, and can be precisely fine-
tuned between 15-70 nm by altering the molecular weight of the component blocks[38]. These 
NPs are capable of releasing doxorubicin, a hydrophobic drug, for up to 6 days[38]. We 
hypothesize that by encapsulating natamycin within nanoparticles, the solubility of the drug can 
be improved, which will enhance the drug loading into the polymer [39]. 
 The aim of the study was to develop a drug delivery platform which combined the 
benefits of both a colloidal carrier and CL material for daily treatment of fungal infections. One 
approach of incorporating NPs into CL materials is to co-polymerize the NP with the lens 
polymer[26]. However, the synthesis of CL polymers typically involves a photoinitiation or a 
heating step[26, 40], both of which are not compatible with light or heat sensitive drugs, such as 
natamycin[41, 42]. Furthermore, by polymerizing the drug-NPs with the lens material, it is likely 
that the NPs will be trapped within the material. While the drug can still diffuse out of this 
system, it would be ideal to develop a system in which the NPs could also diffuse out. This will 
provide more flexibility for future work in regards to modifying the properties of the NPs for 
improved corneal adhesion and penetration. Here, we develop a method for encapsulating 
natamycin using Dex-b-PLA NPs, and incorporating these NPs into SH lens polymer post lens 
synthesis. The effectiveness of this drug delivery system in regards to the uptake and release of 
natamycin from model SH lenses was evaluated.  
 
4.3 Materials and methods 
2-hydroxyethyl methacrylate (HEMA), N,N-dimethylacrylamide (DMAA), ethylene 
glycol dimethacrylate (EGMDA, 3-methacryloxypropyltris(trimethylsiloxy)silane (TRIS), and 
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dimethylsulfoxide (DMSO)were purchased from Sigma-Aldrich (St. Louis, MO). Natamycin 
was purchased from EMD Millipore (Billerica, MA).NPs were formed using block copolymer 
Dextran-b-poly(D,L-lactide), which was synthesized previously[38]. 
 
4.3.1 Contact lens materials 
Model SH materials consisting of HEMA and TRIS were synthesized based on a 
procedure by van Beek[43]. SH materials consisting of DMAA and TRIS were prepared based 
on previously published work[44].The monomer compositions for a 2 mL mixture of the gels are 
listed in Table 4-1. Additionally, 15 µL of EGDMA (cross-linker) and 9.5 µL of 2-hydroxy-2-
methypropiophenone (Irgacure1173, photoinitiatior, Sigma-Aldrich)was also added to the 2 mL 
monomer mixture. The resulting mixture was stirred for 5 minutes before being poured into a 42 
mL aluminum weighing mold (Fisher Scientific, Pittsburg, PA). The mold was then placed inside 
the Dymax Ultraviolet (UV) Curing Chamber (Torrington, CT) and the gel was cured with UV 
light for 30 minutes (min). The molded gels were hydrated overnight in 100 mL of deionized 
(DI) water before they were cut into circular discs using a cork borer (1.45cm diameter). The 
resulting gel discs (1.2mm thickness) were dried overnight before further use.  
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Table 4-1 Compositions of monomer mixtures (mL) for various gels (15 µL of EGDMA and 9.5 
µL 2-hydroxy-2-methypropiophenone were also added to each composition). Equilibrium water 
content of model lens materials. The values reported are the mean ± SD (n=3).  
 HEMA TRIS DMAA Water 
content (%) 
GEL 1 (100% pHEMA) 2.000 - - 35.2±5.5 
GEL 2 (85% pHEMA/15% TRIS) 1.700 0.300 - 26.2± 7.1 
GEL 3 (75% pHEMA/25% TRIS) 1.500 0.500 - 26.3± 0.9 
GEL 4 (75% DMAA/25% TRIS) - 0.300 1.700 43.5±4.3 
GEL 5 (85% DMAA/15% TRIS) - 0.500 1.500 43.7±6.5 
GEL 6 (100% DMAA) - - 2.000 44.2 ±2.8 
 
4.3.2 Encapsulation of natamycin in Dex-b-PLA NPs via nanoprecipitation 
The encapsulation of natamycin in Dex-b-PLA NPs was accomplished using 
nanoprecipitation as described by Verma et al[38]. Natamycin (1.65 mg/mL) and Dex-b-PLA 
(6.6 mg/mL) were dissolved in DMSO to form a solution containing 20% drug initial feed. 1 mL 
of this DMSO solution was added drop-wise into 10 mL of water under stirring for over 5 min. 
The resulting mixture was allowed to stir for an additional 30 min. The NPs in the water were 
filtered through a syringe filter (pore size= 200 nm) to remove drug aggregates. The resulting 
mixture contained approximately 150 µg/mL of natamycin in a 9.1 % DMSO/DI solution. The 
sizes of the NPs were analyzed using a 90Plus Particle Size Analyzer (Brookhaven, λ = 659 nm 
at 90°). The volume-averaged multimode size distribution (MSD) mean diameters are reported.  
Free drug remaining in the solution was further removed by filtering through Amicon 
filtration centrifuge tubes (MWCO = 10 kDa, Millipore). The filtered solution was then re-
dissolved in DMSO and the drug loading in the NPs determined by measuring the absorbance of 
natamycin in the solution using a SpectraMax M5 UV-Vis Spectrophotometer(Molecular 
Devices, Sunnyvale, CA) at 304 nm. The absorbance was correlated with the concentration of 
natamycin using the standard calibration curve obtained previously. 
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4.3.3 Release of natamycin from NPs 
Using the procedure described in the previous section, natamycin-encapsulated NPs were 
prepared and filtered to remove drug aggregates. A purified sample of the NP-drug suspension 
was collected to measure the maximum absorbance, which was used as the 100% release point. 1 
mL of the NP-drug suspension was then injected into a Slide-A-Lyzer Dialysis cassette (MWCO 
= 20kDA, Fisher Scientific) and dialyzed into 200 mL of the release solution containing 
phosphate buffered saline (PBS, pH 7.4) at 32±2oC under mild stirring. At specific time intervals 
t = 0, 2, 4, 6, 7, 12, 20, and 24 h, 200 µL of the release solution was withdrawn in triplicates, and 
the drug release was measured using the SpectraMax M5 UV-Vis Spectrophotometer at 304 nm. 
After the measurement, this solution was then carefully pipetted back into the release medium. 
All experiments were undertaken in light-minimizing conditions. Two drug NP formulations 
containing 2.45% and 4.61% drug to nanoparticle weight were tested.  
 
4.3.4 Uptake studies 
The model lens materials were incubated in amber vials in two conditions: (1) 20 mL of 
30 µg/mL natamycin dissolved in deionized (DI) water, and (2) 4 mL of 150 µg/mL natamycin 
encapsulated within Dex-b-PLA NPs in 10% dimethylsulfoxide (DMSO)/ DI water for 7 days 
(d) at room temperature on an orbital shaker. Both incubation solutions contained a total amount 
of 600 µg of natamycin. The uptake of the drug into the lens materials was measured by the 
depletion of the drug from the solution using the SpectraMax M5 UV-Vis Spectrophotometer at 
304 nm. 200 µL was removed from the solution and pipetted into a UV- Star Transparent Plate 
(Greiner Bio-One, Frickenhausen, Germany) at specific time intervals t = 0, 1, 2, 3, 4, 5, 6, 7 d. 
The sample was returned to the vial after the absorbance measurement. 
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4.3.5 Contact lens release studies 
After the 7 d uptake period, lenses were removed from the natamycin solution and briefly 
rinsed with borate buffered saline, pH 7.4 (Unisol 4, Alcon Labs, TX) to remove any residual 
drug solution not sorbed onto the lens. The lenses were then partially dried on lens paper and 
placed into amber vials containing fresh 2 mL solution of borate buffered saline. The vials were 
incubated at 32±1oC with constant rotation over 7 d. The release solution was replenished with a 
fresh 2 mL of borate buffered saline every 24 h. The release of the drug was monitored using the 
SpectraMax M5 UV-Vis Spectrophotometer at 304 nm by withdrawing 200 µL from the 
solution, which was then pipetted into a UV- Star Transparent Plate at specific time intervals 
t = 0, 1, 30 min, 1, 2, 4, 8, 12, 18, 24 h, 1, 2, 3, 4, 5, 6, 7 d.  
 
4.3.6 Water content 
The wet weight (WW) of the lenses was measured using the Sartorius MA 100H 
(Goettingen, Germany). The lenses were then placed on a piece of lens paper and placed in a 
microwave for 2 minutes. Thereafter, the dry weight (DW) was measured using the Sartorius 
MA 100H. The water content (WC) was calculated using the following formula: 
WC (%) =  
WW − DW
WW
 X 100 
 
4.3.7 Statistical analysis 
Statistical analysis was performed using Statistica 8 software (StatSoft, Tulsa, OK). All 
data are reported as mean ± standard deviation, unless otherwise stated. Repeated measures of 
analysis of variance (RM-ANOVA) were performed to determine the differences across various 
time points within the same lens material. An ANOVA was conducted to determine the 
differences between lens materials at each time point. Post-hoc Tukey multiple comparison tests 
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were used when necessary. In all cases, statistical significance was considered significant for p 
value of < 0.05. Graphs were plotted using GraphPad Prism 5 software (GraphPad, La Jolla, 
CA).  
 
4.4 Results 
As shown in Figure 4-1a, the encapsulation efficiency of Dex-b-PLA NP for 20% initial 
drug feed results in NPs containing 2.35% natamycin, and can be increased to 4.35% when using 
40% initial drug feed. In contrast, the encapsulation of natamycin for PLGA-PEG is only 0.608% 
and 0.697% under the same conditions. PLGA-PEG encapsulation results in particle sizes 
between 137 nm to 151.8nm, which is consistent with the literature (Figure 1b)[35]. Dex-b-PLA 
encapsulation produces NPs with particle sizes of 26.1 nm (2.35% wt) and 26.6 nm (4.61% wt). 
Release studies with natamycin-Dex-b-PLA NP in phosphate buffered saline (PBS, pH 7.4),show 
that the NP containing 4.61% natamycin in weight released more drug than NPs containing 
2.35% natamycin (Figure 4-2). However, both NPs have similar release periods of 12 h before 
reaching a plateau phase(p<0.05). As a result of these data, the 2.35% wt NPs were chosen for 
incubation with the model contact lens materials.  
Amongst the model gels, gel 6 was the only one that was brittle. In the hydrated state, 
DMAA containing gels swelled more than HEMA containing gels. DMAA gels also contain a 
higher equilibrium water content than HEMA gels (p<0.001) (table 4-1).As shown in Figures 4-3 
and 4, the uptake of natamycin within all model lens materials increased between 1 and 7 days 
(p<0.001). There were no differences in drug uptake between materials containing HEMA (gels 
1-3) and DMAA (gels 4-6). However, the uptake of natamycin encapsulated with Dex-b-PLA 
NPs was slightly higher than the uptake of the drug dissolved in DI water (p<0.05). Gel 3 and 
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Gel 5, which contained the highest amount of TRIS, had the highest amount of natamycin uptake 
after 7 days for both drug incubation conditions (p<0.05). 
As shown in Figures 4-5 and 4-6, the release of the drug was observed to be higher in 
materials containing DMAA than HEMA (p<0.05). In the first drug loading condition, DMAA 
gels containing TRIS (gels 4 and 5) released the two highest concentration of drug(p<0.05), 14.2 
± 4.5 µg/lens and 16.1 ± 1.7 µg/lens after 1 day respectively. In the second drug loading 
condition with NPs, gels 4 and 5 also released the highest drug concentration, 67.2 ± 4.0 µg/lens 
and 54.5 ± 7.1 µg/lens (p<0.05), respectively. The percentage of drug release was higher for 
DMAA materials than HEMA materials (p<0.05) after 1 d, as shown in Table 4-2 and 4-3. TRIS 
containing gels (gels 2-5) also had a lower drug release percentage compared to gels without 
TRIS (gels 1 and 6) for both drug loading conditions (p<0.05). 
Overall, gels loaded using natamycin Dex-b-PLA NPs also released significantly more 
drug compared to the gels soaked with natamycin in DI water (0<0.001).The percentage of drug 
release was also higher when the gels were loaded with drug-NPs (p<0.001). After 1 h, CL 
materials loaded with natamycin alone released 28% - 82% of the total drug release. With the 
exception of gel 6, this burst release was reduced to 21% - 54% for CL materials loaded with 
natamycin Dex-b-PLA NPs. In addition, with the exception of gels 2 and 6, the drug 
equilibration time improved for all gels when incubated with natamycin Dex-b-PLA NPs 
compared to natamycin in DI water (table 4-2 and 4-3). The drug release within all materials 
reached an equilibrium within 12 h(p>0.05). However, after replenishing the release solution 
after every 24 h, gels 1 and 2 incubated with natamycin in DI water continued to release drug for 
up to 3 days (p<0.05). Gels 2-5 loaded with natamycin Dex-b-PLA NPs continued to release 
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drugs for up to 4 days (p<0.05), whereas gel 1 releasedthe drug for up to 7 days, when the release 
solution was replenished every 24 h.  
 
Figure 4-1 (a) Drug encapsulation efficiency and (b) particle size (nm) of NP 
 
 
Figure 4-2 Release of natamycin from  2.35 wt% and 4.61 wt% natamycin-Dex-PLA 
nanoparticles in 200 mL PBS (pH 7.4) 
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Figure 4-3 Natamycin uptake (µg/lens) from natamycin in solution for HEMA (gels 1-3) and 
DMAA gels (gels 4-6) over 7 days as measured by spectrophotometry. The values plotted are the 
mean ± standard deviation for 3 trials. 
 
 
 
 
Figure 4-4 Natamycin uptake (µg/lens) from natamycin Dex-b-PLA NPs for HEMA (gels 1-3) 
and DMAA gels (gels 4-6) over 7 days as measured by spectrophotometry. The values plotted 
are the mean ± standard deviation for 3 trials.  
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Figure 4-5 Natamycin release (µg/lens) in Unisol 4 from HEMA (gels 1-3) and DMAA gels 
(gels 4-6) incubated with natamycin in solution as measured by spectrophotometry. The values 
plotted are the mean ± standard deviation for 3 trials.  
 
 
 
 
Figure 4-6 Natamycin release (µg/lens) in Unisol 4 from HEMA (gels 1-3) and DMAA gels 
(gels 4-6) incubated with natamycin Dex-b-PLA NPs as measured by spectrophotometry. The 
values plotted are the mean ± standard deviation for 3 trials.  
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Table 4-2 Natamycin uptake and release incubated with natamycin dissolved in deionized water. 
The values reported are the mean ± standard deviation for 3 trials.  
 GEL 1 GEL 2 GEL 3 GEL 4 GEL 5 GEL 6 
total drug 
uptake  
(µg/lens) 
57.1 ± 2.3 55.6 ± 2.2 176.9 ± 79.0 103.4 ± 10.3 116.4 ± 4.2 37.9 ± 19.7 
% Drug 
uptake 
9.5 ± 0.3 9.2 ± 0.4 29.5 ± 13.1 17.2 ± 1.7 19.4 ± 0.1 6.3 ± 3.3 
24 h drug 
release 
(µg/lens) 
6.3 ± 0.5 4.6 ± 0.2 3.5 ± 1.1 14.2 ± 4.5 16.1 ± 1.7 10.6 ± 1.0 
% Release 11.0 ± 0.6 8.3 ± 0.3 2.7 ± 2.2 13.6 ± 3.4 13.8 ± 1.4 32.3 ± 12.7 
Time to 
equilibrium 
(h) 
6 12 1 0.5 2 2 
 
 
Table 4-3 Natamycin uptake and release incubated with natamycin Dex-b-PLA NPs. The values 
reported are the mean ± standard deviation for 3 trials.  
 GEL 1 GEL 2 GEL 3 GEL 4 GEL 5 GEL 6 
total drug 
uptake 
condition  
(µg/lens) 
146.3 ± 11.9 88.5 ± 7.7 253.1 ± 56.4 126.6 ± 19.4 152.8 ± 13.5 38.2 ± 8.4 
% Drug 
uptake 
24.4 ± 0.2 14.8 ± 1.2 42.2 ± 9.4 21.1 ± 3.2 25.5 ± 2.3 6.4 ± 1.4 
24h drug 
release 
condition  
(µg/lens) 
30.9 ± 2.5 20.6 ± 0.6 23.1 ± 2.4 67.2 ± 5.4 54.5 ± 7.1 27.3 ± 3.1 
% Release 21.3 ± 3.2 23.4 ± 2.6 9.4 ± 1.8 54.3 ± 10.6 35.6 ± 3.2 73.1 ± 13.5 
Time to 
equilibrium 
(h)  
12 12 6 6 2 0.5 
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4.5 Discussion 
The first drug loading condition contained model CL materials soaked with natamycin 
dissolved at its native solubility. The drug uptake into all CL materials in this condition ranged 
between 6.3% and 29.5%, which are comparable to that of a previous study investigating the 
uptake and release of natamycin from commercial CL materials[27]. The percentage of 
natamycin released from these materials after 24 h for SH (2.7%-13.8% ) and conventional 
hydrogel (CH) (11.0%-32.3%) materials are also comparable to results previously reported[27]. 
The partial release of the drug from the CL material can be attributed to the stronger interaction 
between the drug and the CL material, in which the equilibrium in an aqueous media highly 
favours the drug bound to the polymer[27]. Notably, the release time in this study is considerably 
more favourable, reaching up to 6 and 12 h for gel 1 and gel 2, whereas previously, the drug 
release reached a plateau for commercial lens materials within 1 h[27]. These differences are 
likely due to the variations in drug loading protocols, as well as the materials used. 
The encapsulation of natamycin with Dex-b-PLA NPs produced particles containing 
approximately 2.35% natamycin by weight. The PLA chains are suggested to form the 
hydrophobic core containing the drug, whereas the dextran components are suggested to form the 
outer hydrophilic layer[38]. As a result, the hydrophobicity of the drug was masked, and the 
aqueous solubility of natamycin was improved 5-fold. In principle, higher drug concentration in 
the loading solution will result in higher drug uptake in the hydrogel polymer[45]. Not 
surprisingly, all model materials (with the exception of gel 6) had a significantly higher drug 
uptakecompared to the first loading condition, when loaded with the drug NPs. Typically higher 
initial drug loading will consequently lead to an increased drug release. As expected, the gels 
loaded with natamycin Dex-b-PLA NPs released a greater quantity of drug than the first loading 
condition. 
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As shown in Figure 4-2, natamycin encapsulated with Dex-b-PLA NPs can release 
natamycin over a 12 h period in phosphate buffered saline (PBS, pH 7.4). We hypothesize that 
over this time frame, the NPs slowly dissociate in solution to release the drug. Since these NPs 
are less than 30 nm, which is smaller than the pore sizes found in most commercial contact lens 
materials[37], it is possible that these NPs are absorbed and released from the model CL material 
without any change in its structural integrity. Similar to the release of other hydrophilic 
molecules from CL materials, the NPs should equilibrate rapidly in the aqueous release 
solution[46, 47].For this reason, we propose that the release mechanism first involves the release 
of the NPs from the CL material, followed by the slower drug release from the NPs. Since the 
drug is encapsulated, there should be minimal interaction between the drug and the CL material. 
The release rate will be primarily dependent on the interaction between the drug and the NP. 
Thus, the integrity of the released NPs becomes a primary determining factor in sustained drug 
release. Based on this model, we did not expect any material to have a release period exceeding 
12 h. An alternative model would suggest that parts of the NPs could first diffuse from the CL 
material, and likely act as a surfactant to facilitate the release of the drug from the polymer 
network. 
Upon contact with the CL material, the NPs could dissociate to form undesirable 
interactions with the polymer. In the case of SH materials, the PLA core of the NP can rearrange 
to interact with the silicone moieties of the polymer network. As a result, the NPs which are 
released from these materials may have undergone structural changes, therefore, will release the 
encapsulated drugs more quickly. Highly hydrophobic gels containing TRIS (gels 3-5) follow 
this pattern, and release drugs before 12 h. Gel 1(0%TRIS) and gel 2 (15% TRIS) were the only 
gels able to release the drug for the full 12 h duration. Nonetheless, the release period was 
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improved for the majority of the gels compared to the first incubation condition. Additionally, 
we also observed that the percentage of drug release from the polymer also improved.  
In this study, we investigated the effects of two common hydrophilic monomers used in 
soft CL materials, hydroxyethyl methacrylate (HEMA) and dimethylacrylamide (DMAA), on the 
uptake and release of natamycin-NPs. Notably, HEMA differs from DMAA in that it contains a 
hydroxyl pendant group, which allows for hydrogen bonding between its monomers. As a result, 
HEMA materials swelled significantly less than DMAA materials, reflected by the lower 
equilibrium water content in all model HEMA materials compared to DMAA. While we 
expected that higher equilibrium water content would correlate to higher drug absorption[46], 
there were no statistical differences for the uptake of natamycin between DMAA or HEMA gels 
in both incubation conditions. 
The release of the drug-NPs from the CL material initially involves the release of the NPs 
from the hydrogel network into the aqueous phase of the hydrogel, before they are subsequently 
released into the surrounding media[45]. Based on this assumption, materials with higher water 
content should facilitate more drugs released from the polymer[46]. As expected, DMAA 
containing gels (4-6) released more drug than HEMA containing gels (1-3) for both drug 
incubation conditions. The percentage of drug released from DMAA materials was also 
significantly higher than HEMA. However, a high solvent capacity within the hydrogel network 
would also correlate to a faster drug release period. In both incubation conditions, HEMA 
containing gels had a longer sustained drug release than DMAA containing gels. When the 
release solution was replenished after 24 h, HEMA gels could release drugs up to several days. 
Notably, gel 1 was able to release natamycin up to 7 days when incubated with drug-NPs. 
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TRIS (3-methacryloxypropyltris(trimethylsiloxy)silane) is a hydrophobic monomer, 
forming the silicone backbone of the SH materials (gels 2-5)in this study. Interestingly, SH 
materials containing TRIS were able to uptake more drug-NPs than CH materials. As previously 
mentioned, the PLA core of the NP can rearrange to interact with the silicone domains of the 
polymer. This could potentially lead to the drug being exposed, allowing for non-specific 
interactions between the drug and the lens polymer, such as hydrophobic interaction and 
hydrogen bonding, between natamycin and the silicone moieties. Consequently, this interaction 
could result in a slower drug release[39] and a lower percentage of drug release from the 
polymer. As expected, in both drug loading conditions, CL materials containing TRIS had a 
lower percentage of drug release, and the quantity of the drug released from model materials 
were comparable to their CH counterparts. TRIS extended the drug release period only for 
DMAA gels when loaded with drug-NPs, but not HEMA-containing gels.  
In this study, the model CL materials were circular discs, which were approximately 
1.2mm thick. This is at least ten times thicker with less surface area than a commercial CL. 
Thickness is an important parameter in determining drug release, with thicker materials capable 
of longer extended drug release [47, 48]. With commercial contact lenses, we hypothesize the 
release of the drug-NPs would occur more quickly. However, since the rate determining step is 
the release of the drug from the NPs, and not the release of the drug-NPS from the CL, the drug 
release rate in a CL using these NPs would still be relatively similar. 
Dextran-PLA NPs may also be useful in an ophthalmic formulation. However, in the 
form of an ophthalmic drop, this formulation will not be efficient as it will undergo removal 
mechanisms including dilution[49-51], dispersion[52],drainage[49, 51], and non-specific 
absorption[49, 51, 53]. The CL limits drug loss through these routes, while at the same time acts 
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as a temporary drug-NP reservoir. The post-lens tear film has limited tear mixing [54, 55]. 
Therefore, the drug released from the CL into this post-lens tear film will have a prolonged 
contact time with the cornea, leading to enhanced bioavailability [56]. Alternatively, adding 
mucoadhesive properties to the NPs will also prolong the residence time on the eye. 
The delivery of drugs to the ocular surface using CLs have faced considerable challenges 
and have not yet led to a viable product. While the CL and Dex-b-PLA NPs system proposed in 
this paper is capable of releasing the drug for up to 12 h, careful consideration in regards to 
initial release rates should be made. One of the main ongoing challenges for controlled drug 
delivery using CLs is to obtain zero-order release kinetics, without suffering from the initial 
burst. Using conventional drug loading methods, CL show burst drug release ranging from 28% - 
82% of the total drug release after 1 h. This is in agreement with results found previously in 
other studies[27, 46, 47]. Although the use of Dex-b-PLA NPs does minimize this burst release 
to 21% - 54% for CL materials (with the exception of gel 6), the overall burst effect is still 
present. Nonetheless, burst release followed by a steady release of drug could be considered ideal 
in regards to corneal infections. The initial burst is aimed at killing the majority of the infectious 
agents, while the sustained release prevents the growth of the remaining microbes.  
The common infectious agents associated with ocular fungal infections are strains of 
Fusarium and Aspergillus in tropical regions, and Candida in other parts of the world[3].Based 
on previous ocular studies with natamycin, the minimum inhibitory concentration for 90% 
(MIC90) of the fungal isolates for Fusarium spp are 8 µg/mL, 32 µg/mL for Aspergillus spp, and 
1-4µg/mL for Candida spp[57, 58]. Although HEMA gels released drugs slower than DMAA 
gels, the amount of drug released by these gels in a 2 mL volume can only meet the minimum 
inhibitory concentration for 90% (MIC90) of the fungal isolates for Candida spp. DMAA gels 
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released enough drug to the meet the MIC for Fusarium spp and Candida spp, and thus may be 
more suitable hydrophilic monomers in drug delivery for daily treatment of fungal infections. 
Nonetheless, the conditions for the release studies are not reflective of ocular conditions. Further 
in vivo studies need to be conducted in order to determine the true effectiveness of this drug 
delivery platform in the eye. 
 
4.6 Conclusion 
We have demonstrated that the encapsulation of natamycin by Dex-b-PLA NPs yields a 
drug delivery carrier providing extended drug release for up to 12 hours under infinite sink 
conditions. These drug-NPs can be incorporated into CL materials post lens synthesis for 
targeted drug release directly to the cornea for daily treatment of fungal infections. This system 
provides extended natamycin release from CL materials compared to conventional drug loading 
methods. The delivery system was compatible with HEMA, DMAA, and TRIS containing gels. 
Overall, materials containing DMAA-TRIS may be more suitable than HEMA-TRIS materials 
for drug delivery of natamycin due to the higher drug release observed with these materials.  
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5.1 Overview 
5.1.1 Objective 
The antifungal agent natamycin can effectively form inclusion complexes with beta-cyclodextrin 
(β-CD) and 2-hydroxypropyl-β-cyclodextrin (HP-βCD) to improve the water solubility of 
natamycin by 16-fold and 152-fold respectively (Koontz, J. Agric. Food.Chem. 2003). The 
purpose of this study was to develop contact lens (CL) materials functionalized with 
methacrylated β-CD (MβCD) and methacrylated HP-βCD (MHP-βCD), and to evaluate their 
ability to deliver natamycin in vitro.  
 
5.1.2 Methods 
Model conventional hydrogel (CH) materials were synthesized by adding varying amounts of 
MβCD and MHP-βCD (0, 0.22, 0.44, 0.65, 0.87, 1.08 % of total monomer weight) to a monomer 
solution containing 2-hydroxyethyl methacrylate (HEMA). Model silicone hydrogel (SH) 
materials were synthesized by adding similar concentrations of MβCD and MHP-βCD to N,N-
dimethylacrylamide (DMAA)/10% 3-methacryloxypropyltris(trimethylsiloxy)silane (TRIS). The 
gels were cured with UV light, washed with ethanol and then hydrated for 24 hours (h). The 
model materials were then incubated with 2 mL of 100 μg/mL of natamycin in phosphate 
buffered saline (PBS) pH 7.4 for 48 h at room temperature. The release of natamycin from these 
materials in 2 mL of PBS, pH 7.4 at 32±2oC was monitored using UV-Visible spectrophotometry 
at 304 nm over 24 h.  
 
5.1.3 Results 
For both CH and SH materials, functionalization with MβCD and MHP-βCD improved the total 
amount of drugs released up to a threshold loading concentration, after which further addition of 
methacrylated CDs decreased the amount of drugs released (p<0.05). The addition of CDs did 
not extend the drug release duration; the release of natamycin by all model materials reached a 
plateau after 12 hours (p<0.05). Overall, DMAA/10% TRIS materials released significantly more 
drug than HEMA materials (p<0.05). The addition of MHP-βCD had a higher improvement in 
drug release than MβCD for both HEMA and DMAA/10% TRIS gels (p<0.05).  
 
5.1.4 Conclusions 
A high loading concentration of methacrylated CDs decreases overall drug delivery efficiency, 
which likely results from an unfavourable arrangement of the CDs within the polymer network 
leading to reduced binding of natamycin to the CDs. HEMA and DMAA/10% TRIS materials 
functionalized with MHP-βCD are more effective than those functionalized with MβCD to 
deliver natamycin. 
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5.2 Introduction 
There have been numerous cases of fungal eye infections associated with therapeutic and 
daily soft contact lens wear.[1-3] These infections occur as a result of fungal penetration of a 
compromised corneal epithelium,[4] and can lead to vision loss and blindness if left untreated.[5, 
6] In 2006, a worldwide outbreak of ocular fungal infections occurred as a result of a 
multipurpose contact lens solution ReNu MoistureLoc, [7-9] which has prompted further 
research into the management of ocular fungal infections.  
In comparison to bacterial infections, there are few drugs available to treat ocular fungal 
infections. Fungi are eukaryotic and share similarities with human hosts, which make it difficult 
to identify unique drug-targets.[10] Currently, natamycin (pimaricin) is the only commercially 
available and United States Food & Drug Administration (FDA) approved ocular antifungal. [11-
13] The drug has low water solubility at physiological pH, and therefore is prescribed as a 5% 
ophthalmic suspension (Alcon, Fort Worth, TX).  
However, in an eye drop form, the drug delivery is inefficient as the drugs are 
continuously diluted and washed away by tears,[14-16] or dispersed from the eye during 
blinking,[17] drainage,[14, 16] or non-specific absorption.[14, 16, 18] As a result, it has been 
estimated that only 1-7% of the medication within an eye drop reaches the target ocular 
tissue,[17] while the remainder is subjected to systemic absorption.[19] To achieve therapeutic 
drug concentrations to treat ocular fungal infections, multiple dosing is typically required, 
sometimes as often as applications at hourly to two-hourly intervals.[20] This can lead to 
problems relating to patient compliance,[21-23] as well as the potential for drug overdosing.[24]  
 Drug delivery using contact lenses (CLs) can potentially overcome several of the current 
limitations associated with eye drops. The post-lens tear film, formed as a result of placing a CL 
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on the cornea, has limited tear exchange.[25, 26] This is advantageous in regards to drug 
delivery, as drugs released from the CL into the tear film will have prolonged contact time with 
the cornea.[27] It has been estimated that over 50% of the drugs released from a CL can diffuse 
into the cornea, which is at least 35 times more efficient than eye drops.[28] Furthermore, the CL 
polymer can also act as a barrier and reservoir to provide sustained drug release over extended 
periods, which eliminates the need for multiple dosing.[29] CLs have already been used 
therapeutically as ‘bandage’ lenses to treat damaged corneas by preventing painful contact 
between the eyelids and the cornea, to enhance corneal healing, and to prevent further corneal 
complications. [30-32] Pharmaceuticals, including antibiotics and anti-inflammatory drugs are 
typically administered topically in tandem with these CLs.[33] Thus, the application of using 
CLs for antifungal ocular drug delivery would be an extension of an already accepted ophthalmic 
practice.  
 However, simple drug soaking with CLs does not produce optimal results, with drug 
release occurring rapidly within a few hours.[29] We have previously examined the drug 
delivery of natamycin from several commercial CLs, and observed a burst release within the first 
hour, followed by a plateau phase. [34] This is not surprising, as commercial CLs are only 
designed for refractive error correction, and further material modifications are necessary to 
improve drug delivery using these materials. Amongst the various approaches, the synthesis of a 
biomimetic material created through molecular imprinting methods have proven to be very 
successful in providing sustained drug release.[35] These hydrogels contain recognitive sites, 
which can specifically interact with the target drug.[35] However, one major limitation of this 
approach is that each material is specific to its target drug, and the same material cannot be used 
to provide the same effective delivery for other ophthalmic drugs.  
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One alternative approach would be to functionalize hydrogels with monomers capable of 
establishing interactions with a variety of drug molecules. In the pharmaceutical field, 
cyclodextrins (CDs) have proven to be effective and versatile for a wide range of drug delivery 
applications, due to their ability to complex with a wide array of drugs.[36] CDs are a family of 
cyclic oligosaccharides with a hydrophilic outer surface, and a lipophilic central cavity.[36] 
Commonly used CDs in the pharmaceutical field include α- CD, β-CD, and γ-CD, which are 6-
,7-, 8-membered sugar rings respectively.[36] Their unique chemical structure allows them to be 
used as complexing agents to increase the aqueous solubility of poorly water-soluble drugs, to 
increase both drug bioavailability and stability.[37] The use of β-cyclodextrin (βCD) and 2-
hydroxypropyl-β-cyclodextrin (HP-βCD) has been suggested to improve the aqueous solubility 
of natamycin by 16 and 152-fold respectively.[38] Thus, the incorporation of these molecules 
within a CL may allow for improved interactions between the CL and natamycin, leading to 
better drug delivery profiles. The purpose of the current study was to develop CL materials 
functionalized with β-CD and HP-βCD, and evaluate their ability to release natamycin in vitro.  
 
5.3 Materials and methods 
2-hydroxyethyl methacrylate (HEMA), N,N-dimethylacrylamide (DMAA), ethylene 
glycol dimethacrylate (EGMDA, 3-methacryloxypropyltris(trimethylsiloxy)silane (TRIS) were 
purchased from Sigma-Aldrich (St. Louis, MO). Natamycin was purchased from EMD Millipore 
(Billerica, MA). Di-methacrylated β-cyclodextrin (MβCD) and di-methacrylated (2-
hydroxypropyl)-β-cyclodextrin (MHP-βCD) were purchased from Specific Polymers (France). 
The molecular structure of MβCD and MHP-βCD are shown in figure 5-1. 
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Figure 5-1 A Di-methacrylated β-cyclodextrin (MβCD) (MW=1430 g/mol) and B di-
methacrylated (2-hydroxypropyl)-β-cyclodextrin (MHP-βCD) (MW=2710 g/mol) 
 
5.3.1 Equilibration of natamycin with MβCD and MHP-βCD 
Various concentrations of the MβCD and MHP-βCD were dissolved in deionized (DI) 
water and vortexed for 10 minutes to determine the maximum water solubility of these 
compounds. Increasing amounts of natamycin was then added to these solutions, and allowed to 
equilibrate for 24 h to determine the maximum amount of natamycin that can be equilibrated 
(when equilibrated, the solution turns from opaque to clear).  
 
5.3.2 Contact lens materials 
Model conventional hydrogel (CH) contact lens materials consisting of HEMA were 
synthesized based on a procedure previously reported by van Beek.[39] Model silicone hydrogel 
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(SH) materials consisting of DMAA and TRIS were also prepared based on previously published 
work. [40] MβCD and MHP-βCD were dissolved in DI water (or ethanol) to concentrations of 
50, 40, 30, 20, and 10 mg/mL. CH materials were synthesized by adding 400 μL of the above 
cyclodextrin solution to 1.6 mL of HEMA. For the synthesis of SH materials, due to the 
immiscibility of water and TRIS, MβCD and MHP-βCD were dissolved in ethanol at similar 
concentrations, and were added to 1.6 mL of DMAA/10% TRIS. Additionally, 95 µL (5% wt) of 
EGDMA (cross-linker) and 9.5 µL of 2-hydroxy-2-methypropiophenone (Irgacure1173, 
photoinitiatior, Sigma-Aldrich) were also added to the 2 mL monomer mixture. The resulting 
mixture was stirred for 5 minutes before being poured into a 42 mL aluminum weighing mold 
(Fisher Scientific, Pittsburg, PA). The mold was then placed inside the Dymax Ultraviolet (UV) 
Curing Chamber (Torrington, CT) and the gel was cured with UV light for 10 minutes (min). 
The molded gels were washed with ethanol, and hydrated overnight in 100 mL of deionized (DI) 
water before they were cut into circular discs using a cork borer (1.45cm diameter). The resulting 
gel discs (1.2mm thickness) were dried overnight before further use.  
 
5.3.3 Drug incubation and release 
The above CL materials were soaked in a 2 mL suspension (saturated solution) 
containing 100 mg/mL of natamycin in phosphate buffered saline (PBS), pH 7.4 over 48 h. Due 
to the turbidity of the suspension, the uptake of the drug into the CL material could not be 
monitored. After the uptake period, lenses were removed from the natamycin solution and briefly 
rinsed with PBS to remove any residual drug solution not sorbed onto the lens. The lenses were 
then partially dried on lens paper and placed into amber vials containing fresh 2 mL solution of 
PBS. The vials were incubated at 32±1oC with constant rotation over 24 h. The release of the 
drug was monitored using the SpectraMax M5 UV-Vis Spectrophotometer at 304 nm by 
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withdrawing 200 µL from the solution, which was then pipetted into a UV- Star Transparent 
Plate at specific time intervals t = 0, 1, 30 min, 1, 2, 4, 8, 12, 16, 24 h. After each measurement, 
the 200 µL sample solutions were pipetted back into their respective vials.  
 
5.3.4 Water content 
The wet weight (WW) of the lenses was measured using the Sartorius MA 100H 
(Goettingen, Germany). The lenses were then placed on a piece of lens paper and placed in a 
microwave for 2 minutes. Thereafter, the dry weight (DW) was measured using the Sartorius 
MA 100H. The water content (WC) was calculated using the following formula: 
WC (%) =  
WW − DW
WW
 X 100 
 
5.3.5 Statistical analysis 
Statistical analysis was performed using Statistica 8 software (StatSoft, Tulsa, OK). All 
data are reported as mean ± standard deviation, unless otherwise stated. Repeated measures of 
analysis of variance (RM-ANOVA) was performed to determine the differences across various 
time points within the same lens material. An ANOVA was conducted to determine the 
differences between lens materials at each time point. Post-hoc Tukey multiple comparison tests 
were used when necessary. In all cases, statistical significance was considered significant for p 
values of < 0.05. Graphs were plotted using GraphPad Prism 5 software (GraphPad, La Jolla, 
CA). 
 
5.4 Results 
Preliminary experiments in our lab with natamycin established that approximately 125 
mg/mL of 2-hydroxypropyl-β-cyclodextrin in DI water could equilibrate completely with 2 
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mg/mL of natamycin after 24 hours (h). This is comparable to results previously reported by 
Koontz et al.[38] However, the cyclodextrin derivatives, MβCD and MHP-βCD could only be 
solubilized up to a concentration of 50 mg/mL in DI water. In addition, these CD derivatives 
could equilibrate only up to 500 μg/mL of natamycin after 48 h; the inclusion complex efficiency 
of MβCD and MHP-βCD were significantly less than the parent compound.[38]  
For all CL materials, the drug release plateaued after 12 hours, with neither MβCD nor MHP-
βCD affecting the drug release duration (p<0.05). However, functionalization with cyclodextrin 
improved the total amount of drugs released for some materials (p<0.05). As shown in figure 5-
2, the drug release for HEMA materials containing MβCD followed a trend in which an increase 
in cyclodextrin beyond 0.22% of total polymer weight resulted in a reduction of drug release 
(p<0.05). Similarly, HEMA materials containing 0.65% MHP-βCD had the highest drug release, 
and further increase in cyclodextrin loading led to a decline in drug release (figure 5-2B) 
(p<0.05). The amount of natamycin released (µg/lens) as a function of time squared (t1/2 ) for the 
first hour are plotted in figures 5-2C (MβCD) and D(MHP-βCD).  
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Figure 5-2 Total natamycin release (µg/lens) from HEMA gels functionalized with (A) MβCD 
(B) MHP-βCD after 24 h. The relationship between the amount of natamycin released (µg/lens) 
and t1/2 for the first hour are plotted in (C) MβCD and (D) MHP-βCD. The values plotted are the 
mean ± standard deviation for 3 trials. 
 
For DMAA/10% TRIS materials, the amount of drug release correlated with increasing 
concentrations MβCD (figure 5-3A) (p<0.05), which was an exception to the observed trend. 
However, the functionalization of MHP-βCD with these materials continued to follow the trend, 
in which the highest drug release was observed at 0.48% MHP-βCD, and further cyclodextrin 
addition resulted in a decrease in drug release (figure 5-3B) (p<0.05). Figures 5-3C (MβCD) and 
D (MHP-βCD) show the amount of natamycin released from DMAA/10% TRIS materials as a 
function of time squared (t1/2 ).  
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Figure 5-3 Total natamycin release (µg/lens) from DMAA/10% TRIS gels functionalized with 
(A) MβCD (B) MHP-βCD after 24 h. The relationship between the amount of natamycin 
released (µg/lens) and t1/2 for the first hour are plotted in (C) MβCD and (D) MHP-βCD. The 
values plotted are the mean ± standard deviation for 3 trials. 
 
 As a general trend, HEMA and DMAA/10% TRIS CL materials functionalized with 
MHP-βCD produced materials that could release higher amounts of natamycin compared to 
those functionalized with MβCD (p<0.05). However, as shown in figures 5-4A and B, the 
percentage of CD in the polymer and the monomer composition also dictate which CD will be 
more effective. For instance, HEMA gels containing 0.22% MβCD released more drugs than the 
0.22% MHP-βCD formulation (p<0.05). DMAA/10% TRIS gels containing MβCD at 1.20% CD 
of polymer weight released more drugs than the MHP-βCD formulation (p<0.05). Overall, the 
drug release was higher for DMAA/10% TRIS CL materials than HEMA materials (p<0.01).  
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Figure 5-4 The relationship between total natamycin released (µg/lens) and the cyclodextrin 
percent (CD) of total polymer weight for (A) HEMA and (B) DMAA/10% TRIS materials. The 
vertical bars denote 0.95 confidence intervals. 
 
All model CL materials synthesized in this study were clear by visual inspection. When 
hydrated, DMAA/10% TRIS materials swelled more than HEMA containing gels. Furthermore, 
as shown in table 5-1 and 5-2, DMAA/10% TRIS materials also had a higher water content than 
HEMA gels (p<0.001). The addition of either MβCD or MHP-βCD increased the equilibrium 
water content (EWC) of the lens material, in which increasing cyclodextrin concentration 
resulted in higher EWC (p<0.05). Overall, the addition of MβCD resulted in a higher EWC than 
MHP-βCD at similar concentrations (p<0.001). Tables 5-1 and 5-2 summarize the properties of 
the CLs, and total amount of drug released by each gel after 8 and 24 h. The highest drug release 
after 24 h was observed for 0.48% MHP-βCD DMAA/10% TRIS (31.7 ± 1.2 μg after 24 h).  
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Table 5-1 Total amount of natamycin released after 8 and 24 h in 2 mL of PBS, pH 7.4 for 
HEMA materials. The values reported are the mean ± SD (n=3).  
Gel 
(HEMA) 
MβCD (% 
by total 
polymer 
weight) 
MHP-βCD) 
(% by total 
polymer 
weight) 
Water 
content 
(%) 
Total drug 
release 8 h 
(µg/lens) 
Total drug 
release 24 
h (µg/lens) 
1 0 0 15.5 ± 0.7 10.9 ± 1.3 11.0 ± 1.4 
2 0.22 - 17.7 ± 0.1 20.6 ± 0.2  21.0 ± 0.2 
3 0.44 - 21.1 ± 4.6 10.1 ± 0.56 10.4 ± 0.6 
4 0.65 - 22.0 ± 0.5 6.0 ± 0.1 6.6 ± 0.1 
5 0.87 - 23.9 ± 1.0 3.5 ± 0.1 4.7 ± 0.3 
6 1.08 - 24.5 ± 3.0 3.9 ± 0.1 4.2 ± 0.1 
7 - 0.22 15.6 ± 0.3 12.8 ± 0.6 12.8 ± 1.0 
8 - 0.44 16.6 ± 0.6 16.0 ± 0.5 15.3 ± 0.3 
9 - 0.65 20.8 ± 4.0 22.9 ± 1.3 22.8 ± 0.1 
10 - 0.87 20.8 ± 4.0 7.5 ± 0.9  6.4 ± 0.5 
11 - 1.08 18.4 ± 2.1 4.8 ± 0.2 4.5 ± 0.1 
 
Table 5-2 Total amount of natamycin released after 8 and 24 h in 2 mL of PBS, pH 7.4 for 
DMAA/10% TRIS materials. The values reported are the mean ± SD (n=3).  
Gel 
(DMAA/10
% TRIS) 
MβCD (% 
by total 
polymer 
weight) 
MHP-
βCD) (% 
by total 
polymer 
weight) 
Water 
content 
(%) 
Total drug 
release 8 h 
(µg/lens) 
Total drug 
release 24 
h (µg/lens) 
12 0 0 24.1 ± 3.0 9.5 ± 1.0  11.6 ± 0.2 
13 0.24 - 25.2 ± 0.5 8.6 ± 0.8 10.5 ± 0.1 
14 0.48 - 30.1 ± 0.3 8.8 ± 0.4 10.7 ± 1.1 
15 0.72 - 31.4 ± 1.7 11.4 ± 0.5 15.0 ± 0.6 
16 0.96 - 39.0 ± 2.3 21.0 ± 1.0 22.1 ± 0.4 
17 1.20 - 41.6 ± 2.0 22.6 ± 0.2 27.6 ± 1.0 
18 - 0.24 21.8 ± 1.4 11.4 ± 0.5  16.9 ± 0.5 
19 - 0.48 24.2 ± 2.1 30.2 ± 0.9 31.7 ± 1.2 
20 - 0.72 27.1 ± 0.4 27.5 ± 0.6 28.6 ± 0.3 
21 - 0.96 28.9 ± 1.0 18.4 ± 0.5 21.5 ± 0.7 
22 - 1.20 33.0 ± 1.0 12.0 ± 0.4 15.4 ± 1.1 
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5.5 Discussion 
A previous study by Koontz and colleagues that used natamycin, [38] showed that the 
solubility of the antifungal can be increased 16-fold, 152-fold, and 73-fold when dissolved at the 
highest concentration of βCD (1.8% w/v), HP-βCD (50.0% w/v), and γCD (24.6% w/v). It would 
appear that the most effective CD to complex with natamycin would be HP-βCD, followed by 
γCD and βCD. However, one important factor to consider is the maximum water solubility of 
these CD, with βCD only having a maximum solubility at 18 mg/mL compared to HP-βCD at 
500 mg/mL.[38] Thus, when CD solubility is also considered, βCD and HP-βCD have very 
similar inclusion complex efficiency with natamycin. At relatively lower CD concentrations 
below 20 mM, all three CDs were equally effective at complexing with natamycin.[38] As 
expected, the addition of two methacrylated chains to βCD and HP-βCD, to produce MβCD and 
MHP-βCD, resulted in compounds with a water solubility of only 50 mg/mL. This is almost a 
10-fold decrease in solubility for HP-βCD, while the solubility for βCD improved by over two-
fold. However, as shown in table 5-3, the ability of MβCD and MHP-βCD to complex with 
natamycin decreased in comparison to the parent compound.[38]  
Table 5-3 Complexing efficiency of cyclodextrins with natamycin  
Cyclodextrin 
(CD) 
CD 
Concentration 
(mg/mL) 
Average 
molecular 
weight 
(g/mol) 
CD 
Concentration  
(mM) 
Estimated 
natamycin 
solubility 
(µg/mL) 
βCD 18 (max) 1134.94 15.86 500 [38] 
HP-βCD 50 1375.36 36.35 1250 [38] 
γCD 50 1297.12 38.55 1000 [38] 
MβCD 50 1430.00 35.00 500 
MHP-βCD 50 2710.00 18.50 500 
 
 The incorporation of MβCD and MHP-βCD to HEMA and DMAA/10% TRIS model CL 
materials produced some unexpected results. The highest concentration of CDs initially loaded in 
the monomer mixture was 10 mg/mL (1.08-1.20% of total polymer weight). At this 
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concentration, the amount of CDs forming inclusion complexes with natamycin should increase 
linearly with increasing CD concentration.[38] However, only DMAA/10% TRIS gels 
incorporated with MβCD followed the expected trend. For HEMA gels incorporated with either 
MβCD or MHP-βCD above 0.22% and 0.65% of total polymer weight, the amount of natamycin 
released showed a reduction with increasing loading concentration of CDs. This was also 
observed for DMAA/10% TRIS materials functionalized with MHP-βCD at concentrations 
above 0.48%. This effect appears to be dependent on the monomer composition of the material, 
as well as the type of CD.  
The underlying mechanism is not well understood and we propose the following 
hypothesis. Drugs are released from the CD gels from two sites; (1) non-specific sites formed 
randomly throughout the free space within the polymer, and (2) specific sites formed by the CD. 
As the CD concentration increases, there is an increase in specific sites, resulting in increased 
drug release. However, due to volume constraints, as the number of specific sites increase 
beyond a threshold concentration, there is also a reduction in the number of non-specific sites. 
As a result, this offsets any increase in drug release provided by CDs. With a high CD 
concentration, the arrangement of the CD in the polymer becomes over saturated, in which their 
complexing centres are hindered by side chains, and become inaccessible to the drug.  
 We initially expected that the incorporation of CDs within the polymer, which could 
interact with the drug, would lead to a delayed and extended release of the drug from the 
polymer. However, all gels within this study released all the drug within the first 12 h, 
suggesting that time for drugs in CDS to equilibrate with PBS is about 12 h. This release 
duration is similar to what has been reported for two antifungals, naftifine and terbinafine, from 
hydrogels functionalized with βCD.[41] The drug release profile from the model CLs in this 
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study also suggests a diffusion-controlled process, and the CDs did not significantly affect the 
rate of drug release. This suggests while the CDs can improve the total amount of drug that can 
be released, the rate of drug equilibration will remain similar to that of the control material.  
In general, the incorporation of MHP-βCD with HEMA and DMAA/10% TRIS gels 
provides a higher amount of drug release than MβCD. However, the amount of drugs released is 
also dependent on the percent of CD in the polymer and the monomer composition of the gel. 
DMAA/10% TRIS materials released more drug than the HEMA-based materials. This trend has 
been observed previously in another study.[42] The mechanism is not clear, but it has been 
suggested that DMAA based materials typically contain higher water content than HEMA based 
materials, which helps facilitate the release of the drug from the polymer.[42] 
 An important factor in CL synthesis is to ensure a uniform distribution of the individual 
monomers by minimizing phase separation between monomers.[43] This can be accomplished 
by reducing the polymerization time via increasing the cross-linking density.[43] It has been 
reported that a composition of approximately 4% by total weight of a cross-linking agent is most 
optimal to decrease gelation time, and minimize phase separation effects.[43] In this study, a 5% 
EGDMA cross-linking density was used to ensure the distribution of CDs throughout the 
material. However, the typical amount of EGDMA material used in CL synthesis is 
approximately only 0.5% EGDMA.[42, 44] By increasing the cross-linking density in a fixed 
volume, the resulting effect is a decrease in equilibrium water content (EWC).[45] Furthermore, 
EGDMA which is hydrophobic will also increase the overall hydrophobicity of the material. 
Previous studies report HEMA and DMAA materials with 0.5% EGDMA to contain 
approximately 30-35% and 44% EWC respectively.[42] By increasing the concentration of 
EGDMA to 5% in this study, the EWC decreases for both HEMA and DMAA gels to 15.5 ± 
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0.7% and 24.1 ± 3.0% respectively. The addition of either MβCD or MHP-βCD increased the 
EWC for all materials, with increasing CD content correlating to increasing EWC. Surprisingly, 
MβCD provided better improvement in EWC than MHP-βCD, although both of these 
compounds have similar water solubility, and HP-βCD is more water soluble than βCD. The 
mechanism as to why MβCD absorbs more water than MHP-βCD is unclear, however, we 
hypothesize that the additional 2-hydroxypropyl chains on MHP-βCD in a polymer network may 
occupy and displace water molecules in hydrophilic regions of the polymer.  
 One important limitation to consider when applying CDs to a CL is the amount of CDs 
that can be effectively functionalized into the polymer, which correlates to the amount of total 
drugs that can effectively form inclusion complexes with the material. Based on our results, 50 
mg/mL of MβCD or MHP-βCD can effectively equilibrate up to 500 μg/mL of natamycin over 
48 h. However, if we take into account the actual volume of CD present in a lens material, the 
amount of drug that can be complexed with the lens would only be approximately 20 μg per lens. 
Considering the clinical range where natamycin is effective against various fungi strains, such as 
Fusarium spp (MIC90=8 µg/mL) and Candida spp (MIC90=1-4µg/mL), the amount of 
natamycin that can be complexed with the CD in these CLs may be too little.[46, 47] 
Nonetheless, all gels in this study released enough drug in a 2 mL volume to meet the MIC90 for 
Candida spp, and gels 9,16-21 released enough drug to meet the MIC90 for Fusarium spp. 
 In conclusion, CD functionalized CLs used in this study released more drug than the 
control CLs, with no significant differences between MβCD and MHP-βCD. When the loading 
of CDs increases beyond a threshold concentration, the arrangement of the CDs becomes 
crowded and the CD inclusion site becomes inaccessible to the drug. These CDs improve the 
EWC of both HEMA and DMAA/10% TRIS materials, with MβCD providing a better 
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improvement. None of the gels studied released the drug for more than 12 hours, but all model 
CLs released enough drug to meet the MIC90 for Candida spp. The application of MβCD and 
MHP-βCD could be extended to other hydrogels for the delivery of natamycin, and other 
antifungal drugs. 
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6.1 Overview 
6.1.1 Short abstract 
Current in vitro models for evaluating contact lenses (CLs) and other eye-related applications are 
severely limited. The presented ocular platform simulates physiological tear flow, tear volume, 
air exposure and mechanical wear. This system is highly versatile and can be applied to various 
in vitro analyses with CLs. 
6.1.2 Long abstract 
Currently, in vitro evaluations of contact lenses (CLs) for drug delivery are typically performed 
in large volume vials,1-6 which fail to mimic physiological tear volumes.7 The traditional model 
also lacks the natural tear flow component and the blinking reflex, both of which are defining 
factors of the ocular environment. The development of a novel model is described in this study, 
which consists of a unique 2-piece design, eyeball and eyelid piece, capable of mimicking 
physiological tear volume. The models are created from 3-D printed molds 
(Polytetrafluoroethylene or Teflon molds), which can be used to generate eye models from 
various polymers, such as polydimethylsiloxane (PDMS) and agar. Further modifications to the 
eye pieces, such as the integration of an explanted human or animal cornea or human corneal 
construct, will permit for more complex in vitro ocular studies. A commercial microfluidic 
syringe pump is integrated with the platform to emulate physiological tear secretion. Air 
exposure and mechanical wear are achieved using two mechanical actuators, of which one moves 
the eyelid piece laterally, and the other moves the eyeballeyepiece circularly. The model has 
been used to evaluate CLs for drug delivery and deposition of tear components on CLs.  
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6.2 Introduction 
 Two significant areas of interest within the contact lens (CL) arena include discomfort and 
the development of novel CL applications. Elucidating the mechanisms underlying CL 
discomfort is an issue that has eluded the field for decades.8 The development of novel, 
functional CLs, such as drug-delivery devices1,3,9 and biosensors,10-12 is an area of growing 
interest, with substantial potential markets. In both circumstances, a sophisticated in vitro model 
would provide relevant information to assist with selecting appropriate lens materials or design 
characteristics during the development phase. Unfortunately, current in vitro models for 
evaluating CLs and other eye related applications are relatively crude and unsophisticated. 
Traditionally, in vitro CL studies evaluating tear film deposition or drug delivery are performed 
in static, large volume vials containing a fixed fluid volume, which greatly exceeds physiological 
amounts. Furthermore, this simple model lacks the natural tear flow component and the blinking 
reflex, both of which are defining factors of the ocular environment.    
The development of a sophisticated, physiologically relevant eye “model” will 
necessitate a multi-disciplinary approach and require substantial in vivo validation. For these 
reasons, the fundamental framework for our in vitro eye model is highly versatile, such that the 
model can be continually improved through future upgrades and modulations. To date, the model 
is capable of simulating tear volume, tear flow, mechanical wear and air exposure. The aim is to 
create an in vitro model that will provide meaningful results, which is predictive and 
complimentary to in vivo and ex vivo observations. 
 
6.3 Protocol 
All experiments were completed in accordance and compliance with all relevant guidelines 
outlined by the University of Waterloo’s animal research ethics committee. The bovine eyes are 
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generously donated from a local abattoir. 
 
1. Eye model  
1.1 Design and production of molds13 
1.1.1 Design the eye models according to the average physiological dimensions of human adult 
eyes.13  
1.1.2 Leave a gap of 250 µm between the eyeball and the eyelid pieces of the eye model. Design 
the respective molds using computer-aided design (CAD) software.  
1.1.3 Create new .cad file or .sldprt file with AutoCAD or Solidworks. Create 3D models of the 
human eyeball/eyelid. Create molds of the models and save the molds as .stl files. 
1.1.4 Import .stl files into 3D printer software (e.g. makeware for replicator2). Specify 
parameters of the print (location, sparseness, scale, orientation, smoothness, etc.)13. 
1.1.5 Save the file as G-code file for 3D printers to read. Select materials such as PLA (polylactic 
acid), ABS (acrylonitrile butadiene styrene), PC (polycarbonate), or a combination thereof, to print 
the molds13. 
1.1.6 Install desired filament of the material of choice. Import the G-code file into the 3D printer 
to read. Print the mold. 
NOTE: Alternatively, produce the eye molds using a computer numerical controlled (CNC) 
machine, if a smoother surface on the eye model is desired. For CNC mold production, materials 
for molds are no longer limited to thermal plastics, but extend to metal, ceramics, and chemically 
resistive polymers such as Polytetrafluoroethylene. 
1.1.7 Open the CNC software interface that is connected to a cutting drill. Construct 3D molds 
according to front, top, side, and perspective views of the previously-constructed eyeball/eyelid 
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model molds in control software interface. Select appropriate parameters for the machining (bit 
size, substrate material, material thickness) and proceed to cut the mold.  
 
1.2 Synthesis of eyepieces using PDMS 
1.2.1. Using a syringe, measure 10 mL volume of PDMS (polydimethylsiloxane) base and fill it 
into a 15 mL – 50 mL centrifuge tube. Add 10% w/v of the elastomer solution by total weight of 
PDMS. Using a stirring rod, mix the solutions well. 
1.2.2. Pour the PDMS solution into the eyeball and eyelid molds. Allow the PDMS to settle at 
room temperature (RT) overnight (or for at least 12 hours) to start the polymerization and to allow 
bubbles to dissolve out of the polymer. 
NOTE: Ensure that there are no bubbles left in the PDMS that might rise or expand.  
1.2.3. Subsequently, put the molds into a 75oC (167°F) oven for 1 h, or 150oC (302°F) for 5 min. 
For a softer gel, let the PDMS sit at RT for at least 48 h to completely polymerize. 
1.2.4. Put the samples in a freezer for a few minutes; this will shrink the PDMS and simplify the 
removal of the samples from the molds. Extract the eyepieces from the molds using a thin spatula.  
1.2.5. For the delivery of solution into the space between the eyeballand eyelid pieces, connect a 
1/16” x 1/8” polytetrafluoroethylene tube with a 1/16” equal leg coupler tube connector and attach 
it to the eyelid piece at the tubing hole. 
 
1.3 Synthesis of eyeball piece using agarose 
NOTE: The eyeball piece can be synthesized using other polymers such as agarose. The 
following procedure can also be modified to produce eye pieces from a variety of agar types, 
such as PDA (potato dextrose agar) or SDA (sabouraud dextrose agar). 
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1.3.1. To produce a 2% (2g/100mL) gel, measure 2 g of agarose and mix with 100 mL of ultrapure 
water. Bring the solution to a boil (100ºC) such that the agarose dissolves completely. Let the 
solution cool down for 5 min. 
1.3.2. Pour the solution into the eyeball mold and allow the solution to cool for 30 minutes at RT. 
Remove the eyeball pieces with a spatula. Store the eyeball agar in a -20oC freezer for later use. 
For microbiology studies, sterilize the eyeball molds by autoclaving and/or UV-irradiation.  
1.4 Incorporation of bovine cornea on PDMS eyeball 
NOTE: This protocol has been adapted from Parekh et al.14 
1.4.1. Perform the dissection and incorporation of the bovine corneas in sterile conditions under 
a laminar flow hood. Acquire the eyes and dissect them on the same day. 
1.4.2. Turn the flow hood on for 10 minutes prior to use and sanitize with 70% ethanol alcohol. 
Ensure that all materials and instruments are sterile by autoclaving at 273°F/133°C for 45 minutes, 
and positioned no less than 4 inches from the flow hood entrance. 
1.4.3. Immerse the bovine eye in a beaker containing 0.5% povidone-iodine solution for 2 
minutes. Remove the povidone-iodine solution from the beaker, and rinse eye in a beaker 
containing phosphate buffered saline (PBS) pH 7.4. Using forceps gently place the eye on a glass 
petri dish, corneal face up.  
 
1.4.4. Remove the excess muscle and fatty tissue by cutting at the scleral attachment points with 
blunt end dissection scissors. Dispose of the excess tissue into a sterile beaker designated for 
animal waste. 
1.4.5. Using micro-scissors, remove the conjunctiva from the eye. Wrap the eye with sterile 
gauze, maintaining a distance of at least 1 cm from the limbus. 
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1.4.6. Using a scalpel, incise the sclera approximately 2 mm from the limbus region and 
superficially so as to avoid penetration of the underlying choroid and vitreous body. Carefully 
extend the incision by 360° using a scalpel or dissection scissors without deforming the cornea 
from its natural curvature.  
1.4.7. With fine forceps, remove the cornea from the eye. Using forceps, carefully remove any 
adhering uveal tissue and rinse cornea with PBS. 
1.4.8. Store the cornea at 31ºC in a sterile container with culture medium (such as Medium 199) 
containing 3% Fetal Bovine Serum to maintain tissue moisture and cell nourishment.  
1.4.9. Prior to experimentation, rest the excised cornea on the PDMS eyeball, and clamp the two 
pieces together with a specialized clip-on.  
2. Blink-platform 
2.1 Design and production of the blink-platform 
NOTE: The blink-platform is composed of three functional parts: eye model (described in section 
1), gear system, and electronic system. 
2.1.1. Design and manufacture the blink platform using CAD and 3D printing, similar to that 
described for the eye model (section 1.1). Design the gear system such that it translates simple 
rotation of motors into the lateral and rotational motions of the eyepieces.15  
 
2.1.2. Using the pinion and gear mechanism, translate rotational motion of a stepper motor into 
the lateral motion of a pinion, which is connected to the eyelid pieces. 
2.1.3. Using the conjugate gear system, amplify one rotational motion from a stepper motor into 
three (or more) rotational motions for three different eyeball pieces. 
2.1.4. Align the two gear systems, one for the eyelid and one for eyeball, so that the distance 
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between the two are constant. Assemble the electronic system with a microcontroller, motor shield, 
and two motors. 
NOTE: Use two stepper motors to provide rotational motors, which is translated by the gear system 
into a blinking motion. 
2.1.5. Connect the two stepper motors with a system consisting of a motor shield stacked on the 
microcontroller. Connect and configure the electronic components to work with open source 
software products.  
2.1.6. Program the system to control motor parameters such as rounds per minute (RPM), number 
of rounds forward, number of rounds backward, and turning style. NOTE: Refer to the 
supplementary “Arduino code file” for details.  
2.1.7. Download the system software from the manufacturers’ website. 
2.1.8. Install the software and open it. Write the code to control stepper motors in the desired 
configuration. Connect the system with a source to power the electronic system so that the motors 
move in the desired manner as defined by the researcher. NOTE: Refer to the supplementary 
“Arduino code file”. 
 
2.2 Assembly with microfluidics (Artificial Tear Solution) 
2.2.1. Take the synthesized eyeball and eyelid pieces and slip them onto their corresponding clip-
ons for the eye-model. Connect the tubing that is joined with a syringe and positioned on the 
microfluidic pump with the eyelid piece (section 1.2.5). Test run the platform and check for 
consistent movement. 
2.2.2. Prime the tubing and check for a steady flow of artificial tear solution (ATS). The recipe 
for ATS has been previously reported.16 
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2.2.3. Manually move the eye-model parts together on a level plane, such that the eyeball and the 
eyelid are in contact. Set the flow rate of the microfluidic pump to desired values. Set physiological 
flow rates to 1-1.5 µL/min.17  
2.2.4. Start the pump and the actuators to begin experiment. For drug delivery experiments, place 
the drug-containing contact lens on the eyeball piece. 
2.2.5. Allow the flow-through fluid to drip into a 12-well plate. At the desired set time intervals, 
quantify the analyte or drug concentration using common detection methods such as UV-Vis 
spectroscopy or fluorescence.1,4,18  
2.2.6. For studies evaluating deposition of tear components on contact lenses, place the contact 
lens on the “eyeball” piece. Collect the flow-through fluid, which can be discarded. 
2.2.7. After the desired time intervals, remove the contact lens from the eyeball piece and prepare 
the lens for further analysis such as confocal microscopy.19 
 
6.4 Results 
The synthesized eye molds obtained from the machine shop and from 3-D printing are 
shown in Figure 6-1. These molds can be used with a variety of polymers, such as PDMS and 
agarose, to produce eyepieces with the desired properties. The motioned assembly of the eye 
model platform with a microfluidic syringe pump is shown in Figure 6-2. The platform simulates 
mechanical wear via the rotation of the eyeball piece, and air exposure through the lateral in and 
out motion of the eyelid piece. Tear fluid is infused into the eyelid from a microfluidic pump at 
the desired flow rate, and the flow-through fluid can be collected in a 12-well plate.  
The procedure for dissection of a bovine lens, and mounting onto a PDMS eyepiece is 
depicted in Figure 6-3. The excess tissues are separated from the eye and discarded, followed by 
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the removal of the conjunctiva. The removal of the cornea begins with an incision into the sclera 
near the limbus. Figure 6-4 shows the variety of eyepieces that could be used for various in vitro 
analyses. The mounted eyeball pieces shown are synthesized from PDMS, agar, and an ex-vivo 
bovine cornea mounted on a PDMS eyeball piece.  
Figure 6-5 depicts a study evaluating the release of an antibiotic, moxifloxacin, from 
CLs.18 When measured in the traditional vial model, drug release occurs within the first 2 hours 
followed by a plateau phase. In contrast, the novel eye model shows drug release to be slow and 
sustainable for up to 24 hours.18 A study evaluating the deposition of cholesterol on CLs is 
shown in Figure 6-6. The cholesterol in the study was fluorescently tagged in the form of NBD-
cholesterol (7-nitrobenz-2-oxa-1,3-diazol-4-yl-cholesterol), and deposition was imaged using 
laser scanning confocal microscopy. The results indicate that there are substantial differences 
when the deposition studies are performed in a vial as compared to the eye model.  
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Figure 6-1 A Eyeball piece mold from machine shop B Eye lid mold from 3-D printing 
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Figure 6-2 An in vitro ocular platform: A Circular motion simulates mechanical wear B Lateral 
motion produces intermittent air exposure C Tear fluid infusion into eyelid D Collecting well 
plate 
 
 
 
 
 
Figure 6-3 Dissection and incorporation of bovine cornea: A Removal of excess tissue B 
Removal of conjunctiva C Incision into the limbus region D The excised cornea can be stored or 
mounted on a PDMS eye ball piece  
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Figure 6-4 Sample eyepieces: Sample of PDMS eye piece with a contact lens, an agar eye piece, 
and ex-vivo bovine cornea mounted eye piece 
 
 
 
Figure 6-5 Drug delivery using the in vitro ocular platform: Release of moxifloxacin from daily 
disposable contact lenses from A a large volume static vial and B the eye model (Re-print with 
permission from the Association for Research in Vision and Ophthalmology).18 All data are 
reported as mean ± standard deviation. 
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Figure 6-6 Cholesterol deposition using the in vitro ocular platform: Confocal images showing a 
cross-section of etafilcon A, nelfilcon A, nesofilcon A, ocufilcon B, delefilcon A, somofilcon A, 
narafilcon A after 4 h incubation with NBD-cholesterol in the vial and eye model  
 
6.5 Discussion 
 There are three critical steps within the protocol that require special attention: design and 
production of molds (section 1.1), platform assembly (section 2.2.1-2.2.3), and monitoring the 
experimental run (section 2.2.4-2.2.7). In terms of the design and production of molds (section 
1.1), the eyeball piece should be designed according to the dimensions of a human cornea. 
However, it may require multiple prototypes of the mold before an eyeball piece can be created 
that perfectly fits a commercial contact lens (CL). In addition, the 250 µm needs to be 
maintained when the eyeball and eyelid piece are in contact to ensure the tear fluid flows 
smoothly throughout the entire eye model when a CL is present. This distance could be changed 
in future iterations, but should not be less than 150 µm to allow for enough spacing to fit a CL. 
The platform assembly (section 2.2.1-2.2.3) requires careful attention such that the eyeball and 
eyelid piece come into contact during the blink motion. If the eyepieces are not in perfect 
contact, then simulation of a closed eyelid and mechanical rubbing fails. The operator should 
observe the platform in motion for a few cycles to ensure that both the eyeball and eyelid are in 
contact, and that rubbing occurs as programmed. The current platform is designed to run 
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continuously over one month, but an operator should always check on the stability of the system 
every 24 hours when running an experiment (section 2.2.4-2.2.7). This is important as the current 
platform does not possess a temperature or humidity control, and fluctuations in these parameters 
could dry up the CLs. If this occurs, place the eye model within a controlled humidity and 
temperature chamber. In addition, for drug delivery experiments, the collected flow-through fluid 
should be analyzed or stored at least every 2 hours to avoid significant evaporation of the 
sample.  
 There are currently two limitations of the presented eye model. The first limitation is in 
regards to exposure to the surrounding environment. Currently, because the eye pieces are not 
enclosed in a controlled chamber, changes such as temperature and humidity in the work area 
will influence various aspects of the experiments. For instance, if the environment is too dry, 
then the CLs dry up quicker and could separate from the eyeball piece, or the flow-through fluid 
could evaporate. To address this problem, future iterations will house the eye model in a 
controlled temperature and humidity chamber. The second limitation pertains to the complexity 
eyeball piece. Currently, the eyepieces are simple, consisting of either PDMS or agarose, neither 
of which truly represents corneal surface properties. Future work will aim to produce eye models 
which closer mimics the corneal surface structures. 
 In vitro ocular research is generally viewed as the preceding testing phase to in vivo research. 
However, it is important to keep in mind that in vitro research can also be complementary to in 
vivo data, providing critical insights that otherwise cannot be achieved from in vivo studies alone. 
Regrettably, the current in vitro models for testing CLs are rudimentary and lack several key 
components to adequately mimic the in vivo environment. For instance, in vitro CL studies are 
performed in vials containing 2-5 mL of phosphate buffered saline,1-6 which greatly exceeds 
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physiological tear volumes at 7.0 ± 2 μL.7 Moreover, two important factors of the ocular 
environment, natural tear flow and the blinking reflex, are absent from the simple static vial 
model. The limitations of the conventional vial model have been recognized by researchers, and 
attempts have been made to create unique in vitro eye models simulating the ocular environment, 
by including a microfluidic tear replenishment component20-24 and/or intermittent air 
exposure.25,26 Not surprisingly, the results generated from these experiments are very different 
than those obtained with the conventional vial model, and may more closely resemble in vivo 
data.20-25 Thus, developing an intricate in vitro eye model to examine CLs will provide new 
insights on the interaction of lens materials with the ocular surface, and help facilitate the 
development of new materials and new applications for CLs in the coming decades.  
Arguably, one of the most debated aspects of the in vitro eye model is whether the eye 
resembles an infinite sink, which is particularly important when it comes to drug delivery from 
CLs. Under infinite sink conditions, the volume of the surrounding solution is significantly 
higher than the drug saturation volume, such that drug release is not affected by the drug’s 
solubility.27 Advocates for the vial as an acceptable eye model argue that the cornea, conjunctiva, 
and surrounding ocular tissues together function as an infinite sink. While in theory this may be 
true, the drug must first dissolve into the tear fluid. This rate limiting step is likely not a sink 
condition, and will be dependent on both tear volume and flow as simulated by our model. 
The unique identity of the presented model lies in its ability to emulate the tear film. By 
adopting a two-piece design, a “corneal/scleral” eyeball section and an “eyelid”, it is possible to 
create an evenly spread thin layer of tear film across the eyeball piece when both pieces come 
into contact. To further simulate the ocular surface, mechanical wear and air exposure is 
incorporated into the model through two mechanical actuators. As the eyelid piece moves 
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laterally, it simulates the closing of the eye and intermittent air exposure. The rotation of the 
eyeball simulates the mechanical wear produced during blinking. The system is coupled with a 
microfluidic pump, which infuses the eye model with tear fluid at a physiological flow rate or 
any other desired flow rate. The tear film is formed each time the two pieces come into contact, 
and tear break-up occurs when the two pieces separate.  
The aim is to create a universal testing platform to evaluate CLs for various in vitro 
analyses. In order to be versatile, the eyeball pieces can be synthesized from various polymers, 
such as polydimethylsiloxane (PDMS) or agar. For simple ocular studies, these polymers, which 
represent hydrophobic and hydrophilic surfaces respectively, will suffice. However, as more 
complex analyses are required, for example ocular drug penetration or toxicity studies, the eye 
pieces will need to be further modified. These additional modifications to the model, such as the 
inclusion of an ex vivo cornea as shown, are relatively feasible. However, further validation 
studies are required, and future work will aim to improve the validity of this model by comparing 
it with in vivo models.  
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7.1 Overview 
7.1.1 Objective 
The burst release of a drug followed by a plateau phase is a common observation with drug 
delivery studies using contact lenses (CLs). However, this phenomenon may be attributed to the 
properties of the release system. The aim of this study was to evaluate and compare the release of 
fluconazole from seven different commercially available daily disposable (DD) CLs using a 
conventional vial-based method with a novel in vitro eye model.  
7.1.2 Methods 
An eye model was created using two 3-D printed molds, which were filled with 
polydimethylsiloxane (PDMS) to obtain an inexpensive model that would mimic the eyeball and 
eyelid. The model was integrated with a microfluidic syringe pump, and the flow-through was 
collected in a 12-well microliter plate. Four commercial DD conventional hydrogels (CH) 
(nelfilcon A, omafilcon A, etafilcon A, ocufilcon B) and three silicone hydrogels (SH) 
(somofilcon A, narafilcon A, delefilcon A) were evaluated. These CLs were incubated with 
fluconazole for 24 h. The drug release was measured in (1) a vial containing 4.8 mL of PBS and 
(2) in the PDMS eye model with a 4.8 mL tear flow over 24 h 
7.1.3 Results 
Overall, CH CLs had a higher uptake and release of fluconazole than SH CLs (p<0.05). A higher 
drug release was observed in the vial condition compared to the eye model (p<0.001). As 
expected, in the vial system, the drugs were rapidly released from the CL within the first 2 h 
followed by a plateau phase. In contrast, drug release in the eye model was sustained, and did not 
reach a plateau over 24 h (p<0.05).  
7.1.4 Conclusions 
Rapid drug release results from using a vial as the release system. Under low tear volume at 
physiological tear flow, commercial CLs can maintain a sustained drug release profile for up to 
24 h. 
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7.2 Introduction 
In the treatment of ocular diseases, eye drops remain the most common method for ocular 
drug delivery, accounting for 90% of all ophthalmic formulations.1 There are several advantages 
of using eye drops, including favorable production cost, formulations are simple to develop, 
flexibility in dosing regimen, and excellent acceptance by patients.1 However, eye drops suffer 
extensively from pre-corneal drug loss resulting from tear dilution,2-4 and dispersion from the eye 
during blinking,5 drainage,2, 4 and non-specific absorption.2, 4 It has been approximated that less 
than 7% of the medication within an eye drop reaches the target area,5 while the remainder is 
routed to systemic absorption.6 Therefore, to achieve therapeutic drug concentrations to treat 
these infections, multiple dosing is often required.7 This in turn leads to problems with patient 
compliance,8, 9 and the potential for drug overdosing.10 
Drug delivery using contact lenses (CLs) can potentially overcome the current limitations 
associated with eye drops by limiting pre-corneal drug loss.11 The placement of a CL on the 
cornea divides the tear film into the pre-lens and post-lens tear film. The post-lens tear film 
located between the CL and the cornea has very limited tear exchange.12, 13 In regards to ocular 
drug delivery, this is advantageous as the drug released from the CL into the post-lens tear film 
will have prolonged contact time with the cornea.11 Not surprisingly, modelling studies have 
predicted that over 50% of the drugs released from a CL diffuses into the cornea, which is over 
35 times more effective than eye drops.14 Drug delivery using CLs can also eliminate the need 
for multiple dosing by serving as a reservoir and barrier to provide sustained and controlled drug 
release over extended periods.15 Consequently, in the past decade, there has been extensive 
research in developing smart CL materials for drug delivery using techniques such as vitamin E 
coating,16 molecular imprinting,17 nanoparticles,18 and cyclodextrins.19  
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Although there are no commercial CL products yet available for drug delivery, CLs have 
already been approved for applications in a similar ophthalmic setting. Currently, CLs can be 
used therapeutically as ‘bandage’ lenses to treat corneal damage.20-22 They act by preventing 
painful contact between the cornea and the eyelids, enhancing corneal healing, and preventing 
further complications from secondary infection.20-22 In many cases, pharmaceuticals such as 
antibiotics and anti-inflammatory drugs are administered topically in tandem with these CLs.23  
One of the main drawbacks of using CLs as a drug delivery device is the rapid drug 
release that occurs within the first hour, followed by a plateau phase.16, 24-27 To address this 
problem, the primary focus of research in this field has been dedicated to developing new CL 
materials capable of providing slow and sustained drug release.15, 17, 28-30 However, we theorize 
that although drug and material properties are both deciding factors for controlling drug release, 
another important factor that has been overlooked is the property of the release system. For many 
studies, the in vitro system used to study the drug release is performed in a static vial-based 
system containing 2 – 5 mL of saline buffer.16, 24-27 Because drug release is dependent on the 
drug’s aqueous solubility, in this type of system, it should not be surprising that drug release is 
rapid and plateaus, as the CL is immediately exposed to a high fluid volume. Of significant 
relevance is that this static fluid model does not reflect the ocular environment, in which the tear 
volume is approximately 7.0 ± 2 μL,31 with an average tear flow of 0.95-1.55μL/min.32 In 
contrast, at a low tear volume and tear flow, we do not expect CLs to exhibit a burst release or 
plateau because the amount of fluid that is available to dissolve the drug from the lens is 
significantly lower.  
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In this study, the objective was to build an appropriate in vitro eye model to study the 
release kinetics of drugs from CLs, and use this model to evaluate the release of an antifungal 
drug (fluconazole) from daily disposable CLs compared to the conventional vial method. 
 
7.3 Materials and methods 
Four commercially available daily disposable conventional hydrogel (CH) CLs [nelfilcon 
A (Alcon), omafilcon A (CooperVision), etafilcon A (Johnson & Johnson), ocufilcon B 
(CooperVision)] and three silicone hydrogel (SH) lenses [somofilcon A (CooperVision), 
narafilcon A (Johnson & Johnson), delefilcon A (Alcon)] were evaluated in the study. All lenses 
had a dioptric power of -3.00 and base curve of 8.6mm, obtained from the manufacturer in the 
original packaging. Tables 7-1 and 7-2 detail the properties of the CH and SH disposable CLs 
respectively. 
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Table 7-1 Properties of conventional hydrogels (CH) used in the study 
 
BioMedics 
1Day 
1-DAY 
ACUVUE 
MOIST 
Proclear 1 Day 
DAILIES 
AquaComfort Plus 
United States adopted name 
(USAN) 
ocufilcon B etafilcon A omafilcon A nelfilcon A 
Manufacturer CooperVision 
Johnson & 
Johnson 
CooperVision Alcon 
Water content (%) 52% 58% 60% 69% 
FDA group IV IV II II 
Centre thickness (mm) 0.07 0.08 0.09 0.10 
Oxygen permeability (x10-11) 16.8 28 33 26 
Oxygen transmissibility 
(x10-9) 
24.0 25.5 36.3 26.0 
Principal monomers 
HEMA, PVP, 
MA 
HEMA,  
PVP, MA 
HEMA, MA,  
PC, EGDMA 
PVA, FMA, 
 HPMC, PEG 
EGDMA, ethyleneglycol dimethacrylate; FMA, N-formylmethyl acrylamide; HEMA, 
hydroxyethyl methacrylate; HPMC, hydroxypropylmethylcellulose; MA, methacrylic acid; PC, 
phosphorylcholine; PEG, polyethylene glycol; PVA, polyvinyl alcohol; PVP, polyvinyl 
pyrrolidone;  
 
 
Table 7-2 Properties of silicone hydrogels (SH) used in the study 
 DAILIES TOTAL1® 
1-DAY ACUVUE® 
TruEye® 
clariti™ 1day 
United States adopted name 
(USAN) 
delefilcon A narafilcon A somofilcon A 
Manufacturer Alcon Johnson & Johnson  CooperVision 
Water content (%) 33% (surface >80%) 46% 56% 
FDA group V V V 
Centre thickness (mm) 0.09 0.09 0.07 
Oxygen permeability (x10-11) 140 100 60 
Oxygen transmissibility 
(x10-9) 
156.0 118.0 86 
Principal monomers 
Not disclosed 
 
MPDMS, DMA, 
HEMA, siloxane 
macromer, TEGDMA, 
PVP 
Not disclosed 
 
DMA, N,N-dimethylacrylamide; HEMA, hydroxyethyl methacrylate; MPDMS, monofuncional 
polydimethylsiloxane; PVP, polyvinyl pyrrolidone; TEGDMA, tetraethyleneglycol 
dimethacrylate;  
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7.3.1 Eye model fabrication and set up 
An eye model was created using two 3-D printed molds (eyeball and eyelid), designed 
with Solid Works 2013. Depending on the required application, the molds can be filled with the 
desired polymer. In this study, the molds were filled with polydimethylsiloxane (PDMS) to 
obtain an inexpensive two-piece product representing the eyeball and the eyelid. This particular 
2-piece design was chosen to mimic the eyeball and the eyelid, and when they are placed 
together and when fluid flows through those two pieces, it would simulate physiological tear 
volume by minimizing the amount of tear volume that comes in contact with the CLs (figure 7-
1). The set up for the eye model is shown in figure 7-1. To emulate tear secretion and tear flow in 
the human eye, a microfluidic syringe pump (PHD UltraTM, Harvard Apparatus) is integrated 
with the eye model. Also, unique to this model is the vertical orientation of the model, which 
correctly simulates the natural eye position during the day, and utilizes gravity to generate a 
natural flow. The limitations of the eye model will be discussed in the discussion section. The 
flow-through is collected in a standard 12-well microliter plate. This work was undertaken in 
collaboration with Medella Health (Kitchener, ONT).  
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Figure 7-1 Schematic of the two-piece eye model 
7.3.2 Uptake studies 
Six lenses of each type were incubated in 1.0 mg/mL fluconazole (VWR International, 
Mississauga, ONT) in PBS, pH 7.4 over 24 h. The absorbance of fluconazole in this experiment 
was measured at 259 nm using the SpectraMax M5 UV-Vis Spectrophotometer (Molecular 
Devices, Sunnyvale, CA), which is similar to the absorbance maxima of fluconazole reported in 
the literature.33 The initial and final absorbances were measured at 0 minutes and after 24 h. The 
difference in absorbance was calculated and converted to the amount of drug uptake for each 
lens.  
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7.3.3 Release studies 
Vial 
After the 24 h drug incubation, the lenses were removed from the drug solution and 
partially blotted on lens paper. The lenses were then placed in a vial containing 4.8 mL solution 
of PBS, pH 7.4. At specific time intervals, t = 0, 1, 5, 15, 30 min, 1, 2, 4, 8, 12, 16, and 24 h, 200 
µL of the sample was withdrawn from the vial and pipetted into a UV- Star transparent plate 
(Greiner Bio-One). After each absorbance measurement at 259 nm, the sample solutions were 
pipetted back into their respective vials.  
 
Eye model 
Each lens was placed in the eye model, and the model was set up as shown in figure 7-
1B. The flow rate was controlled using a syringe pump at a rate of 200 µL/ h (4.8 mL/ day), and 
the flow through fluid was collected in the 12-well plate. At specified time intervals, t = 0, 1, 2, 
3, 4, 5, 6, 8, 12, 16, and 24 h, 200 µL of this solution was withdrawn and pipetted into a UV- 
Star transparent plate and measured. 
7.3.4 Statistical analysis 
Statistical analysis was performed using Statistica 8 software (StatSoft, Tulsa, OK). All 
data are reported as mean ± standard deviation, unless otherwise stated. Repeated measures of 
analysis of variance (RM-ANOVA) were performed to determine the differences across various 
time points within the same lens material. An ANOVA was conducted to determine the 
differences between lens materials at each time point. Post-hoc Tukey multiple comparison tests 
were used when necessary. In all cases, statistical significance was considered significant for p 
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value of < 0.05. Graphs were plotted using GraphPad Prism 5 software (GraphPad, La Jolla, 
CA).  
 
7.4 Results 
The uptake and release of fluconazole after 24 h for the seven daily disposable CLs are 
summarized in table 7-3. The drug uptake was higher than the amount of drug released in either 
the vial or the eye model eye (p<0.05). Overall, CH lens materials had a higher uptake of 
fluconazole than SH CLs (p<0.05). Consequently, CH CLs also released statistically 
significantly more drug than SH CLs (p<0.05).  
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Table 7-3 Uptake and release (µg/lens) of fluconazole after 24 h from conventional hydrogel 
(CH) and silicone hydrogel (SH) daily disposable contact lenses 
Commercial name Material 
FDA 
Group 
Water 
Content 
(%) 
Drug 
uptake 
µg/lens 
Drug 
release in 
vial(µg/len
s) 
Drug 
release in 
eye model 
(µg/lens) 
CHDailies Aqua Comfort 
Plus 
nelfilcon A II 59 165.3±16.0 47.8±14.6 75.6±9.70 
CHProclear 1 Day omafilcon A II 62 202.3±18.7 128.5±20.9 128.1±7.64 
CH1-Day Acuvue Moist etafilcon A IV 58 203.0±11.7 155.5±29.9 101.6±17.5 
CHBiomedics 1 Day ocufilcon B IV 52 257.3±17.7 191.9±15.0 137.5±13.8 
SHClariti 1 Day somofilcon A V 56 74.2±9.3 86.2±6.0 88.9±16.6 
SH1-Day Acuvue TruEye narafilcon A V 46 83.7±28.0 80.14±1.2 45.2±3.75 
SHDailies Total 1 delefilcon A V 33 182.3±65.9 148.9±6.0 82.05±21.8 
 
As a general trend, there was a higher quantity of drug released in the vial condition than 
the eye model, as seen with etafilcon A, ocufilcon B, and delefilcon A (p<0.001). However, there 
were no differences in the amount of drug released after 24 h for nelfilcon A, omafilcon A, 
somofilcon A, and narafilcon A (p>0.05). In the vial model, the majority of the drug release 
occurred within the first 2-4 hours (p<0.05), followed by a plateau phase, as shown in figure 7-2. 
In contrast, as depicted in figure 7-3, the drug released in the eye model was sustained and did 
not reach plateau within the 24 h time period (p<0.05). However, although the release profiles 
over 24 h are significantly different between these two release models, the overall trend in drug 
release for each material is fairly similar. Ocufilcon B (Biomedics 1 Day) had the highest amount 
of drugs released in both the vial and the eye model. Similarly, the lowest drug release was 
observed for nelfilcon A(Dailies Aqua Comfort Plus) and narafilcon A (1-Day Acuvue True 
Eye) in both systems. All lenses were virtually clear throughout all phases of the study. The eye 
model was washed with 400 µL of PBS to wash off any residual fluconazole on the eye model. 
However, there was no detectable sorption of fluconazole on the eye model.  
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Figure 7-2 Release of fluconazole (µg/lens) from daily disposable commercial contact lenses in 
4.8 mL of PBS. The values plotted are the mean ± standard deviation for 3 trials.  
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Figure 7-3 Release of fluconazole (µg/lens) from eye model with a flow rate of 4.8 mL over 24 
h. The values plotted are the mean ± standard deviation for 3 trials.  
 
7.5 Discussion 
In the United States, the only approved drug for the topical treatment of fungal keratitis is 
natamycin.34-36 However, this drug has very low water solubility at physiological pH, and 
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therefore has to be prescribed as a 5% ophthalmic suspension. While currently not FDA-
approved, fluconazole has been suggested as a potential ocular antifungal agent for the treatment 
of fungal keratitis.37 As a member of the azole class of antifungal compounds, it exhibits its 
action by limiting ergosterol synthesis via inhibition of P450-dependent enzyme 14-α-
demethylase.37 Azoles are considered fungistatic at low concentrations, but can become 
fungicidal at higher doses.38 Unlike natamycin, fluconazole is stable, water-soluble, and has a 
low molecular mass, which results in high bioavailability and low toxicity.37  
Due to costs and convenience, the majority of in vitro studies with CLs have used the 
static vial as an accepted model for the eye. Studies observing in vitro deposition of protein and 
lipid are typically performed by incubating CLs in a vial containing 1-2 mL of incubation 
fluid.39, 40 Similarly, for drug delivery using CLs, the release studies are performed in vials 
containing 2 – 5 mL of release buffer.16, 24-27 Under these circumstances, it should not be 
surprising that rapid drug release and plateau would occur, as the CL is rapidly exposed to a 
static and high fluid reservoir. Nonetheless, this phenomenon has been reported and accepted as 
a drawback of drug delivery using CLs,16, 24-27 although it is more plausible that these 
observations are due to the system used to study the drug release.  
The approximated 2 mL volume used in the vial method is based on the average 
physiological tear flow, 0.95-1.55μL/min,32 which in a 24 h period accumulates into 1.4-2.2 mL 
of fluid. However, we would expect that exposing a CL to a static 2 mL volume compared to 2 
mL over a 24h period should yield significantly different release profiles. As seen in this study, 
the release of fluconazole from commercial CLs in a vial follows the typical burst release pattern 
within the first 2 hours, followed by a plateau phase.16, 24-27 However, using our eye model, in 
conjunction with a microfluidic pump, we show that the release of fluconazole from CLs is slow 
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and sustained over this time frame, and does not exhibit a plateau effect. This release profile is 
similar to those of other studies observing the release of other drugs from CLs using a 
microfluidic system.41-45 This confirms that our model produces results that are in agreement 
with other studies using microfluidic systems.  
However, more important than sustained drug release is the rate of drug release, which 
determines the overall efficacy and toxicity of the drug delivery device, and consequently the 
therapeutic outcome.46-48 Unfortunately, as seen in this study, the release rates obtained in vitro 
will be highly dependent on the parameters of the release system, such as tear flow rate and tear 
volume. Other parameters, such as temperature, pH, proteins, lipids, drug sorption, drug elution, 
and drug penetration can also affect the rate of drug release.49, 50 This is a fundamental drawback 
of in vitro models, and thus we should be cautious when making absolute conclusions in terms of 
device efficacy based on the release rates obtained from in vitro studies. For this reason, 
although all CLs are capable of sustained release, without further investigation it is difficult to 
state if any of these CLs could effectively kill fungi based solely on the release rates. 
Nonetheless, these values still serve as very useful predictors and indicators of materials which 
could perform well in vivo. For example, oculfilcon B, which released the most drug in this 
study, could be the most effective material amongst the seven CLs for ocular drug delivery of 
fluconazole. However, we should note that the ideal release kinetic profile for drug delivering 
contact lenses has not yet been established, and further in vivo studies are required to answer this 
question.  
An important topic in modelling drug delivery on the eye is the notion of “perfect sink” 
conditions. A perfect sink condition is defined when the volume of the release medium is at least 
three to ten times higher than the drug saturation volume.51 Under these conditions, drug release 
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is not affected by the saturation of the drug in solution. For most drugs, the conventional vial 
incubation methods represents perfect sink conditions. Part of the acceptance of the vial as an 
appropriate model is the thought that the corneal epithelium, the conjunctiva, and the 
surrounding ocular tissues could potentially act as an infinite sink. However, in order for drugs to 
be absorbed by these ocular tissues, they must first be solubilized by the tear film. As a result, 
the initial drug dissolution would be primarily dependent on the amount of tears exposed to the 
contact lens matrix, which is very small. Thus, it is our opinion that it is more likely that a model 
of a non-sink condition dictates drug release from a lens on the eye, as simulated by our eye 
model.  
Despite significant differences in the release patterns and the amounts of drug released 
between the vial method and the eye model, the overall trends in drug delivery efficacy from 
these CL materials are similar. For instance, the amount of drug released was observed to be 
generally higher in CH than the SH material, similar to previously reported results, regardless of 
what system was used to measure the release.24, 25 Furthermore, the CLs that released the highest 
(ocufilcon B) and lowest (nelfilcon A, narafilcon A) amount of drug were also similar in both 
release conditions. These results suggest that the vial system can still be a viable method to 
determine the relative efficacy of CL materials in drug delivery, such as which material is better 
in delivering a particular drug. However, for the field of ocular drug delivery with CLs to further 
advance, it becomes increasingly important to have a relevant eye model to help close the gap 
between in vitro and in vivo results. 
The ocular microenvironment is highly complex, with a multitude of ocular factors that 
can influence how a CL behaves. However, to replicate all these factors in an in vitro model 
would be expensive and unfeasible. As such, researchers have identified key elements, such as 
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blinking52 and physiological tear flow, 41-44, 53 as important factors to include in their in vitro eye 
models. However, these current eye models are still relatively expensive to set up and maintain, 
which poses barriers to adopting these eye models into regular practice.  
To address these issues, our eye model platform is designed to emulate normal 
physiological tear flow in normal eyes, while still maintaining relatively low cost for set up and 
production. Unlike previous models, the two piece design in our eye model, consisting of an 
eyeball piece and an eyelid piece, allows for high precision control of the thin film of tears found 
on the eye. In addition, our model is positioned vertically to simulate the natural waking position, 
and to utilize gravity to help move the fluid across the eyeball. To reduce the overall production 
costs, 3D printing technology is utilized in the manufacturing process. Furthermore, our model is 
designed for ease of integration with any microfluidic system and inexpensive flow-through 
collecting unit.  
There are several important shortcomings of our model that will need to be improved 
upon for future studies. Firstly, the current model only simulates a closed eye environment and 
lacks a proper blink mechanism. The effect of blinking has been show to facilitate drug release 
from hydrogels.54 Secondly, both the eyelid and corneal eye pieces are synthesized from 
polydimethylsiloxane (PDMS), a highly hydrophobic material. The hydrophobicity and surface 
roughness of PDMS could affect drug release. Thirdly, 3D printing does not produce a smooth 
surface that mimics the ocular surface. At the stage when we need to mimic the smoothness of 
the ocular surface, the eye models can be created using Teflon molds. Fourthly, the current eye 
models are chemically inert and release is evaluated in the absence of other interactions. 
However, in an in vivo settings, the released drugs can interact with several tear components, as 
well as be absorbed by the surrounding ocular tissues. Thus, the amount of drugs released using 
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the current model may be an overestimation. Future iterations would (ideally) include a cellular 
interface consisting of corneal epithelial cells and include a mechanism to mimic the action of 
blinking, and include some ability to mimic the inter-blink drying period by exposing the 
lens/tear/drug to the atmosphere. Previous studies have shown that incorporating such a drying 
phase increases lipid adsorption52 and thus the interaction of hydrophobic drugs with the material 
would likely be impacted. 
The drug release profiles observed in the eye model assumes physiological tear flow. 
However, for eye infections such as fungal keratitis, increased tearing55, 56 may occur which 
could significantly accelerate the release of drugs from CLs. For this reason, drug release would 
be highly variable between patients depending on their individual tear flow rates. In the case of 
excessive tearing, all the drugs could be released within 2 hours, as shown under infinite sink 
conditions. In an animal study by Hui et al., control lenses which have a similar release profile as 
that of the vial in this study, were unsuccessful in an in vivo keratitis model.17 This may suggest 
that these animals may have increased tearing that rendered the control lenses ineffective. Future 
studies will examine the effects of flow rate using this system on drug release profiles from CLs. 
In order for the CL drug delivery field to move forward, in vivo studies are necessary to 
validate that these devices are superior to conventional eye drops. However, to date, there are a 
limited number of animal studies (in dogs and rabbits), that have shown the effectiveness of a 
drug delivering CL.17, 57 The aim of our eye model development is to provide a reliable in vitro 
platform that will help facilitate studies in the in vitro phase, prior to moving ahead with in vivo 
studies. With future iterations of the model, we hope to provide a complementary model to in 
vivo animal studies to reduce the amount of animal testing required. 
  
 129 
 
In this study, we show that the release profile from CLs using a large volume, static vial-
based model is significantly different than in vitro eye model that mimics physiological tear flow 
and volume. CLs in the physiological flow-based eye model show sustained release of 
fluconazole over 24 h, while in the vial, the release reaches a plateau within 2 h. These results 
indicate that the parameters of the release system also need to be taken into consideration when 
making conclusions about the properties of a CL material. Future work aims to improve this eye 
model and incorporate other mechanical elements such as blinking motion, as well as extend this 
model to evaluate other contact lens applications. 
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8.1 Overview 
8.1.1 Objective 
To evaluate the effects of two commercial silicone hydrogel contact lenses (CLs) soaked with 
natamycin (NA) or fluconazole (FL) on the growth of Candida albicans in an in vitro eye model. 
8.1.2 Methods 
3-D printed molds were used as a cast for making eye shaped models comprised of potato 
dextrose agar (PDA). Senofilcon A (SA) and lotrafilcon B (LB) CLs were incubated with either 
2 mL of NA or FL at a concentration of 1 mg/mL for 24 h. To simulate a fungal infection, the 
eye models were coated with C. albicans. The drug-soaked lenses were placed on top of the eye 
models. Seven experimental conditions were examined: (1) NA-SA (2) NA-LB (3) FL-SA (4) 
FL-LB (5) SA (6) LB (7) control - no lens. At specified time points (t=1, 8, 16, 24, 48 h), the 
agar eyes from each experimental condition were removed from the incubator and photographed. 
The yeast cells from the 24 and 48 h time point were also analyzed using light microscopy.  
8.1.3 Results 
At 24 and 48 h, there was considerable growth observed for all conditions except for the NA-SA 
and NA-LB conditions. When observed under the microscope at 24 and 48 h, the morphology of 
the yeast cells in the FL-SA and SA condition were similar to that of the control (oval shaped). 
There was limited hyphae growth observed for LB and significant visible hyphae growth for the 
NA-LB group. For NA-SA, NA-LB, and FL-LB groups, the cells were significantly smaller 
compared to the control.  
8.1.4 Conclusions 
For NA-SA and NA-LB, there was limited growth of C. albicans observed on the eye models 
even after 48 h. Under the microscope, the cell morphology differs noticeably between each 
testing condition, and is dependent on drug-lens combinations.  
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8.2 Introduction 
Fungal keratitis is a major cause of vision loss and blindness in the world.1, 2 These 
infections attracted substantial attention in 2006 when several cases of fungal keratitis were 
linked to a multipurpose contact lens (CL) solution.3-5 Unfortunately, treatment for ocular 
mycoses are inadequate. The only antifungal FDA-approved for topical applications is 
natamycin, formulated as an ophthalmic suspension.6-8 Treatment for fungal keratitis requires 
multiple dosing as often as hourly intervals,9 and patients often have to be hospitalized to ensure 
compliance.10, 11 Thus, an improved method of drug delivery to reduce the need for multiple 
dosing would be invaluable in the management of fungal eye infections.  
 In the past decade, there has been considerable interest in developing CLs for ocular 
drug delivery. Treating microbial and fungal infections have been suggested as potential 
applications for these devices. A CL, when placed on the cornea, partitions the tear film into pre- 
and post-lens layers. In regards to ocular drug delivery, the post-lens tear film is of great 
importance due to the limited amount of tear mixing and exchange within this partition.12, 13 As a 
result, drugs released from a CL into the post-lens tear film have extended contact with the 
cornea in comparison to topical administration with eye drops.14 The CL also provides another 
advantage by functioning as a drug-reservoir, which could be modified to provide slow and 
sustained drug release.15-18  
  One of the major barriers to commercializing a CL as an ocular drug delivery device is 
the limited amount of in vivo data to support the claims of this approach. To date, there are only 
three published studies on animals, which have shown that CLs are more effective drug delivery 
vehicles than eye drops.17, 19, 20 The lack of in vivo studies can be attributed to current in vitro 
models used to evaluate drug release from CLs, which are rudimentary and fail to adequately 
simulate the ocular environment. For instance, the typical in vitro model consists of testing drug 
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release from a CL in a 2-5 mL vial,18, 21-24 which neither mimics the on-eye tear volume nor the 
tear flow. Furthermore, measuring the quantity of drugs released from a CL over time does not 
necessarily correlate with the inhibition or killing of microbes. Thus, a more suitable in vitro eye 
model is needed to determine the anti-microbial efficacy of drug releasing CLs, prior to their 
receiving clearance for in vivo studies.  
The aim of this study is to develop an in vitro agar-based eye model that can be used to 
qualitatively assess the growth of Candida albicans when exposed to a drug delivering CL. To 
model drug delivery from CLs, two commercial silicone hydrogel lenses, senofilcon A and 
lotrafilcon B, were doped with natamycin and fluconazole, and their effects on yeast-containing 
agar eye models were evaluated.  
 
8.3 Materials and methods 
8.3.1 Materials 
Senofilcon A (SA) (Johnson & Johnson) and lotrafilcon B (LB) (CIBA Vision) silicone 
hydrogel contact lenses (CLs) were selected as the model drug delivery CLs in this study. The 
agar eye models and the corresponding lid pieces (see figure 8-1) were casted from novel 3-D 
printed molds (polycarbonate-acrylonitrile-butadiene-styrene) using potato dextrose agar (PDA). 
Each eye model measured 24 mm in diameter and 12 mm in height.  
 
8.3.2 Drug incubation solution 
Natamycin (NA) (EMD Millipore, Billerica, MA, USA) was dissolved in phosphate 
buffered saline (PBS), pH 7.4 as a 1 mg/mL suspension. Fluconazole (FL) (VWR International, 
Mississauga, ONT) was dissolved completely in PBS, pH 7.4 at 1 mg/mL. 10 CLs of each type 
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were incubated in 2 mL of the natamycin suspension, and another 10 CLs were incubated with 
2 mL of fluconazole for 24 h at room temperature. The drug incubation with natamycin was 
performed in light minimizing conditions. 
 
8.3.3 Experimental setup for visual observations 
Candida albicans (C. albicans) ATCC 10231 (ATCC Rockville, MD, USA) were 
regrown from frozen stocks onto potato dextrose agar (EMD Millipore, MA, USA), and 
incubated at 37 ºC for 24 h. The organism was harvested with 10 mL of PBS, placed in a 
centrifuge tube, and centrifuged for 10 minutes at 500 x g. After centrifugation, the supernatant 
was discarded and the pellet was re-suspended in 10 mL of PBS. With the aid of the SpectraMax 
M5 UV-Vis Spectrophotometer (Molecular Devices, Sunnyvale, CA), the fungal cell 
concentration was then adjusted to 1.0 x 108 CFU/mL. For this instrument, the optical density 
(OD) equivalent to this cell concentration is 0.3.  
After the 24 h drug incubation period, each eye model was coated with 70 µL of a 
solution containing approximately 3.3x107 CFU/mL (2.3x106 CFU) of C. albicans. The agar eye 
models were then placed in a petri dish and divided into seven experimental conditions: (1) NA-
SA (2) NA-LB (3) FL-SA (4) FL-LB (5) SA (6) LB (7) control - no lens. The drug-containing 
lenses were blot dried on lens paper before being placed on top of the agar eye models. Two 
independent experiments were performed for each condition to confirm the results (n=2). To 
prevent evaporation, the corresponding lid pieces were placed on top of each eye model. The 
petri dish was then inverted and incubated at 37oC. At specified time points, t=1, 8, 16, 24, and 
48 h, the eye models from each experimental condition were removed from the incubator and 
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photographed. The amount of yeast growth was qualitatively characterized based on the relative 
amount of beige colonies covering the surface of the eye model and the contact lens. 
 
Figure 8-1 Outline of the experimental procedure for qualitative analysis of agar eye models 
 
8.3.4 Morphology analysis 
The agar eye models and their corresponding lids at 24 h and 48 h were ground and 
homogenized in 10 mL of PBS using the PT10/35 homogenizer (Kinematica GmbH, 
Switzerland) for 3 minutes. Between each grinding and homogenization step, the homogenizer 
was rinsed with 70% ethanol and milliQ water to prevent cross-contamination of the samples. 2 
mL of the homogenate was centrifuged at 3500 RPM for 30 seconds to separate the agar. The 
resulting solution was diluted to 100, 10-1, 10-2 and 10-3, and 100 µL of each dilution was spread 
plated on PDA. Yeast cells from the PDA plates with a count between 30 colony forming units 
(CFU) and 300 CFU were transferred to a microscope slide using a culture swab and analyzed 
under a microscope. The slides were analyzed at 400X and 1000X magnification, and the 
morphology of C. albicans for each experimental condition was noted.  
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8.4 Results 
As shown in figure 8-2, there were no visual signs of C. albicans growth observed at 1 h 
or 8 h for any condition. At 16 h, considerable growth was observed for the control (7), SA (5), 
and LB (6) conditions. Medium amount of growth was apparent for FL-SA (3), and limited 
growth for FL-LB (4). From 24 h onwards, there was considerable growth on the agar eye 
models for all conditions except NA-SA (1) and NA-LB (2), which had very limited amounts of 
growth. For these conditions, only a small amount of growth was visually detected on the 
periphery of the eye model; the CL and the corresponding lid component did not have any visual 
signs of growth. These observations suggest that NA-CLs but not FL-CLs can effectively inhibit 
the growth of yeasts on the agar eye models for 48 h.  
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Figure 8-2 Growth of Candida albicans on the agar eye models over 48 h for natamycin (NA) or 
fluconazole (FL) containing lenses: (1) NA-SA (senofilcon A) (2) NA-LB (lotrafilcon B) (3) FL-
SA A (4) FL-LB (5) SA (6) LB (7) control no lens. The corresponding lid pieces are also shown 
for the 48 h time point (far right). NA conditions show very limited amount of yeast growth at all 
time points. 
 
At the 24 h and 48 h time points, the yeast cells were transferred to a microscope slide 
and examined at 400 X and 1000X magnification. As the images were identical for both these 
time points, only the 24 h images are shown in figure 8-3. Of interest was the colony 
morphology observed for the NA groups, which were smaller and more translucent, compared to 
the other experimental conditions. When observed under the light microscope, the morphology 
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of the yeast cells in the FL-SA and SA groups were similar to the control, which were oval-
shaped. For the LB condition, there was presence of hyphal growth. There were significant 
amounts of hyphal growth for the NA-LB condition, although the hyphae were smaller in size. 
No hyphae were observed in the FL-LB condition. The morphology of cells in NA-SA, and FL-
LB were significantly smaller and rounder compared to the control.  
 
 
Figure 8-3 Candida albicans under the light microscope at 400X and 1000X magnification for 
natamycin (NA) or fluconazole (FL) containing lenses: (1) NA-SA (senofilcon A) (2) NA-LB 
(lotrafilcon B) (3) FL-SA (4) FL-LB (5) SA (6) LB (7) control no lens at 24 h. The circled area 
shows (A) cells which are significantly smaller and rounder in size, (B) small hyphae, (C) 
hyphae, and (D) typical oval cell shape of Candida albicans.  
 
8.5 Discussion 
Drug delivery using contact lenses (CLs) provides an interesting approach to address the 
problems associated with ocular drug delivery. However, while this concept appears viable in 
theory, currently there are only a limited number of studies to validate its efficacy in vivo.17, 19, 20 
Furthermore, previous in vitro studies only provided an understanding of drug release kinetics.18, 
21-24 In developing a drug delivery device for ocular mycoses, it is also important to show that 
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these CLs are effective in inhibiting microbial growth. Thus, in this study an agar-based eye 
model was developed and used to evaluate the growth of C. albicans when exposed to an 
antifungal containing CL. 
The two antifungals, natamycin (NA) and fluconazole (FL), were selected based on their 
differing drug properties. NA, a polyene antifungal, inhibits fungi by binding directly to 
ergosterol, a sterol present only in fungal cytoplasmic membranes.25, 26 The drug has a high 
molecular weight,27 and is highly hydrophobic.28 In contrast, FL, an azole antifungal, impedes 
ergosterol synthesis by inhibiting 14-α-demethylase.29 FL also has a lower molecular mass and a 
higher water solubility as compared to NA.29 Another important difference is that azoles, such as 
fluconazole are fungistatic at low concentrations and are fungicidal only at high concentrations.30  
The two silicone hydrogels, senofilcon A (SA) and lotrafilcon B (LB), were selected due to 
their unique material properties.31, 32 Notably, SA contains an internal wetting agent, whereas 
lotrafilcon B is coated with a 25 nm plasma coating.31, 32 In comparison to conventional 
hydrogels, silicone hydrogel contact lenses with their superior oxygen permeability, can be worn 
for extended periods without adverse hypoxic effects.33, 34 Thus, silicone hydrogels would be 
better candidates than conventional hydrogel lenses for drug delivery, and SA is already 
approved for therapeutic use.35  
As yeast cells are able to grow inside the agar, the agar eye models were homogenized and 
re-plated on PDA plates. Surprisingly, even though the eye models appeared clear for the NA-SA 
and NA-LB conditions, the plates yielded colony forming units (CFU) counts similar to other 
experimental conditions and the control. While the underlying mechanism is unclear, we 
hypothesize that natamycin, which is hydrophobic,28 does not readily diffuse into the hydrophilic 
agar. As a result, the observed inhibition is superficial and the yeast cells can continue growing 
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inside the agar. Further work is necessary to develop a protocol to reliably quantify the CFU 
using this eye model.  
The morphology of the yeast cells was analyzed using light microscopy after 24 h and 48h. 
Interestingly, the morphology of the cells were dependent on both the CL material and drug 
properties. As shown in figure 8-3, the control cells of C. albicans are oval shaped. This cell 
morphology was also observed for the FL-SA and SA conditions. A small amount of hyphae 
growth was observed for the LB condition, and a significant amount was observed for the 
NA-LB group. Morphogenesis to hyphae in C. albicans is controlled by multiple pathways, 
which respond to various conditions present in the environment.36 While the mechanism for 
hyphae growth is not entirely clear, it may be attributed to the 25 nm plasma surface 
modification present on LB, but not SA.31, 32 Hyphae growth also appears to be dependent on 
drug-lens combination, as hyphae were not observed for the FL-LB condition, while substantial 
growth was observed for the NA-LB group. The general acceptance is that hyphae growth is a 
sign of virulence, as it grants fungal cells the ability to penetrate host tissues.36  
The fungal cells in the NA-SA and NA-LB conditions were significantly smaller and rounder 
compared to the control. These observations are similar to what has been previously reported 
with an azole antifungal, sertaconazole.37 In the presence of sub lethal doses of antifungals, the 
yeast cells retain the capacity for budding, however, newer cells do not reach maturity and 
separate prematurely from the parent.37 As a consequence, the number of cells increases, while 
their sizes are significantly reduced. This effect appears to be more pronounced for NA than FL, 
and may be attributed to their mechanism of inhibition.  
The in vitro uptake and release of NA from SA and LB have been previously reported to be 
comparable.18 The release of FL from these lenses also have been reported to be similar.24 In 
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both studies, the in vitro release of the drugs is rapid within the first hour, followed by a plateau 
phase.18, 24 This suggests that observed differences in yeast inhibition and morphologies between 
lens types are not likely due to the amount of drugs sorbed or released.  
One of the limitations of the current eye model is the absence of ocular cells or immune cells. 
As such, the yeasts are not subjected to several growth pressures, such as those from the immune 
system, which would otherwise be present in an in vivo environment.38 Furthermore, the current 
model only provides a qualitative assessment of yeast growth in response to an antifungal 
delivering CL. Future work will aim to develop a methodology using this eye model to 
quantitatively analyze yeast growth. Nonetheless, the current agar-based eye model provides a 
convenient method to visually assess the effects of an antifungal containing CL on the growth of 
C. albicans.  
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Chapter 9 – General Discussion 
For over half a century, the notion of using contact lenses (CL) for drug delivery was but 
a dream.1, 2 However, within the last few decades, significant progress has been made with 
biomaterials, and specifically CL materials, which have addressed the problems associated with 
corneal hypoxia.3, 4 As a result, extended CL wear was made possible, and various medical 
applications for CL have become a possibility.5-11 This breakthrough, combined with an 
increased understanding of the interactions of CLs with biomolecules12-22 and therapeutic 
agents,23-28 have been pivotal in setting the stage for research towards CL drug delivery.  
 As mentioned in Chapter 2, fungal keratitis is an ideal candidate for ocular drug delivery 
with CLs. These infections, often overlooked due to their low prevalence in North America, 29-34 
can lead to severe vision loss and blindness.35, 36 Treatment for fungal keratitis requires an 
intensive dosing regimen, which can be extremely taxing for the patient.37 A simple yet effective 
treatment approach for ocular mycoses is therefore in high demand.  
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9.1 Key factors affecting drug release 
In developing new materials for ocular drug delivery, two important elements need to be 
considered: (1) the total quantity of drugs released and (2) the rate at which such drugs are 
released. The work in the previous chapters have described the development of novel CL 
materials for antifungal drug delivery and a unique in vitro model to test this concept. In light of 
this work, we have furthered our understanding of the factors influencing the quantity and rate of 
drug release from CLs. These findings, in conjunction with the published literature (Table 9-1), 
can be summed up in Figure 9-1 as the key factors influencing general drug delivery from CLs. 
The three key components, (1) material, (2) drug, and (3) system dynamically interact with one 
another to influence the uptake and release of drugs from CLs. It is important to note that many 
properties are inter-related; for example increasing silicone content in a material reduces water 
content and swelling size.  
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Table 9-1 Factors affecting drug delivery from CLs 
Material Drug System 
Monomer composition38 Solubility27, 39, 40 
Drug release faster in artificial tear 
solution than in water.41 
Cross-link density42 
Hydrophobicity/ 
Hydrophilicity39, 40 
Drug release faster at higher 
temperatures43 
Thickness27, 44 
Molecular diffusivity27, 
40, 44 
Drug release follows zero-order 
release rate under microfluidic 
flow45 
Silicone content40 Molecular size39, 40 
Drug release in a vial is rapid 
within the first few hours, followed 
by a plateau27, 40, 42, 46-49 
Water content40 Chemical structure39, 40 
Drug release higher in infinite sink 
conditions compared to a 
microfluidic flow system45 
Swelling size39 
Drug loading 
concentration40, 50 
Drug release is faster with rubbing 
(unpublished Ocuflow data) 
Ionicity40  
Drug release is affected by air 
exposure (unpublished Ocuflow 
data) 
Drug loading capacity38, 51, 52   
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Figure 9-1 Summary of key factors which can potentially influence release kinetics of drugs 
from contact lenses 
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9.2 Material-drug interactions 
There are several important material-drug interactions generally observed throughout this 
thesis. One key finding is that materials with higher water content typically release more drugs, 
irrespective of the drug’s properties, than materials with lower water content.46, 53, 54 This is in 
part also related to the amount of silicone content within the material, where higher silicone 
content negatively impacts water content and material swelling. As a result, conventional 
hydrogels (CH), such as pHEMA-based lenses, will release more drugs than their silicone 
hydrogel (SH) counterparts.40, 46, 47, 53-55 The predicted trends for drug uptake and release from a 
CL, based on our studies and published literature, are summarized in Table 9-2. 
 
Table 9-2 trends for drug uptake and release from conventional (CH) and silicone hydrogels 
(SH). The terms high vs. low are meant as a “relative comparison” between CH vs. SH. There 
are some exceptions to this trend.  
 
 
 
Hydrophobic drug Hydrophilic drug 
Conventional hydrogels 
 
high uptake46, 47 
high release40, 46, 47, 53-55 
 
high uptake40 
high release40, 55 
Silicone hydrogels 
 
high uptake46, 47 
low release40, 46, 47, 53-55 
 
high uptake40 
low release40, 55 
  
One assumption would be that lower drug release in SH materials would also be 
correlated to a lower amount of drug uptake in these materials. Surprisingly, drug sorption in SH 
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lenses is similar to that seen with CH lenses.40, 46 This important finding suggests that drugs can 
irreversibly bind to the CL polymer, or be immobilized in regions where drug elution is not 
possible. This observation was most pronounced for SH materials with natamycin, which is 
hydrophobic, where the majority of drugs sorbed are not released.46 However, based on the 
hydrophobic-hydrophobic interaction principle,56 this is not surprising, as a hydrophobic drug 
will prefer a hydrophobic substrate over the surrounding aqueous environment. Previous studies 
have also reported that partial drug release from CLs is a common phenomenon.40, 47 To 
understand this important material-drug interaction, a schematic has been proposed in figure 9-2 
which illustrates the general mechanisms underlying drug uptake and release from materials.  
 
 
Figure 9-2 Schematic for general drug uptake and release from conventional hydrogel (CH) and 
silicone hydrogel (SH) materials. CH materials have increased swelling and water content 
compared to SH, leading to a higher quantity and rate of drugs released. For hydrophobic drugs, 
irreversible drug binding to the polymer could occur at the silicone moieties.  
 
Since drug release is primarily a diffusion process, increasing material thickness will 
extend the time of drug release.27, 44 However, what was not as apparent was that thickness also 
plays a crucial role in determining the overall effectiveness of a bulk polymer modification 
approach. Our strategy to modify the lens chemistry with the incorporation of cyclodextrin (CD) 
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moieties to interact with natamycin did not yield a significant increase in drug release time.54 The 
CDs were shown to complex effectively with natamycin in solution, but when incorporated into 
a gel, their effects were ambiguous. Increasing the concentration of CDs within the material 
improved drug release up to a threshold concentration, after which further increases in CDs had 
the opposite effect.54 One proposed mechanism is that beyond a critical concentration, due to the 
dimensional constraints of a CL, the arrangements of the CDs become crowded and the drug 
interaction sites become inaccessible.54 These CDs then occupy the space that would otherwise 
have been available for drug binding. So while thicker gels could benefit significantly from a 
bulk polymer modification approach, when the same strategies are applied to a CL (with a 
thickness of less than 100 µm),57 the effects will be less pronounced. 
Considering the ratio of thickness (~ 100 µm) to surface area (~ 14 mm diameter) of a 
CL, it should be apparent that CL surface area plays a substantial role in determining the rate at 
which drugs are released. We hypothesize that the majority of the drugs released from a CL are 
in fact bound on the surface of the lens, rather than within the bulk of the material. The observed 
burst release profiles of drugs within the first few hours from our studies, as well as from other 
published papers, support this hypothesis.27, 40, 46, 47, 53, 54 That being said, modifications to the 
lens surface to act as a diffusion barrier or interact with the target drugs to some extent, should 
have the most impact on extending drug delivery time. To this end, we had considerable success 
in extending the release duration of natamycin by coating lens materials with natamycin-dex-b-
PLA nanoparticles (chapter 4).  
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9.3 Material-drug-system interactions 
The importance of the testing system, although a critical component in developing any 
drug delivery device, has often been overlooked. It is somewhat odd that CLs designed for 
external ocular drug delivery are tested under conditions that contrast markedly with the ocular 
environment.27, 40, 47 These results are then extrapolated to predict the performance of the device 
in vivo, without considering the parameters of the system used to test the device. 
The ideal testing system for a drug delivering CL is a human being. Understandably, this 
is currently not possible and therefore we must rely on other systems, both in vivo and in vitro, to 
predict the performance of these CLs on a human eye (figure 9-3). In vivo results from animal 
studies will provide useful data on toxicology and efficacy.23-25 On the other hand, in vitro results 
will help elucidate the “how” and “why” a CL behaves, and this information will facilitate the 
development of better materials.40, 46, 47, 53-55 In both cases, the parameters of the testing system 
need to be considered carefully to avoid making erroneous predictions about the behavior of 
these devices on the eye.  
 
Figure 9-3 In vitro and in vivo models complement each other to help make predictions on how 
a drug delivering CL would behave on the human eye.  
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One of the missing links that a simple fixed volume vial model cannot provide are the 
release rates in vivo. The rates of drug release from CLs are highly dependent on the system used 
to test them. For the majority of the studies performed in-vial for commercial CLs, the reported 
release rates have followed a ‘burst’ release profile followed by a plateau.27, 40, 46, 47, 53, 54 From 
these studies, there are no marked differences between hydrophobic and hydrophilic drugs; both 
types of drugs are released rapidly. This is puzzling, as hydrophobic drugs should elute much 
slower into an aqueous environment. With the developed Ocuflow model, we were able to show 
that the elution of a hydrophilic drug (moxifloxacin) does happen much faster than the release of 
a hydrophobic drug (ciprofloxacin).55 
Arguably, one the most debated topics in ocular drug delivery from CLs is whether the 
eye resembles an infinite (perfect) sink. Under infinite sink conditions, the volume of the release 
media is significantly higher than the drug saturation volume, by a factor of at least 3-10 times 
more.58 As a result, the elution or dissolution of the drug from the CL to the surrounding system 
is not affected by its solubility. Proponents for using the vial as a representative model argue that 
the corneal epithelium, conjunctiva, and surrounding ocular tissues act as perfect sinks. In 
theory, this may be true for hydrophilic drugs, which dissolve readily in low tear volume. 
However, for more hydrophobic drugs, the drugs first must be solubilized by the tear film before 
they can be absorbed by the ocular tissues. The initial drug dissolution is dependent on the 
volume of tears exposed to the contact lens matrix, which is significantly less than the 2 mL 
volume used for vial studies. In this case, the vial is a poor model for drug release studies. Our 
hypothesis is that although the eye as a whole is an infinite sink, the rate limiting step, the 
dissolution of the drug into the tear film, represents a non-sink condition. For this reason, as 
simulated by our developed eye model, the rate of drug release from a CL is significantly 
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dependent on tear volume and tear flow. Nonetheless, until in vitro models become even more 
sophisticated, judgment should be reserved on which model is truly representative of the human 
eye.  
 One of the biggest limitations of all in vitro models thus far, including our Ocuflow 
model, is that they only measure drug release from CLs as a whole. There is no distinction 
between the amounts of drug released to the pre-lens tear film from the anterior CL surface, and 
the quantity of drugs released to the post-lens tear film from the posterior CL side. This 
distinction is important, as drugs released to the pre-lens tear film are effectively subjected to the 
ocular removal mechanisms discussed previously. Furthermore, even drugs which are released 
into the posterior-lens tear film are not guaranteed to be absorbed by the cornea. As a result, the 
quantity of drugs released from CLs measured using the current in vitro models do not predict 
true efficacy of the device. A more sophisticated model, in which the parameters for corneal drug 
absorption are also taken into account, will be able to provide better in vivo predictions. 
 
Figure 9-4 drugs released from the CL into the pre-lens tear film are subjected to ocular removal 
mechanisms; even drugs released to the post-lens tear film are not guaranteed to be absorbed by 
the cornea. 
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9.4 Barriers to commercialization 
While this thesis has elucidated the majority of the mechanisms for drug release from 
CLs, there are still several hurdles that need to be overcome before commercialization of such a 
device will be possible. These challenges are highlighted in table 9-2, and will need to be 
addressed before these devices will gain acceptance from the CL industry, clinicians, and 
patients. Some of these concerns warrant further attention and will be discussed below. 
One of the key challenges is determining whether continuous drug release is ideal. 
Firstly, because the release is strictly diffusion-controlled, the majority of the drugs are released 
immediately, followed by a decreasing release rate over time. If consistent dosing is required to 
treat fungal keratitis, then this type of non-zero-order release kinetic is undesirable and will need 
to be addressed. Secondly, it is not certain whether continuous release is beneficial over pulsed 
release, such as in eye drops, when it relates to treating fungal keratitis. Thirdly, continuous drug 
release could also result in a variety of clinical complications, such as ocular irritation or 
increased microbial resistance. The drugs released from CLs can be trapped underneath the post-
lens tear film,59 which is less than 4 microns thick.60, 61 As a consequence, even minute amounts 
of drugs released in this micro environment over time can significantly increase drug 
concentrations to toxic levels.  
The second main challenge is developing materials which are compatible with current 
manufacturing processes. Current strategies to chemically modify the CL polymer are still 
exploratory, and thus do not follow industry standards for CL manufacturing. However, in order 
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Table 9-3 Key challenges that need to be addressed before commercialization for a drug delivering contact lens 
Technical Clinical Regulatory Market  
 
Rate of drug release 
continuously decreases over 
time 
 
System is confined to 
continuous release - may be 
that pulse release is more 
beneficial 
 
Current chemical 
modifications to CL polymer 
are not compatible with the 
industry’s manufacturing 
processes  
 
Maintaining lens properties 
(water content, transparency, 
oxygen permeability) limits 
amounts of drugs that can be 
loaded 
 
A drug delivering CL might be 
an improvement over one eye 
drop instillation, but is it able 
to outperform multiple eye 
drops?  
 
May not be safe for patients 
with microbial infections to 
wear contact lenses 
 
Continuous drug release could 
lead to ocular irritation or 
microbial resistance 
 
Classified as FDA class III 
medical device – requires 
highest level of safety and 
control 
 
Requires enormous investment 
in time and money 
 
Significant financial risks may 
deter industry  
 
 
More expensive than eye drop 
treatment 
 
Patients willingness to wear 
contact lenses as a medical 
device 
 
Unattractive technology for 
non-contact lens wearers  
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for the industry to adopt this technology, the methods to produce these medical devices must be 
in parallel with industry manufacturing processes.  
The third challenge, and the most difficult to overcome, is to pass the regulatory hurdle. 
To enter the North American market, the device must gain Food and Drug Administration (FDA) 
approval. Under FDA regulations, a drug delivering CL would be classified as a class III medical 
device, which requires the highest level of control and safety assurance. This regulatory process 
requires an enormous investment in time and money. Since no device of its kind has been 
released, the financial risks are exceedingly high and therefore many companies will shy away 
from being the first to take on this venture.  
 
9.5 Addressing barriers 
Maintaining lens properties, notably water content, transparency, and oxygen 
permeability, significantly limits the amount of drug that can be loaded into a CL. To address 
this issue, the device can be designed with the option of reloading the drugs on a daily basis. In 
this manner, the patient wears the device during the day, and reloads the device with drugs 
during the night. These drugs could be incorporated within the CL cleaning solution, in a dropper 
bottle that is added to the cleaning solution during the overnight soak or in a dropper bottle that 
is dripped over the lens prior to sleep (in the case of an extended wear lens). 
The development of a CL drug delivery device should be done with the industry’s 
manufacturing process in mind. This likely means that chemical changes to the main polymer 
structures may not be a practical approach. It may be worthwhile to devote future efforts in 
developing novel coatings, such as drug-nanoparticles, for commercial CLs. Furthermore, with 
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this approach, new CL materials do not need to be developed, which considerably simplifies the 
FDA approval process.  
 To de-risk this technology and make it more attractive to industry partners, alternative 
CL drug delivery approaches should be explored. For example, CLs could also be used to release 
comfort agents or anti-allergy drugs. This type of CL release device would have a much better 
chance for FDA approval, and its entry to the market will significantly help open doors for its 
future drug-delivery successors. 
 
9.6 Conclusion 
This thesis has attempted to explore and develop CLs for antifungal ocular drug delivery. 
Several important findings have been reported, and the shortcomings also have been discussed in 
this chapter. In light of this, with the right approach, an antifungal ocular drug delivery CL is a 
commercial possibility, but not in the near future.
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